Injectable formulations
Injectable pharmaceutical compositions with aldehyde-reactive compounds address the harmful effects of toxic aldehydes by scavenging them, thereby reducing inflammation and tissue damage, offering therapeutic benefits for a range of diseases and conditions.
Patent Information
- Application Number
- JP2024137889
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-12-05
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Toxic aldehydes such as malondialdehyde (MDA), 4-hydroxy-2-nonenal (HNE), and glyoxal are highly reactive and contribute to metabolic and inflammatory processes, leading to damage in biological molecules and tissues, causing mutagenesis and chronic inflammation, necessitating therapeutic agents to mitigate their harmful effects.
Pharmaceutical compositions comprising aldehyde-reactive compounds, formulated as injectable depot formulations, including compounds of specific structures and optionally substituted with deuterium or halogen atoms, are developed to scavenge toxic aldehydes and reduce their harmful effects.
The compositions effectively scavenge toxic aldehydes, reducing pathological inflammatory responses and associated tissue damage, providing therapeutic benefits for various diseases and conditions characterized by elevated aldehyde levels.
Smart Images

Figure 2024164107000105 
Figure 2024164107000106 
Figure 2024164107000107
Abstract
Description
[Technical field]
[0001] 1. CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 62 / 775,779, filed December 5, 2018, the entire contents of which are incorporated herein by reference. [Background technology]
[0002] 2. Background Metabolic and inflammatory processes in cells can lead to the formation of toxic aldehydes such as malondialdehyde (MDA), 4-hydroxy-2-nonenal (HNE or 4-HNE), glyoxal and acetaldehyde. MDA, HNE and other toxic aldehydes are involved in the regulation of fatty alcohol, sphingolipid, glycolipid, phytol, fatty acid and arachidonic acid metabolism (Rizzo et al., 2007, Mol Genet Metab. 90(1):1-9), polyamines, and the like. metabolism (Wood et al., 2006, Brain Res. 1122(1):184-90), lipid peroxidation, oxidative metabolism (Buddi et al., 2002, Histochem Cytochem. 50(3):341-51; Zhou et al., 2005, Exp Eye Res. 80(4):567-80; Zhou et al., 2005, J Biol Chem. 280(27):25377-82) and glucose metabolism (Pozzi et al., 2009, J Am Soc Nephrol. 20(10):2119-25). Aldehydes are highly reactive with proteins, carbohydrates, lipids and DNA, leading to chemically modified biological molecules, activation of inflammatory mediators such as NF-kappa B and damage to a wide variety of tissues. Aldehydes react with primary amino groups and other chemical moieties on proteins, phospholipids, carbohydrates and DNA, often resulting in mutagenesis and carcinogenesis (Marnett, 2002, Toxicology 181-182:219-22) as well as acute or chronic inflammation. Given the implication of toxic aldehydes in numerous disease indications, there is a need for therapeutic agents and pharmaceutical compositions to treat, prevent, and / or reduce the risk of diseases, disorders, or conditions associated with the presence of toxic aldehydes. [Prior art documents] [Non-patent literature]
[0003] [Non-Patent Document 1] Rizzo et al., 2007, Mol Genet Metab. 90(1):1-9 [Non-Patent Document 2] Wood et al., 2006, Brain Res. 1122(1):184-90) [Non-Patent Document 3] Buddi et al., 2002, Histochem Cytochem. 50(3):341-51 [Non-Patent Document 4] Zhou et al., 2005, Exp Eye Res. 80(4):567-80 [Non-Patent Document 5] Zhou et al., 2005, J Biol Chem. 280(27):25377-82 [Non-Patent Document 6] Pozzi et al., 2009, J Am Soc Nephrol. 20(10):2119-25 [Non-Patent Document 7] Marnett, 2002, Toxicology 181-182:219-22 Summary of the Invention [Means for solving the problem]
[0004] 3. Overview The present disclosure provides pharmaceutical compositions of compounds that react with aldehydes for treating diseases, disorders and conditions characterized by the presence of toxic aldehydes.In some embodiments, one or more toxic aldehydes are increased or improved in these diseases, disorders or conditions.In particular, the pharmaceutical compositions are injectable compositions, such as compositions that can be administered subcutaneously, intradermally, intraocularly (e.g., intravitreal or periocular), intramuscularly, intraperitoneally, or in some embodiments, intravenously.In some embodiments, the pharmaceutical compositions are depot formulations.
[0005] In one embodiment, the pharmaceutical composition comprises a compound of formula I: [ka] or a pharma- ceutically acceptable salt thereof, W, X, Y and Z are N, O, S, CU, CH and C-NH 2 and one of W, X, Y or Z is C-NH 2 and R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 Aliphatic; or R a and R b together with the carbon atom to which they are attached form a 3-8 membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; k is 0, 1, 2, 3 or 4; U is halogen, cyano, -R, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 is selected independently of R, two U's present on adjacent carbon atoms can form an optionally substituted fused ring selected from a fused phenyl ring; a fused 5-6 membered saturated or partially unsaturated fused heterocyclic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; and a fused 5-6 membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; R is hydrogen, deuterium, and C 1~6 aliphatic; a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8-10 membered bicyclic aryl ring; a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur). Includes.
[0006] In some embodiments, the pharmaceutical composition comprises a compound of formula II: [ka] or a pharma- ceutically acceptable salt thereof, R1 , R 7 and R 8 are each independently H, D, halogen, -NH 2 , -CN, -OR, -SR, C substituted as needed 1~6 Aliphatic, or [ka] and R 1 , R 7 and R 8 One of them is -NH 2 and R 1 , R 7 and R 8 The other one is [ka] and R 2 is absent or -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 Selected from R, R 3 is absent or -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 Selected from R, R 4is absent or -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 Selected from R, R 5 is absent or -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 Selected from R, R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 Aliphatic; or R a and R b together with the carbon atom to which they are attached form a 3-8 membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; R is hydrogen, deuterium, and C 1~6aliphatic; a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8-10 membered bicyclic aryl ring; a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur). Includes.
[0007] In some embodiments, the pharmaceutical composition comprises a compound of formula III: [ka] or a pharma- ceutically acceptable salt thereof, Q, T and V are independently S, N, O or -CR; R 1 , R 6 , R 7 and R 8 are each independently H, D, halogen, -NH 2 , -CN, -OR, -SR, C substituted as needed 1~6 Aliphatic, or [ka] and R 1 , R 6 , R 7 and R 8 One of them is -NH 2 and R 1 , R 6 , R 7 and R 8 The other one is [ka] and R ais C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 Aliphatic; or R a and R b together with the carbon atom to which they are attached form a 3-8 membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; R is hydrogen, deuterium, and C 1~6 aliphatic, 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl; 8-10 membered bicyclic aryl ring, 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, 6-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen and sulfur, optionally substituted groups selected from Includes.
[0008] In some embodiments, the pharmaceutical composition comprises a compound of formula I-22: [ka] or a pharma- ceutically acceptable salt thereof.
[0009] In some embodiments, the pharmaceutical composition comprises a compound of formula I-5: [ka] or a pharma- ceutically acceptable salt thereof.
[0010] In some embodiments, the pharmaceutical composition comprises a compound of formula I-6: [ka] or a pharma- ceutically acceptable salt thereof.
[0011] In one aspect, the pharmaceutical composition comprises the compound and a viscosity enhancing agent. In some embodiments, the pharmaceutical composition has a viscosity between 1 kcP and 200 kcP. In some embodiments, the pharmaceutical composition has a viscosity enhancing agent selected from hyaluronate, hyaluronic acid or a pharma- ceutically acceptable salt thereof, cross-linked hyaluronic acid, polyvinylpyrrolidone (PVP), hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, glycerol, and mixtures thereof.
[0012] In some embodiments, the viscosity enhancing agent is hyaluronate, hyaluronic acid, or a pharma- ceutically acceptable salt thereof. In some embodiments, the hyaluronate or hyaluronic acid or a pharma- ceutically acceptable salt thereof is from about 500,000 to about 5×10 6 It has a molecular weight of 100 daltons.
[0013] In some embodiments, the pharmaceutical composition comprising the compound and a viscosity enhancing agent further comprises one or more excipients selected from a tonicity agent, a buffering agent, a chelating agent, a surfactant, a preservative, and an antioxidant.
[0014] In another aspect, the pharmaceutical composition comprises a compound formulated in liposomes. In some embodiments, the liposomes are submicron sized, for example, liposomes with an average particle size of about 20 nm to about 1 um or less.
[0015] In some embodiments, the liposomes containing the compound comprise one or more of phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, gangliosides, glycolipids, phosphatidylglycerol, and cholesterol. In some embodiments, the liposome comprises at least one phosphatidylcholine selected from L-α-phosphatidylcholine, egg phosphatidylcholine (EPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-O-ethyl-3-phosphocholine, 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and mixtures thereof. In some embodiments, in addition to phosphatidylcholine or its derivative, the liposome further comprises cholesterol, or a derivative thereof suitable for forming liposomes.
[0016] In some embodiments, the liposome comprises (a) 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC); (b) egg phosphatidylcholine (EPC) and 1-α-distearoylphosphatidylcholine (DSPC); (c) egg phosphatidylcholine (EPC) or 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol or a derivative thereof; (d) dioleoylphosphatidylcholine (DOPC), dioleoylphosphatidylglycerol (DOPG) and cholesterol; or (e) dipalmitoylphosphatidylcholine (DPPC), palmitoyl-oleoylphosphatidylcholine (POPC) and cholesterol.
[0017] In another embodiment, the pharmaceutical composition comprises a compound formulated in a microparticle or nanoparticle, wherein the microparticle or nanoparticle comprises a biodegradable polymer.
[0018] In some embodiments, the microparticles or nanoparticles comprise a biodegradable polymer selected from poly(esters), poly(ester amides), poly(anhydrides), poly(carbonates), poly(amino acids), poly(amides), poly(urethanes), poly(ortho-esters), poly(iminocarbonates), poly(phosphazenes), and combinations thereof.
[0019] In some embodiments, the biodegradable polymer comprises poly(lactide-co-glycolide) (PLGA). In some embodiments, the biodegradable polymer comprises poly(ester amide).
[0020] In some embodiments, the pharmaceutical composition comprises a compound formulated in microparticles, the microparticles comprising a biodegradable polymer, hi some embodiments, the microparticles have an average particle size of about 1 um to about 250 um.
[0021] In some embodiments, the pharmaceutical composition comprises a compound formulated in nanoparticles, the nanoparticles comprising a biodegradable polymer. In some embodiments, the nanoparticles have an average particle size of less than 1 um.
[0022] In a further aspect, the pharmaceutical composition comprises a compound formulated in calcium phosphate particles.
[0023] In some embodiments, the calcium phosphate particles include tricalcium phosphate (β-TCP) or hydroxyapatite. In some embodiments, the calcium phosphate particles have an average particle size of less than 1 um.
[0024] In some embodiments, the calcium phosphate particles have a coating of polyethylene glycol or lipid. In some embodiments, the compound is disposed or absorbed onto the surface of the calcium phosphate particles.
[0025] In another embodiment, the pharmaceutical composition comprises the compound and a complexing agent selected from a polyamino acid, a galactomannan polymer or a cationic galactomannan polymer, a cellulose polymer, a quaternary ammonium polymer, and combinations thereof.
[0026] In some embodiments, the complexing agent is a polyamino acid. In some embodiments, the polyamino acid is poly-L-lysine.
[0027] In some embodiments, the complexing agent is a galactomannan polymer or a cationic galactomannan polymer.
[0028] In another embodiment, the pharmaceutical composition comprises the compound and a cyclodextrin, and the composition is suitable for parenteral administration, in particular for intraocular administration.
[0029] In some embodiments, the cyclodextrin is selected from α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, derivatives thereof, and combinations thereof. In some embodiments, the cyclodextrin is selected from carboxyalkyl cyclodextrins, hydroxyalkyl cyclodextrins, sulfoalkyl ether cyclodextrins, and alkyl cyclodextrins.
[0030] In some embodiments, the cyclodextrin is a β-cyclodextrin. In some embodiments, the β-cyclodextrin is a hydroxyalkyl-β-cyclodextrin or a sulfoalkylether-β-cyclodextrin.
[0031] In a further aspect, the pharmaceutical composition comprises a compound formulated in a hydrogel. In some embodiments, the hydrogel is a thermoresponsive, ion-responsive, or pH-responsive hydrogel.
[0032] In some embodiments, the hydrogel is composed of polyethylene oxide; polypropylene oxide; polyoxyethylene-polyoxypropylene block copolymers (e.g., poloxamer 407 and poloxamer 188); acrylic polymers such as, but not limited to, carbomer (e.g., Carbopol® 974P); polyvinylpyrrolidone; polyethylene glycol (PEG); gelatin, polyvinyl alcohol (PVA); polyhydroxyethyl methacrylate (poly-HEMA or PHEMA); cellulose; alginate; chitin, or combinations thereof.
[0033] In some embodiments, the pharmaceutical composition further comprises one or more excipients selected from a tonicity agent, a viscosity enhancing agent, a buffering agent, a chelating agent, a surfactant, a preservative, and an antioxidant.
[0034] In another aspect, the pharmaceutical compositions are used to treat a disease, disorder, or condition characterized by increased or elevated levels of toxic aldehydes.
[0035] In some embodiments, the pharmaceutical compositions are used to treat, reduce the risk of, or prevent the occurrence of ocular diseases, disorders, or conditions characterized by increased or elevated levels of toxic aldehydes. In some embodiments, the ocular diseases, disorders, or conditions are characterized by the presence of a pathological inflammatory response.
[0036] In some embodiments, the ocular disease, disorder or condition comprises macular degeneration, including age-related macular degeneration (AMD), wet age-related macular degeneration, and dry age-related macular degeneration; Stargardt's disease; dry eye syndrome or disease; cataracts; keratoconus; bullous and other keratopathy; Fuchs endothelial dystrophy; allergic conjunctivitis; ocular cicatricial pemphigoid; lacrimal gland dysfunction; uveitis, including anterior uveitis, posterior uveitis, and panuveitis; scleritis; ocular Stevens-Johnson syndrome; ocular rosacea, with or without meibomian gland dysfunction; diabetic macular edema (DME), macular edema, including non-clinically significant macular edema (non-CSME) and clinically significant macular edema (CSME); endophthalmitis; and inflammation and / or fibrosis associated with ocular injury.
[0037] In some embodiments, the ocular disease, disorder or condition treated or prevented by the pharmaceutical composition is inflammation and / or fibrosis associated with ocular injury, such as trauma to the eye or ocular surgery.
[0038] In some embodiments, the pharmaceutical composition is used to treat, reduce the risk of, or prevent the occurrence of non-ocular diseases, disorders, or conditions characterized by increased or elevated levels of toxic aldehydes.In some embodiments, non-ocular diseases, disorders, or conditions with elevated levels of toxic aldehydes include non-ocular inflammatory diseases or disorders; autoimmune diseases or disorders; neurological or neurodegenerative diseases or disorders; chronic liver diseases or disorders; chronic obstructive pulmonary diseases or disorders, and non-ocular fibrotic diseases or disorders.
[0039] In some embodiments, the disease, disorder or condition for treatment with the pharmaceutical composition is a genetic condition that has a defect in aldehyde metabolism, resulting in increased or elevated levels of toxic aldehydes. In some embodiments, the genetic disease, disorder or condition is Sjogren-Larsson syndrome or succinic semialdehyde dehydrogenase (SSADH) deficiency. [Brief description of the drawings]
[0040] [Figure 1]1A and 1B show the total ocular inflammation scores of endotoxin-induced uveitis in rats treated topically with vehicle, compound I-5, or compound I-22.
[0041] [Diagram 2] 2A and 2B show anterior chamber inflammation scores of endotoxin-induced uveitis in rats treated topically with vehicle, compound I-5, or compound I-22.
[0042] [Diagram 3] 3A and 3B show retinal-choroidal inflammation scores of endotoxin-induced uveitis in rats treated topically with vehicle, compound I-5, or compound I-22.
[0043] [Figure 4] 4A and 4B show the total ocular inflammation scores of endotoxin-induced uveitis in rats treated intravitreally with vehicle, compound I-5, or compound I-22.
[0044] [Diagram 5] 5A and 5B show anterior chamber inflammation scores of endotoxin-induced uveitis in rats treated intravitreally with vehicle, compound I-5, or compound I-22.
[0045] [Figure 6] 6A and 6B show retinal-choroidal inflammation scores of endotoxin-induced uveitis in rats treated intravitreally with vehicle, compound I-5, or compound I-22.
[0046] [Figure 7] FIG. 7 shows the effect of intravitreal administration of compound I-5 and compound I-22 on the formation of A2E in the retinas of abcr− / − mice.
[0047] [Figure 8] FIG. 8 shows retinal thickness in untreated control animals or animals with chemically induced diabetes treated with vehicle or intravitreal administration of compound I-22.
[0048] [Figure 9] FIG. 9 shows the effect on neutrophil infiltration in the eyes of untreated control animals or animals with chemically induced diabetes treated with vehicle or intravitreal administration of compound I-22.
[0049] [Figure 10] FIG. 10 shows the effects on retinal vascularity in untreated control animal eyes or in animals with chemically induced diabetes treated with vehicle or intravitreal administration of compound I-22. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0050] 4. Detailed Description The present disclosure provides pharmaceutical compositions of compounds with aldehyde scavenging activity. The pharmaceutical compositions are injectable compositions, particularly parenteral formulations such as subcutaneous, intradermal, intramuscular, intraocular (e.g., intravitreal) and intraperitoneal administration. In certain embodiments, the compositions are formulated for intravenous administration, where appropriate. In some embodiments, the pharmaceutical compositions are used to treat diseases, disorders, or conditions characterized by the presence of toxic aldehydes. In some embodiments, the pharmaceutical compositions are used to treat diseases, disorders, or conditions characterized by pathological inflammatory responses.
[0051] 4.1. Definition Compounds of the present disclosure include those generally described herein above, and are further exemplified by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this disclosure, chemical elements are defined as defined in the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75 th In addition, general principles of organic chemistry are described in "Organic Chemistry," Thomas Sorrell, University Science Books, Sausalito: 1999 and "March's Advanced Organic Chemistry," 5th Ed., the entire contents of which are incorporated herein by reference. th Ed., Smith, M. B. and March, J., eds., John Wiley & Sons, New York (2001).
[0052] "Aliphatic" or "aliphatic group," as used herein, means a linear (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is fully saturated or contains one or more units of unsaturation, or a monocyclic or bicyclic hydrocarbon that is fully saturated or contains one or more units of unsaturation, but is not aromatic (also referred to herein as "carbocyclic," "alicyclic," or "cycloalkyl"), which has one point of attachment to the remainder of the molecule. Unless otherwise specified, an aliphatic group contains 1-6 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1-5 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-4 aliphatic carbon atoms. In still other embodiments, an aliphatic group contains 1-3 aliphatic carbon atoms, and in still other embodiments, an aliphatic group contains 1-2 aliphatic carbon atoms. In some embodiments, "alicyclic" (or "carbocycle" or "cycloalkyl") refers to a monocyclic C ring that is fully saturated or contains one or more units of unsaturation, but is not aromatic. 3 ~C 6 refers to a hydrocarbon, which has one point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl groups, alkenyl groups, alkynyl groups, and hybrids thereof, such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl, or (cycloalkyl)alkenyl.
[0053] "Lower alkyl" is C 1~4 It refers to a straight or branched chain alkyl group. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.
[0054] "Lower haloalkyl" refers to a straight or branched C alkyl group substituted with one or more halogen atoms. 1~4 Refers to an alkyl group.
[0055] "Heteroatom" refers to oxygen, sulfur, nitrogen, phosphorus, or silicon (including any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or substitutable nitrogen of a heterocyclic ring, e.g., N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR + (as in N-substituted pyrrolidinyl)).
[0056] "Unsaturated," as used herein, means that a moiety has one or more units of unsaturation.
[0057] "Divalent C 1~8 (or C 1~6 ) Saturated or unsaturated, straight or branched hydrocarbon chain" refers to divalent straight or branched alkylene, alkenylene, and alkynylene chains, as defined herein.
[0058] "Alkylene" refers to a divalent alkyl group. An "alkylene chain" is a polymethylene group, i.e., -(CH 2 ) n - and n is a positive integer, preferably 1 to 6, 1 to 4, 1 to 3, 1 to 2 or 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced by a substituent. Suitable substituents include those described below for substituted aliphatic groups.
[0059] "Alkenylene" refers to a divalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced by a substituent. Suitable substituents include those described below for substituted aliphatic groups.
[0060] "Halogen" means F, Cl, Br or I.
[0061] "Aryl," used alone or as part of a larger moiety such as in "aralkyl," "aralkoxy," or "aryloxyalkyl," refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, at least one ring in these systems is aromatic, and each ring in these systems contains three to seven ring members. The term "aryl" can be used interchangeably with the term "aryl ring."
[0062] "Aryl," used alone or as part of a larger moiety, such as in "aralkyl," "aralkoxy," or "aryloxyalkyl," refers to monocyclic and bicyclic ring systems having a total of 5-10 ring members, in which at least one ring in these systems is aromatic, and in which each ring in these systems contains 3-7 ring members. The term "aryl" can be used interchangeably with the term "aryl ring." In certain embodiments of the invention, "aryl" refers to aromatic ring systems, including but not limited to phenyl, biphenyl, naphthyl, anthracyl, and the like, which may bear one or more substituents. Similarly, the scope of the term "aryl," as used herein, also includes groups in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthoimidyl, phenanthridinyl, or tetrahydronaphthyl.
[0063] "Heteroaryl" and "heteroar-" used alone or as part of a larger moiety, such as "heteroaralkyl" or "heteroaralkoxy", refer to heteroaryl groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms, a cyclic group, or a cyclic arrangement. refers to a group having 6, 10, or 14 pi-electrons shared among them, and having from 1 to 5 heteroatoms in addition to the carbon atoms. The term "heteroatom" refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, but are not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms "heteroaryl" and "heteroar-" Also includes groups in which a heteroaromatic ring is fused to one or more aryl, alicyclic or heterocyclyl rings, and the radical or point of attachment is on the heteroaromatic ring. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzothiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl and pyrido[2,3-b]-1,4-oxazin-3(4H)-one. Heteroaryl groups can be monocyclic or bicyclic. The term "heteroaryl" can be used interchangeably with the terms "heteroaryl ring," "heteroaryl group," or "heteroaromatic," any of which terms include rings that are optionally substituted. The term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl, where the alkyl and heteroaryl portions independently are optionally substituted.
[0064] "Heterocycle", "heterocyclyl", "heterocyclic radical" and "heterocyclic ring" are used interchangeably and refer to a stable 5-7 membered monocyclic or 7-10 membered bicyclic heterocyclic moiety, either saturated or partially unsaturated, having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen can be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or . + It may also be NR (as in the case of N-substituted pyrrolidinyl).
[0065] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure, and any of these ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, but are not limited to, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms "heterocycle", "heterocyclyl", "heterocyclyl ring", "heterocyclic group", "heterocyclic moiety" and "heterocyclic radical" are used interchangeably herein and include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl or alicyclic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl or tetrahydroquinolinyl, where the radicals or points of attachment are on the heterocyclyl ring. Heterocyclyl groups can be monocyclic or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted by a heterocyclyl, where the alkyl and heterocyclyl moieties, independently, are optionally substituted.
[0066] "Partially unsaturated" refers to a ring moiety that contains at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as defined herein.
[0067] As described herein, the compounds of the invention may contain "optionally substituted" moieties. In general, the term "substituted", whether preceded by the term "optionally" or not, means that one or more hydrogens of the specified moiety are replaced with suitable substituents. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be the same or different at each position. The combination of substituents envisioned by the present invention is preferably one that results in the formation of a stable or chemically feasible compound. The term "stable" as used herein refers to a compound that is not substantially altered when subjected to conditions that allow for its production, detection, and, in certain embodiments, its recovery, purification, and use for one or more purposes disclosed herein.
[0068] Suitable monovalent substituents on a substitutable carbon atom of an "optionally substituted" group are independently halogen, -(CH 2 ) 0~4 R°;-(CH 2 ) 0~4 OR°;-O(CH 2 ) 0~4 R o , -O-(CH 2 ) 0~4 C(O)OR°;-(CH 2 ) 0~4 CH(OR°) 2 ;-(CH 2 ) 0~4SR°; optionally substituted by R° -(CH 2 ) 0~4 Ph; optionally substituted by R° -(CH 2 ) 0~4 O(CH 2 ) 0~1 Ph; -CH=CH, optionally substituted by R°; -(CH 2 ) 0~4 O(CH 2 ) 0~1 -Pyridyl; -NO 2 ;-CN;-N 3 ;-(CH 2 ) 0~4 N(R°) 2 ;-(CH 2 ) 0~4 N(R°)C(O)R°;-N(R°)C(S)R°;-(CH 2 ) 0~4 N(R°)C(O)NR° 2 ;-N(R°)C(S)NR° 2 ;-(CH 2 ) 0~4 N(R°)C(O)OR°;-N(R°)N(R°)C(O)R°;-N(R°)N(R°)C(O)NR° 2 ;-N(R°)N(R°)C(O)OR°;-(CH 2 ) 0~4 C(O)R°;-C(S)R°;-(CH 2 ) 0~4 C(O)OR°;-(CH 2 ) 0~4 C(O)SR°;-(CH 2 ) 0~4 C(O)OSiR° 3 ;-(CH 2 ) 0~4 OC(O)R°;-OC(O)(CH 2 ) 0~4 SR-, SC(S)SR°;-(CH 2 ) 0~4 SC(O)R°;-(CH 2 ) 0~4 C(O)NR° 2 ;-C(S)NR° 2 ;-C(S)SR°;-SC(S)SR°,-(CH 2 )0~4 OC(O)NR° 2 ;-C(O)N(OR°)R°;-C(O)C(O)R°;-C(O)CH 2 C(O)R°;-C(NOR°)R°;-(CH 2 ) 0~4 SSR°;-(CH 2 ) 0~4 S(O) 2 R°;-(CH 2 ) 0~4 S(O) 2 OR°;-(CH 2 ) 0~4 OS(O) 2 R°;-S(O) 2 NR° 2 ;-(CH 2 ) 0~4 S(O)R°;-N(R°)S(O) 2 NR° 2 ;-N(R°)S(O) 2 R°;-N(OR°)R°;-C(NH)NR° 2 ;-P(O) 2 R°;-P(O)R° 2 ;-OP(O)R° 2 ;-OP(O)(OR°) 2 ;SiR° 3 ;-(C 1~4 Linear or branched alkylene)ON(R°) 2 ; or -(C 1~4 Linear or branched alkylene)C(O)ON(R°) 2 wherein each R° is optionally substituted as defined below and is independently hydrogen, C 1~6 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0~1 Ph, -CH 2-(5-6 membered heteroaryl ring), or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, or, where as defined above, two independently occurring R° together with their intervening atoms form a 3-12 membered saturated monocyclic or bicyclic ring, partially unsaturated monocyclic or bicyclic ring, or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, which may be substituted as defined below.
[0069] Suitable monovalent substituents on R° (or the ring formed by two independently occurring R° taken together with their intervening atoms) are independently halogen, -(CH 2 ) 0~2 R ● , -(Halo R ● ), -(CH 2 ) 0~2 OH, -(CH 2 ) 0~2 OR ● , -(CH 2 ) 0~2 CH(OR ● ) 2 ;-O(HaloR ● ), -CN, -N 3 , -(CH 2 ) 0~2 C(O)R ● , -(CH 2 ) 0~2 C(O)OH, -(CH 2 ) 0~2 C(O)OR ● , -(CH 2 ) 0~2 S.R. ● , -(CH 2 ) 0~2 SH, -(CH 2 ) 0~2 NH 2 , -(CH 2 ) 0~2 NHR ● , -(CH 2 ) 0~2 NR ● 2 , -NO2 , -SiR ● 3 , -OSiR ● 3 , -C(O)SR ● , -(C 1~4 Linear or branched alkylene)C(O)OR ● Or -SSR ● and R ● Each of is unsubstituted or, if preceded by "halo", substituted only with one or more halogens; 1~4 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0~1 and a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =O and =S.
[0070] Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include the following: =O, =S, =NNR * 2 , =NNHC(O)R * , =NNHC(O)OR * , =NNHS(O) 2 R * , =NR * , =NOR * , -O(C(R * 2 )) 2~3 O- or -S(C(R * 2 )) 2~3 S- is included and exists independently. * each represents hydrogen, C which may be substituted as defined below 1~6 The "optionally substituted" group is selected from the group consisting of aliphatic and unsubstituted 5-6 membered saturated, partially unsaturated, or aryl rings having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Preferred divalent substituents attached to adjacent substitutable carbon atoms of the "optionally substituted" group include -O(CR * 2 ) 2~3O- and independently existing R * each represents hydrogen, C which may be substituted as defined below 1~6 It is selected from aliphatic and unsubstituted 5-6 membered saturated, partially unsaturated or aryl rings having 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0071] R * Suitable substituents on the aliphatic groups include halogen, -R ● , -(Halo R ● ), -OH, -OR ● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH 2 , -NHR ● , -NR ● 2 OR -NO 2 Contains R ● each is unsubstituted or, when preceded by "halo", substituted with only one or more halogens, and independently represents C 1~4 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0~1 Ph, or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0072] Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R † , -NR † 2 , -C(O)R † , -C(O)OR † , -C(O)C(O)R † , -C(O)CH 2 C(O)R † , -S(O) 2 R † , -S(O) 2 NR † 2 , -C(S)NR † 2 , -C(NH)NR† 2 or -N(R † )S(O) 2 R † Contains R † each independently represents hydrogen, C which may be substituted as defined below 1~6 aliphatic, unsubstituted -OPh, or an unsubstituted 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, or, even if defined above, two independently present R † together with their intervening atoms form an unsubstituted 3-12 membered saturated monocyclic or bicyclic ring, partially unsaturated monocyclic or bicyclic ring, or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0073] R † Suitable substituents on the aliphatic groups are independently halogen, -R ● , -(Halo R ● ), -OH, -OR ● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH 2 , -NHR ● , -NR ● 2 OR -NO 2 and R ● each is unsubstituted or, when preceded by "halo", substituted with only one or more halogens, and independently represents C 1~4 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0~1 Ph, or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0074] "Pharmaceutically acceptable salt" refers to a salt that is suitable for use in contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic reaction, etc., within the scope of sound medical judgment, and is commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference, describes pharma- ceutically acceptable salts in detail. The pharmaceutically acceptable salts of the compounds of the present invention include those derived from suitable inorganic and organic acids and inorganic and organic bases.The examples of pharmaceutically acceptable non-toxic acid addition salts are the salts of amino groups formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid, or organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid, or by using other methods used in the art such as ion exchange. Other pharma- ceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, proline, and the like. These include pionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like.
[0075] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+ (C 1~4 Alkyl) 4 Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc. Additionally, pharma- ceutically acceptable salts include, where appropriate, non-toxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkylsulfonate, and arylsulfonate.
[0076] Unless otherwise indicated, the structures depicted herein are also intended to include all isomers of the structures (e.g., enantiomers, diastereomeric isomers, and geometric (or conformational) isomers), such as the R and S configurations, Z and E double bond isomers, and Z and E conformational isomers, for each asymmetric center. Thus, single stereochemical isomers, as well as mixtures of enantiomeric, diastereomeric, and geometric (or conformational) isomers of the compounds are within the scope of the invention. Unless otherwise indicated, all tautomers of the compounds of the invention are within the scope of the invention.
[0077] "Bioerodible polymer" refers to a polymer that degrades in vivo. Erosion of the polymer over time results in the release of the active agent. By way of example and without limitation, hydrogels such as methylcellulose, which act to release drugs by polymer swelling, are specifically excluded from the term "bierodible (or biodegradable) polymer. The words "bierodible" and "biodegradable" are synonymous and are used interchangeably herein.
[0078] "Pharmaceutically acceptable" means, for example, a carrier, diluent, or excipient that is compatible with the other ingredients of the formulation and is generally safe for administration to a recipient thereof or does not elicit undesired adverse physical reactions upon administration.
[0079] 4.2. Compounds for use in pharmaceutical compositions In one aspect, the pharmaceutical compositions herein, such as for parenteral formulations, comprise a compound of formula I: [ka] or a pharma- ceutically acceptable salt thereof, W, X, Y and Z are N, O, S, CU, CH and C-NH 2 and one of W, X, Y or Z is C-NH 2 and R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 Aliphatic; or R a and R b together with the carbon atom to which they are attached form a 3-8 membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; k is 0, 1, 2, 3 or 4; U is halogen, cyano, -R, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 is selected independently of R, two U's present on adjacent carbon atoms can form an optionally substituted fused ring selected from a fused phenyl ring; a fused 5-6 membered saturated or partially unsaturated fused heterocyclic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; and a fused 5-6 membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; R is hydrogen, deuterium, and C 1~6 aliphatic; a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8-10 membered bicyclic aryl ring; a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur). Includes.
[0080] In some embodiments, -C-NH 2 Group and -CR a R b The OH groups are present on adjacent carbon atoms of the depicted ring of formula I.
[0081] As defined above and described herein, W is N, O, S, CU, CH and C—NH 2 In some embodiments, W is N. In some embodiments, W is O. In some embodiments, W is S. In some embodiments, W is CU. In some embodiments, W is CH. In some embodiments, W is C-NH 2 It is.
[0082] As defined above and described herein, X is N, O, S, CU, CH and C—NH2 In some embodiments, X is independently selected from the following: In some embodiments, X is N. In some embodiments, X is O. In some embodiments, X is S. In some embodiments, X is CU. In some embodiments, X is CH. In some embodiments, X is C—NH 2 It is.
[0083] As defined above and described herein, Y is N, O, S, CU, CH and C—NH 2 In some embodiments, Y is N. In some embodiments, Y is O. In some embodiments, Y is S. In some embodiments, Y is CU. In some embodiments, Y is CH. In some embodiments, Y is C—NH 2 It is.
[0084] As defined above and described herein, Z is N, O, S, CU, CH and C—NH 2 In some embodiments, Z is independently selected from: In some embodiments, Z is N. In some embodiments, Z is O. In some embodiments, Z is S. In some embodiments, Z is CU. In some embodiments, Z is CH. In some embodiments, Z is C—NH 2 It is.
[0085] As defined above and described herein, k is 0, 1, 2, 3, or 4. In some embodiments, k is 0. In some embodiments, k is 1. In some embodiments, k is 2. In some embodiments, k is 3. In some embodiments, k is 4.
[0086] As defined above and as described herein, each U is halogen, cyano, -R, -OR, -SR, -N(R), 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2, -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 is selected independently from R.
[0087] In some embodiments, U is a halogen. In some embodiments, U is a fluorine. In some embodiments, U is a chlorine. In some embodiments, U is a bromine.
[0088] In some embodiments, U is -R. In some embodiments, U is hydrogen. In some embodiments, U is deuterium. In some embodiments, U is an optionally substituted C 1~6 It is aliphatic. In some embodiments, U is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, U is an optionally substituted 8-10 membered bicyclic aryl ring. In some embodiments, U is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, U is an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, U is an optionally substituted 6-10 membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, U is an optionally substituted 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0089] In some embodiments, U is -S(O) 2 In some embodiments, U is -S(O) 2 CH 3 It is.
[0090] In some embodiments, U is an optionally substituted phenyl ring. In some embodiments, U is an optionally halogen substituted phenyl ring. In some embodiments, U is an optionally fluorine substituted phenyl ring. In some embodiments, U is an optionally chlorine substituted phenyl ring.
[0091] As defined above and described herein, two U's present on adjacent carbon atoms can form an optionally substituted fused ring selected from a fused phenyl ring; a 5-6 membered saturated or partially unsaturated fused heterocyclic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; and a 5-6 membered fused heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0092] In some embodiments, two Us present on adjacent carbon atoms form a fused phenyl ring. In some embodiments, two Us present on adjacent carbon atoms form a fused phenyl ring that is optionally substituted. In some embodiments, two Us present on adjacent carbon atoms form a fused phenyl ring that is optionally substituted with one or more halogen atoms. In some embodiments, two Us present on adjacent carbon atoms form a fused phenyl ring that is optionally substituted with one halogen atom. In some embodiments, two Us present on adjacent carbon atoms form a fused phenyl ring that is optionally substituted with fluorine. In some embodiments, two Us present on adjacent carbon atoms form a fused phenyl ring that is optionally substituted with chlorine. In some embodiments, two Us present on adjacent carbon atoms form a fused phenyl ring that is optionally substituted with two halogen atoms. In some embodiments, two Us present on adjacent carbon atoms form a fused phenyl ring that is optionally substituted with two fluorines. In some embodiments, two Us present on adjacent carbon atoms form a fused phenyl ring that is optionally substituted with two chlorines. In some embodiments, two Us present on adjacent carbon atoms form a fused phenyl ring that is optionally substituted with fluorine and chlorine.
[0093] In some embodiments, two U's on adjacent carbon atoms form a 5-6 membered fused heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, two U's on adjacent carbon atoms form a 5-6 membered fused heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, which is optionally substituted.
[0094] In some embodiments, two U's on adjacent carbon atoms form a 5-membered fused heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, two U's on adjacent carbon atoms form an optionally substituted 5-membered fused heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0095] In some embodiments, two U's on adjacent carbon atoms form a 5-membered fused heteroaryl ring containing one nitrogen heteroatom and one oxygen heteroatom. In some embodiments, two U's on adjacent carbon atoms form a 5-membered fused heteroaryl ring containing one nitrogen heteroatom and one oxygen heteroatom, optionally substituted. In some embodiments, two U's on adjacent carbon atoms form a 5-membered fused heteroaryl ring containing one nitrogen heteroatom and one oxygen heteroatom, optionally substituted with phenyl. In some embodiments, two U's on adjacent carbon atoms form a 5-membered fused heteroaryl ring containing one nitrogen heteroatom and one oxygen heteroatom, optionally substituted with tosyl. In some embodiments, two U's on adjacent carbon atoms form a 5-membered fused heteroaryl ring containing one nitrogen heteroatom and one oxygen heteroatom, optionally substituted with C 1~6 In some embodiments, two U's on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing one nitrogen heteroatom and one oxygen heteroatom, optionally substituted with an aliphatic group. 1~6 Form a 5-membered fused heteroaryl ring containing one nitrogen heteroatom and one oxygen heteroatom, optionally substituted with alkyl. In some embodiments, two U's present on adjacent carbon atoms form a 5-membered fused heteroaryl ring containing one nitrogen heteroatom and one oxygen heteroatom, optionally substituted with cyclopropyl.
[0096] In some embodiments, two U's on adjacent carbon atoms form a 5-membered fused heteroaryl ring containing one nitrogen heteroatom and one sulfur heteroatom. In some embodiments, two U's on adjacent carbon atoms form a 5-membered fused heteroaryl ring containing one nitrogen heteroatom and one sulfur heteroatom, which is optionally substituted. In some embodiments, two U's on adjacent carbon atoms form a 5-membered fused heteroaryl ring containing one nitrogen heteroatom and one sulfur heteroatom, which is optionally substituted with phenyl.
[0097] In some embodiments, two U's on adjacent carbon atoms form a 5-membered fused heteroaryl ring containing two nitrogen heteroatoms. In some embodiments, two U's on adjacent carbon atoms form a 5-membered fused heteroaryl ring containing two nitrogen heteroatoms, optionally substituted. In some embodiments, two U's on adjacent carbon atoms form a 5-membered fused heteroaryl ring containing two nitrogen heteroatoms, optionally substituted with phenyl.
[0098] In some embodiments, two U's on adjacent carbon atoms form a 6-membered fused heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, two U's on adjacent carbon atoms form an optionally substituted 6-membered fused heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0099] In some embodiments, two U's on adjacent carbon atoms form a 6-membered fused heteroaryl ring containing one nitrogen heteroatom. In some embodiments, two U's on adjacent carbon atoms form a 6-membered fused heteroaryl ring containing one nitrogen heteroatom, which is optionally substituted. In some embodiments, two U's on adjacent carbon atoms form a 6-membered fused heteroaryl ring containing two nitrogen heteroatoms. In some embodiments, two U's on adjacent carbon atoms form a 6-membered fused heteroaryl ring containing two nitrogen heteroatoms, which is optionally substituted.
[0100] In some embodiments, the fused ring system formed by two U's present on adjacent carbon atoms is quinazolinyl. In some embodiments, the fused ring system formed by two U's present on adjacent carbon atoms is an optionally substituted quinazolinyl.
[0101] In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is quinolinyl. In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is optionally substituted quinolinyl. In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is quinolinyl optionally substituted with 1-2 halogen atoms. In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is quinolinyl optionally substituted with one halogen atom. In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is quinolinyl optionally substituted with fluorine. In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is quinolinyl optionally substituted with chlorine.
[0102] In some embodiments, the fused ring system formed by two Us on adjacent carbon atoms is benzoxazolyl. In some embodiments, the fused ring system formed by two Us on adjacent carbon atoms is benzoxazolyl, optionally substituted with phenyl. In some embodiments, the fused ring system formed by two Us on adjacent carbon atoms is benzoxazolyl, optionally substituted with phenyl and halogen atoms. In some embodiments, the fused ring system formed by two Us on adjacent carbon atoms is benzoxazolyl, optionally substituted with phenyl and chlorine. In some embodiments, the fused ring system formed by two Us on adjacent carbon atoms is benzoxazolyl, optionally substituted with tosyl and chlorine.
[0103] In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is benzisoxazolyl. In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is benzisoxazolyl, which is optionally substituted. In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is benzisoxazolyl, which is optionally substituted with phenyl. In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is benzisoxazolyl, which is optionally substituted with cyclopropyl and halogen atoms. In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is benzisoxazolyl, which is optionally substituted with cyclopropyl and chlorine.
[0104] In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is benzothiazolyl. In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is an optionally substituted benzothiazolyl. In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is an optionally substituted benzothiazolyl. In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is an optionally substituted phenyl.
[0105] In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is benzisothiazolyl. In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is an optionally substituted benzisothiazolyl. In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is an optionally substituted benzisothiazolyl with phenyl.
[0106] In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is benzimidazolyl. In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is an optionally substituted benzimidazolyl. In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is an optionally substituted benzimidazolyl. In some embodiments, the fused ring system formed by two U's on adjacent carbon atoms is an optionally substituted benzimidazolyl with phenyl.
[0107] In some embodiments, W, X, Y and Z result in a phenyl ring. In some embodiments, W, X, Y and Z result in a phenyl ring substituted with k U's present. In some embodiments, where W, X, Y and Z result in a phenyl ring, one of W, X, Y and Z is -C-NH 2 It is.
[0108] In some embodiments, W, X, Y and Z result in a pyridinyl ring. In some embodiments, W, X, Y and Z result in a pyridinyl ring substituted with k U's present. In some embodiments, W, X, Y and Z result in a pyridinyl ring, one of W, X, Y and Z is -C-NH 2 It is.
[0109] In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y and Z is CH and k is 0. In some embodiments, one of W, X and Y is -C-NH 2 and one or more of W, X or Y is CH; Z is N; and k is 0.
[0110] In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 1 and U is a halogen. In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 1 and U is fluorine. In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 1 and U is chlorine. In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 1 and U is bromine.
[0111] In some embodiments, one of W, X and Y is -C-NH 2 and one or more of W, X, and Y are CH, Z is N, k is 1, and U is optionally substituted phenyl. In some embodiments, one of W, X, and Y is -C-NH 2and one or more of W, X, and Y are CH, Z is N, k is 1, and U is phenyl optionally substituted with halogen. In some embodiments, one of W, X, and Y is -C-NH 2 and one or more of W, X, and Y are CH, Z is N, k is 1, and U is phenyl optionally substituted with chlorine. In some embodiments, one of W, X, and Y is -C-NH 2 and one or more of W, X and Y are CH, Z is N, k is 1 and U is phenyl optionally substituted with fluorine.
[0112] In some embodiments, W is N and one of X, Y and Z is -C-NH 2 and the remaining X, Y and Z are CH, k is 1 and U is optionally substituted phenyl. In some embodiments, W is N and one of X, Y and Z is -C-NH 2 and the remaining X, Y and Z are CH, k is 1 and U is phenyl optionally substituted with halogen. In some embodiments, W is N and one of X, Y and Z is -C-NH 2 and the remaining X, Y and Z are CH, k is 1 and U is phenyl optionally substituted with chlorine. In some embodiments, W is N and one of X, Y and Z is -C-NH 2 and each of X, Y and Z is CH, k is 1 and U is phenyl optionally substituted with fluorine.
[0113] In some embodiments, one of W, X and Y is -C-NH 2 and one or more of W, X, and Y are CH, Z is N, k is 2, and two U's on adjacent carbon atoms form a fused phenyl ring. In some embodiments, one of W, X, and Y is -C-NH 2and one or more of W, X, and Y are CH, Z is N, k is 2, and two U's on adjacent carbon atoms form an optionally substituted fused phenyl ring. In some embodiments, one of W, X, and Y is -C-NH 2 and one or more of W, X, and Y are CH, Z is N, k is 2, and two U's on adjacent carbon atoms form a fused phenyl ring optionally substituted with halogen. In some embodiments, one of W, X, and Y is -C-NH 2 and one or more of W, X, and Y are CH, Z is N, k is 2, and two U's on adjacent carbon atoms form a fused phenyl ring optionally substituted with chlorine. In some embodiments, one of W, X, and Y is -C-NH 2 and one or more of W, X and Y is CH, Z is N, k is 2, and two U's on adjacent carbon atoms form a fused phenyl ring optionally substituted with fluorine.
[0114] In some embodiments, W is N and one of X, Y and Z is -C-NH 2 and the remaining X, Y and Z are CH, k is 2, and two U's on adjacent carbon atoms form a fused phenyl ring. In some embodiments, W is N and one of X, Y and Z is -C-NH 2 and the remaining X, Y and Z are CH, k is 2, and two U's on adjacent carbon atoms form an optionally substituted fused phenyl ring. In some embodiments, W is N and one of X, Y and Z is -C-NH 2 and the remaining X, Y and Z are CH, k is 2, and two U's on adjacent carbon atoms form a fused phenyl ring, optionally substituted with halogen. In some embodiments, W is N and one of X, Y and Z is -C-NH 2and the remaining X, Y and Z are CH, k is 2, and two U's on adjacent carbon atoms form a fused phenyl ring, optionally substituted with fluorine. In some embodiments, W is N and one of X, Y and Z is -C-NH 2 and the remaining X, Y and Z are CH, k is 2, and two U's on adjacent carbon atoms form a fused phenyl ring, optionally substituted with chlorine. In some embodiments, W is N and one of X, Y and Z is -C-NH 2 and the remaining X, Y and Z are CH, k is 2, and two U's on adjacent carbon atoms form a fused phenyl ring, optionally substituted with chlorine and fluorine. In some embodiments, W is N and one of X, Y and Z is -C-NH 2 and the remaining X, Y and Z are CH, k is 2, and two U's on adjacent carbon atoms form a fused phenyl ring optionally substituted at the 2-position with chlorine.
[0115] In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y, and Z is CH, k is 2, and two U's on adjacent carbon atoms form a 5-6 membered fused heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, one of W, X, Y, and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 2, and two U's on adjacent carbon atoms form a fused, optionally substituted, 5-6 membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0116] In some embodiments, one of W, X, Y and Z is -C-NH 2and one or more of W, X, Y, and Z are CH, k is 2, and two U's on adjacent carbon atoms form an optionally substituted 6-membered fused heteroaryl ring containing one nitrogen heteroatom. In some embodiments, one of W, X, Y, and Z is -C-NH 2 and one or more of W, X, Y, and Z are CH, k is 2, and two U's on adjacent carbon atoms form a fused pyridine ring. In some embodiments, one of W, X, Y, and Z is -C-NH 2 and one or more of W, X, Y, and Z are CH, k is 2, and two U's on adjacent carbon atoms form an optionally substituted fused pyridine ring. In some embodiments, one of W, X, Y, and Z is -C-NH 2 and one or more of W, X, Y, and Z are CH, k is 2, and two U's on adjacent carbon atoms form an optionally substituted 6-membered fused heteroaryl ring containing two nitrogen heteroatoms. In some embodiments, one of W, X, Y, and Z is -C-NH 2 and one or more of W, X, Y, and Z is CH, k is 2, and two U's on adjacent carbon atoms form a fused pyrimidine ring. In some embodiments, one of W, X, Y, and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 2, and two U's on adjacent carbon atoms form an optionally substituted fused pyrimidine ring.
[0117] In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y, and Z are CH, k is 2, and two U's on adjacent carbon atoms form a fused aryl ring with two heteroatoms. In some embodiments, one of W, X, Y, and Z is -C-NH 2and one or more of W, X, Y, and Z are CH, k is 2, and two U's on adjacent carbon atoms form a fused 5-membered oxazole ring. In some embodiments, one of W, X, Y, and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 2, and two U's on adjacent carbon atoms form a fused 5-membered oxazole ring optionally substituted with phenyl.
[0118] In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y, and Z are CH, k is 2, and two U's on adjacent carbon atoms form an optionally substituted 5-membered fused heteroaryl ring containing one nitrogen heteroatom and one oxygen heteroatom. In some embodiments, one of W, X, Y, and Z is -C-NH 2 and one or more of W, X, Y, and Z are CH, k is 2, and two U's on adjacent carbon atoms form a 5-membered fused heteroaryl ring containing one nitrogen heteroatom and one oxygen heteroatom, optionally substituted with phenyl. In some embodiments, one of W, X, Y, and Z is -C-NH 2 and one or more of W, X, Y and Z are CH, k is 2, and two U's on adjacent carbon atoms form a 5-membered fused heteroaryl ring containing one nitrogen heteroatom and one oxygen heteroatom, optionally substituted with tosyl. In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 2, and two U's on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing one nitrogen heteroatom and one oxygen heteroatom, optionally substituted with cyclopropyl.
[0119] In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y, and Z are CH, k is 2, and two U's on adjacent carbon atoms form an optionally substituted fused oxazole ring. In some embodiments, one of W, X, Y, and Z is -C-NH 2 and one or more of W, X, Y and Z are CH, k is 2, and two U's on adjacent carbon atoms form a fused oxazole ring, optionally substituted with phenyl. In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 2, and two U's on adjacent carbon atoms form a fused oxazole ring, optionally substituted with tosyl.
[0120] In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y, and Z are CH, k is 2, and two U's on adjacent carbon atoms form an optionally substituted fused isoxazole ring. In some embodiments, one of W, X, Y, and Z is -C-NH 2 and one or more of W, X, Y and Z are CH, k is 2, and two U's on adjacent carbon atoms form a fused isoxazole ring, optionally substituted with phenyl. In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 2, and two U's on adjacent carbon atoms form a fused isoxazole ring, optionally substituted with cyclopropyl.
[0121] In some embodiments, one of W, X, Y and Z is -C-NH 2and one or more of W, X, Y, and Z are CH, k is 2, and two U's on adjacent carbon atoms form an optionally substituted 5-membered fused heteroaryl ring containing one nitrogen heteroatom and one sulfur heteroatom. In some embodiments, one of W, X, Y, and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 2, and two U's on adjacent carbon atoms form a fused 5-membered heteroaryl ring containing one nitrogen heteroatom and one sulfur heteroatom, optionally substituted with phenyl.
[0122] In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y, and Z are CH, k is 2, and two U's on adjacent carbon atoms form an optionally substituted fused thiazole ring. In some embodiments, one of W, X, Y, and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 2, and two U's on adjacent carbon atoms form a fused thiazole ring, optionally substituted with phenyl.
[0123] In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y, and Z are CH, k is 2, and two U's on adjacent carbon atoms form an optionally substituted 5-membered fused heteroaryl ring containing two nitrogen heteroatoms. In some embodiments, one of W, X, Y, and Z is -C-NH 2 and one or more of W, X, Y and Z are CH, k is 2, and two U's on adjacent carbon atoms form an optionally substituted fused imidazole ring. In some embodiments, one of W, X, Y and Z is -C-NH 2and one or more of W, X, Y and Z is CH, k is 2, and two U's on adjacent carbon atoms form a fused imidazole ring optionally substituted with phenyl.
[0124] In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 3, and U 1 is chlorine and U on the adjacent carbon atom 2 and U 3 forms an optionally substituted 5-membered fused heteroaryl ring containing one nitrogen heteroatom and one oxygen heteroatom. In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 3, and U 1 is chlorine and U on the adjacent carbon atom 2 and U 3 forms a 5-membered fused heteroaryl ring containing one nitrogen heteroatom and one oxygen heteroatom, optionally substituted with phenyl. In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 3, and U 1 is chlorine and U on the adjacent carbon atom 2 and U 3 forms a 5-membered fused heteroaryl ring containing one nitrogen heteroatom and one oxygen heteroatom, optionally substituted with tosyl.
[0125] In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 3, and U 1 is chlorine and U on the adjacent carbon atom 2 and U 3form an optionally substituted fused oxazole ring. In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 3, and U 1 is chlorine and U on the adjacent carbon atom 2 and U 3 forms a fused oxazole ring, optionally substituted with phenyl. In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 3, and U 1 is chlorine and U on the adjacent carbon atom 2 and U 3 forms a fused oxazole ring optionally substituted with tosyl.
[0126] In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 3, and U 1 is chlorine and U on the adjacent carbon atom 2 and U 3 forms an optionally substituted fused isoxazole ring. In some embodiments, one of W, X, Y and Z is -C-NH 2 and one or more of W, X, Y and Z is CH, k is 3, and U 1 is chlorine and U on the adjacent carbon atom 2 and U 3 forms a fused isoxazole ring which is optionally substituted by cyclopropyl.
[0127] R is hydrogen, deuterium, and C, as defined above and described herein. 1~6and optionally substituted groups selected from aliphatic; a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8-10 membered bicyclic aryl ring; a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0128] In some embodiments, R is hydrogen. In some embodiments, R is deuterium. In some embodiments, R is C 1~6 In some embodiments, R is an optionally substituted C 1~6 In some embodiments, R is an optionally substituted methyl. In some embodiments, R is an optionally substituted ethyl. In some embodiments, R is a phenyl. In some embodiments, R is an optionally substituted phenyl. In some embodiments, R is a phenyl optionally substituted with halogen. In some embodiments, R is a phenyl optionally substituted with fluorine.
[0129] As generally described above, R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic.
[0130] In some embodiments, R a is C 1~4 In some embodiments, R a is C optionally substituted with one, two or three deuterium atoms 1~4In some embodiments, R a is C optionally substituted by 1, 2 or 3 halogen atoms; 1~4 It is aliphatic.
[0131] In some embodiments, R a is C 1~4 In some embodiments, R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 In some embodiments, R a is C optionally substituted by 1, 2 or 3 halogen atoms; 1~4 In some embodiments, R a is methyl or ethyl, optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R a is methyl.
[0132] As generally defined above, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic.
[0133] In some embodiments, R b is C 1~4 In some embodiments, R b is C optionally substituted with one, two or three deuterium atoms 1~4 In some embodiments, R b is C optionally substituted by 1, 2 or 3 halogen atoms; 1~4 It is aliphatic.
[0134] In some embodiments, R b is C 1~4 In some embodiments, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4In some embodiments, R b is C optionally substituted by 1, 2 or 3 halogen atoms; 1~4 In some embodiments, R b is methyl or ethyl, optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R b is methyl.
[0135] As generally defined above, in some embodiments, R a and R b together with the carbon atom to which they are attached form a 3-8 membered cycloalkyl or heterocyclyl ring containing 1 to 2 heteroatoms selected from nitrogen, oxygen and sulfur.
[0136] In some embodiments, R a and R b together with the carbon atom to which they are attached form a 3-8 membered cycloalkyl ring. a and R b together with the carbon atom to which they are attached form a 3-8 membered heterocyclyl ring containing 1 to 2 heteroatoms selected from nitrogen, oxygen and sulfur.
[0137] In some embodiments, R a and R b together with the carbon atom to which they are attached form a cyclopropyl ring, a cyclobutyl ring, or a cyclopentyl ring. a and R b together with the carbon atom to which they are attached form an oxirane, oxetane, tetrahydrofuran, or aziridine.
[0138] In some embodiments, R a and R b is methyl.
[0139] In some embodiments, the pharmaceutical composition comprises a compound of formula II: [ka] or a pharma- ceutically acceptable salt thereof, R 1 , R 7 and R 8 are each independently H, D, halogen, -NH 2 , -CN, -OR, -SR, C substituted as needed 1~6 Aliphatic, or [ka] and R 1 , R 7 and R 8 One of them is -NH 2 and R 1 , R 7 and R 8 The other one is [ka] and R 2 is absent or -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 Selected from R, R 3 is absent or -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O)2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 Selected from R, R 4 is absent or -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 Selected from R, R 5 is absent or -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 Selected from R, R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 Aliphatic; or R a and R b together with the carbon atom to which they are attached form a 3-8 membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; R is hydrogen, deuterium, and C 1~6 aliphatic; a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8-10 membered bicyclic aryl ring; a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur). Includes.
[0140] In some embodiments, -NH 2 Group and -CR a R b The OH groups are present on adjacent carbon atoms in the compound of formula II.
[0141] In some embodiments of Formula II, R a is C 1~4 In some embodiments, R a is C optionally substituted with one, two or three deuterium atoms 1~4 In some embodiments, R a is C optionally substituted by 1, 2 or 3 halogen atoms; 1~4 It is aliphatic.
[0142] In some embodiments of Formula II, R a is C 1~4 In some embodiments, R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 In some embodiments, R a is C optionally substituted by 1, 2 or 3 halogen atoms; 1~4In some embodiments, R a is methyl or ethyl, optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R a is methyl.
[0143] As generally defined above, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic.
[0144] In some embodiments of Formula II, R b is C 1~4 In some embodiments, R b is C optionally substituted with one, two or three deuterium atoms 1~4 In some embodiments, R b is C optionally substituted by 1, 2 or 3 halogen atoms; 1~4 It is aliphatic.
[0145] In some embodiments of Formula II, R b is C 1~4 In some embodiments, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 In some embodiments, R b is C optionally substituted by 1, 2 or 3 halogen atoms; 1~4 In some embodiments, R b is methyl or ethyl, optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R b is methyl.
[0146] As generally defined above, in some embodiments, R a and R btogether with the carbon atom to which they are attached form a 3-8 membered cycloalkyl or heterocyclyl ring containing 1 to 2 heteroatoms selected from nitrogen, oxygen and sulfur.
[0147] In some embodiments of Formula II, R a and R b together with the carbon atom to which they are attached form a 3-8 membered cycloalkyl ring. a and R b together with the carbon atom to which they are attached form a 3-8 membered heterocyclyl ring containing 1 to 2 heteroatoms selected from nitrogen, oxygen and sulfur.
[0148] In some embodiments of Formula II, R a and R b together with the carbon atom to which they are attached form a cyclopropyl ring, a cyclobutyl ring, or a cyclopentyl ring. a and R b together with the carbon atom to which they are attached form an oxirane, oxetane, tetrahydrofuran, or aziridine.
[0149] In some embodiments of Formula II, R 1 , R 7 and R 8 -NH on one of 2 , and other R 1 , R 7 and R 8 The carbinols above are present on adjacent carbon atoms of the pyridine moiety.
[0150] In some embodiments, the compound is a compound of formula II-a, II-b, or II-c: [ka] or a pharma- ceutically acceptable salt thereof, R 1 , R 7 and R 8each, if present, independently represents H, D, halogen, -CN, -OR, -SR, optionally substituted C 1~6 Aliphatic, or [ka] and R 1 , R 7 and R 8 One of them is [ka] and R 2 , R 3 , R 4 , R 5 , R a , R b and R is as defined for formula II. It is.
[0151] In some embodiments, the pharmaceutical composition comprises a compound of formula II-d, II-e, II-f or II-g: [ka] or a pharma- ceutically acceptable salt thereof, R 1 and R 7 are independently H, D, halogen, -CN, -OR, -SR, optionally substituted C 1~6 It is aliphatic, R 2 , R 3 , R 4 , R 5 , R a , R b and R is as defined for formula II. Includes.
[0152] In some embodiments, the pharmaceutical composition comprises a compound of formula III: [ka] or a pharma- ceutically acceptable salt thereof, Q, T and V are independently S, N, O or -CR; R 1 , R 6 , R 7 and R 8 are each independently H, D, halogen, -NH 2 , -CN, -OR, -SR, C substituted as needed 1~6 Aliphatic, or [ka] and R 1 , R 6 , R 7 and R 8 One of them is -NH 2 and R 1 , R 6 , R 7 and R 8 The other one is [ka] and R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 Aliphatic; or R a and R b together with the carbon atom to which they are attached form a 3-8 membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; R is hydrogen, deuterium, and C 1~6aliphatic, 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl; 8-10 membered bicyclic aryl ring, 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, 6-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen and sulfur, optionally substituted groups selected from Includes.
[0153] In some embodiments of Formula III, R 1 , R 6 , R 7 and R 8 -NH on one of 2 , and other R 1 , R 6 , R 7 and R 8 The carbinols above are present on adjacent carbon atoms of the phenyl moiety.
[0154] In some embodiments of formula III, one of Q, T and V is N and the remaining Q, T and V are O. In some embodiments, Q is O, V is N and T is CR. In some embodiments, Q is N, T is O and V is CR.
[0155] In some embodiments of Formula III, the compound is a compound of formula III-a or III-b: [ka] or a pharma- ceutically acceptable salt thereof, R 1 , R 6 , R 7 and R 8each, if present, independently represents H, D, halogen, -CN, -OR, -SR, optionally substituted C 1~6 Aliphatic, or [ka] and R 1 , R 6 , R 7 and R 8 One of them is [ka] and Q, T, V, R, R a and R b is as defined in formula III. It is.
[0156] In some embodiments of Formula III, the compound is a compound of formula III-c, III-d, or III-e: [ka] or a pharma- ceutically acceptable salt thereof, R 1 , R 6 and R 7 each, if present, independently represents H, D, halogen, -CN, -OR, -SR, optionally substituted C 1~6 It is aliphatic, Q, T, V, R, R a and R b is as defined in formula III. It is.
[0157] In some embodiments of Formula III, the compound is a compound of formula III-f, III-g, III-h, or III-i: [ka] or a pharma- ceutically acceptable salt thereof, R 1 , R 6 , R7 and R 8 each, if present, independently represents H, D, halogen, -CN, -OR, -SR, optionally substituted C 1~6 Aliphatic, or [ka] and R 1 , R 6 , R 7 and R 8 One of them is [ka] and R, R a and R b is as defined in formula III).
[0158] In some embodiments of Formula III, the compound is a compound of formula III-j, III-k, III-l, III-l', III-m or III-m': [ka] or a pharma- ceutically acceptable salt thereof, R 1 , R 6 , R 7 and R 8 each, if present, independently represents H, D, halogen, -CN, -OR, -SR, optionally substituted C 1~6 It is aliphatic, R, R a and R b is as defined in formula III. It is.
[0159] In some embodiments of formula III, the compound is a compound of formula III-n: [ka] or a pharma- ceutically acceptable salt thereof, R 1 , R6 , R 7 and R 8 are each independently H, D, halogen, -NH 2 , -CN, -OR, -SR, C substituted as needed 1~6 Aliphatic, or [ka] and R 1 , R 6 , R 7 and R 8 One of them is -NH 2 and R 1 , R 6 , R 7 and R 8 The other one is [ka] and R, R a and R b is as defined in formula III. It is.
[0160] In some embodiments of Formula III, the compound is a compound of formula III-o, III-p, III-q, or III-r: [ka] or a pharma- ceutically acceptable salt thereof, R 1 , R 6 , R 7 and R 8 each, if present, independently represents H, D, halogen, -CN, -OR, -SR, optionally substituted C 1~6 Aliphatic, or [ka] and R 1 , R 6 , R 7 and R 8 One of them is [ka] and R, R a and R b is as defined in formula III. It is.
[0161] In some embodiments of Formula III, the compound is a compound of formula III-s, III-t, III-u, III-v, III-w, or III-x: [ka] or a pharma- ceutically acceptable salt thereof, R 1 , R 6 , R 7 and R 8 each, if present, independently represents H, D, halogen, -CN, -OR, -SR, optionally substituted C 1~6 It is aliphatic, R, R a and R b is as defined in formula III. It is.
[0162] In some embodiments, the pharmaceutical composition comprises a compound of formula IV: [ka] or a pharma- ceutically acceptable salt thereof, Ring A is a 5-membered partially unsaturated heterocyclic or heteroaromatic ring containing 1 to 3 nitrogen atoms, 1 or 2 oxygen atoms, 1 sulfur atom, or 1 nitrogen and 1 sulfur atom; or a 6-membered partially unsaturated heterocyclic or heteroaromatic ring containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-membered partially unsaturated heterocyclic or heteroaromatic ring containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R 1 is H, D, halogen, -CN, -OR, -SR or optionally substituted C1~6 It is aliphatic, R 2 is absent or -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 Selected from R, R 3 is absent or -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 Selected from R, R 4 is absent or -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 Selected from R, R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic, Rb is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 is aliphatic, or R a and R b together with the carbon atom to which they are attached form a 3-8 membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; R is hydrogen, deuterium, and C 1~6 aliphatic; a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8-10 membered bicyclic aryl ring; a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur). Includes.
[0163] As generally defined above, Ring A is a 5-membered partially unsaturated heterocyclic or heteroaromatic ring containing 1 to 3 nitrogen atoms, 1 or 2 oxygen atoms, 1 sulfur atom, or 1 nitrogen and 1 sulfur atom; or a 6-membered partially unsaturated heterocyclic or heteroaromatic ring containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-membered partially unsaturated heterocyclic or heteroaromatic ring containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0164] In some embodiments, ring A is a 5-membered partially unsaturated heterocyclic or heteroaromatic ring containing 1-3 nitrogen atoms, 1 or 2 oxygen atoms, 1 sulfur atom, or 1 nitrogen and 1 sulfur atom. In some embodiments, ring A is a 6-membered partially unsaturated heterocyclic or heteroaromatic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, ring A is a 7-membered partially unsaturated heterocyclic or heteroaromatic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0165] In some embodiments, ring A is imidazole or triazole. In some embodiments, ring A is thiazole. In some embodiments, ring A is thiophene or furan. In some embodiments, ring A is pyridine, pyrimidine, pyrazine, pyridazine or 1,2,4-triazine. In some embodiments, ring A is pyridine.
[0166] As generally defined above, R 1 is H, D, halogen, -CN, -OR, -SR or optionally substituted C 1~6 It is aliphatic.
[0167] In some embodiments, R 1 is H. In some embodiments, R 1 is D. In some embodiments, R 1 is a halogen. In some embodiments, R 1 In some embodiments, R 1 is -OR. In some embodiments, R 1 In some embodiments, R 1 is replaced as necessary 1~6 It is aliphatic.
[0168] Generally, as described above, R 2 is absent or -R, halogen, -CN, -OR, -SR, -N(R) 2, -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 R is selected.
[0169] In some embodiments, R 2 is absent. In some embodiments, R 2 is -R. In some embodiments, R 2 is a halogen. In some embodiments, R 2 In some embodiments, R 2 is -OR. In some embodiments, R 2 In some embodiments, R 2 is -N(R) 2 In some embodiments, R 2 is -N(R)C(O)R. In some embodiments, R 2 is -C(O)N(R) 2 In some embodiments, R 2 is -N(R)C(O)N(R) 2 In some embodiments, R 2 is -N(R)C(O)OR. In some embodiments, R 2 is -OC(O)N(R) 2 In some embodiments, R 2 is -N(R)S(O) 2 R. In some embodiments, R 2 -SO 2 N(R) 2 In some embodiments, R 2 is -C(O)R. In some embodiments, R 2 is -C(O)OR. In some embodiments, R 2 is -OC(O)R. In some embodiments, R 2is -S(O)R. In some embodiments, R 2 -S(O) 2 It's R.
[0170] In some embodiments, R 2 is hydrogen. In some embodiments, R 2 is deuterium. In some embodiments, R 2 is replaced as necessary 1~6 In some embodiments, R 2 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocycle. In some embodiments, R 2 is optionally substituted phenyl. In some embodiments, R 2 is an optionally substituted 8-10 membered bicyclic aryl ring. In some embodiments, R 2 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 2 is an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 2 is an optionally substituted 6-10 membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 2 is an optionally substituted 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0171] In some embodiments, R 2 is Cl or Br. In some embodiments, R 2 is Cl.
[0172] As generally defined above, R 3 is absent or -R, halogen, -CN, -OR, -SR, -N(R)2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 R is selected.
[0173] In some embodiments, R 3 is absent. In some embodiments, R 3 is -R. In some embodiments, R 3 is a halogen. In some embodiments, R 3 In some embodiments, R 3 is -OR. In some embodiments, R 3 In some embodiments, R 3 is -N(R) 2 In some embodiments, R 3 is -N(R)C(O)R. In some embodiments, R 3 is -C(O)N(R) 2 In some embodiments, R 3 is -N(R)C(O)N(R) 2 In some embodiments, R 3 is -N(R)C(O)OR. In some embodiments, R 3 is -OC(O)N(R) 2 In some embodiments, R 3 is -N(R)S(O) 2 R. In some embodiments, R 3 -SO 2 N(R) 2 In some embodiments, R 3 is -C(O)R. In some embodiments, R 3 is -C(O)OR. In some embodiments, R 3 is -OC(O)R. In some embodiments, R 3is -S(O)R. In some embodiments, R 3 -S(O) 2 It's R.
[0174] In some embodiments, R 3 is hydrogen. In some embodiments, R 3 is deuterium. In some embodiments, R 3 is replaced as necessary 1~6 In some embodiments, R 3 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocycle. In some embodiments, R 3 is optionally substituted phenyl. In some embodiments, R 3 is an optionally substituted 8-10 membered bicyclic aryl ring. In some embodiments, R 3 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 3 is an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 3 is an optionally substituted 6-10 membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 3 is an optionally substituted 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0175] In some embodiments, R 3 is Cl or Br. In some embodiments, R 3 is Cl.
[0176] As generally defined above, R 4 is absent or -R, halogen, -CN, -OR, -SR, -N(R)2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 R is selected.
[0177] In some embodiments, R 4 is absent. In some embodiments, R 4 is -R. In some embodiments, R 4 is a halogen. In some embodiments, R 4 In some embodiments, R 4 is -OR. In some embodiments, R 4 In some embodiments, R 4 is -N(R) 2 In some embodiments, R 4 is -N(R)C(O)R. In some embodiments, R 4 is -C(O)N(R) 2 In some embodiments, R 4 is -N(R)C(O)N(R) 2 In some embodiments, R 4 is -N(R)C(O)OR. In some embodiments, R 4 is -OC(O)N(R) 2 In some embodiments, R 4 is -N(R)S(O) 2 R. In some embodiments, R 4 -SO 2 N(R) 2 In some embodiments, R 4 is -C(O)R. In some embodiments, R 4 is -C(O)OR. In some embodiments, R 4 is -OC(O)R. In some embodiments, R 4is -S(O)R. In some embodiments, R 4 -S(O) 2 It's R.
[0178] In some embodiments, R 4 is hydrogen. In some embodiments, R 4 is deuterium. In some embodiments, R 4 is replaced as necessary 1~6 In some embodiments, R 4 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocycle. In some embodiments, R 4 is optionally substituted phenyl. In some embodiments, R 4 is an optionally substituted 8-10 membered bicyclic aryl ring. In some embodiments, R 4 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 4 is an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 4 is an optionally substituted 6-10 membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 4 is an optionally substituted 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0179] In some embodiments, R 4 is Cl or Br. In some embodiments, R 4 is Cl.
[0180] As generally described above, R ais C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic.
[0181] In some embodiments, R a is C 1~4 In some embodiments, R a is C optionally substituted with one, two or three deuterium atoms 1~4 In some embodiments, R a is C optionally substituted by 1, 2 or 3 halogen atoms; 1~4 It is aliphatic.
[0182] In some embodiments, R a is C 1~4 In some embodiments, R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 In some embodiments, R a is C optionally substituted by 1, 2 or 3 halogen atoms; 1~4 In some embodiments, R a is methyl or ethyl, optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R a is methyl.
[0183] As generally defined above, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic.
[0184] In some embodiments, R b is C 1~4 In some embodiments, R b is C optionally substituted with one, two or three deuterium atoms 1~4 In some embodiments, R bis C optionally substituted by 1, 2 or 3 halogen atoms; 1~4 It is aliphatic.
[0185] In some embodiments, R b is C 1~4 In some embodiments, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 In some embodiments, R b is C optionally substituted by 1, 2 or 3 halogen atoms; 1~4 In some embodiments, R b is methyl or ethyl, optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R b is methyl.
[0186] As generally defined above, in some embodiments, R a and R b together with the carbon atom to which they are attached form a 3- to 8-membered cycloalkyl ring.
[0187] In some embodiments, R a and R b together with the carbon atom to which they are attached form a 3-8 membered cycloalkyl ring. a and R b together with the carbon atom to which they are attached form a 3-8 membered heterocyclyl ring containing 1 to 2 heteroatoms selected from nitrogen, oxygen and sulfur.
[0188] In some embodiments, R a and R b together with the carbon atom to which they are attached form a cyclopropyl ring, a cyclobutyl ring, or a cyclopentyl ring. a and R btogether with the carbon atom to which they are attached form an oxirane, oxetane, tetrahydrofuran, or aziridine.
[0189] In some embodiments, R a and R b is methyl.
[0190] In some embodiments, the pharmaceutical composition comprises a compound of formula V: [ka] or a pharma- ceutically acceptable salt thereof, R 2 is -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 Selected from R, R 3 is -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 Selected from R, R 4 is -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2, -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 Selected from R, R 5 is -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 Selected from R, R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 Aliphatic or R a and R b together with the carbon atom to which they are attached form a 3-8 membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; R is hydrogen, deuterium, and C 1~6aliphatic; a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8-10 membered bicyclic aryl ring; a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur). Includes.
[0191] Generally, as mentioned above, R 2 is -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 R is selected.
[0192] In some embodiments, R 2 is -R. In some embodiments, R 2 is a halogen. In some embodiments, R 2 In some embodiments, R 2 is -OR. In some embodiments, R 2 In some embodiments, R 2 is -N(R) 2 In some embodiments, R 2 is -N(R)C(O)R. In some embodiments, R 2 is -C(O)N(R) 2 In some embodiments, R2 is -N(R)C(O)N(R) 2 In some embodiments, R 2 is -N(R)C(O)OR. In some embodiments, R 2 is -OC(O)N(R) 2 In some embodiments, R 2 is -N(R)S(O) 2 R. In some embodiments, R 2 -SO 2 N(R) 2 In some embodiments, R 2 is -C(O)R. In some embodiments, R 2 is -C(O)OR. In some embodiments, R 2 is -OC(O)R. In some embodiments, R 2 is -S(O)R. In some embodiments, R 2 -S(O) 2 It's R.
[0193] In some embodiments, R 2 is hydrogen. In some embodiments, R 2 is deuterium. In some embodiments, R 2 is replaced as necessary 1~6 In some embodiments, R 2 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R 2 is optionally substituted phenyl. In some embodiments, R 2 is an optionally substituted 8-10 membered bicyclic aryl ring. In some embodiments, R 2 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 2 is an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 2is an optionally substituted 6-10 membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 2 is an optionally substituted 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0194] In some embodiments, R 2 is Cl or Br. In some embodiments, R 2 is Cl.
[0195] As generally defined above, R 3 is -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 R is selected.
[0196] In some embodiments, R 3 is -R. In some embodiments, R 3 is a halogen. In some embodiments, R 3 In some embodiments, R 3 is -OR. In some embodiments, R 3 In some embodiments, R 3 is -N(R) 2 In some embodiments, R 3 is -N(R)C(O)R. In some embodiments, R 3 is -C(O)N(R) 2 In some embodiments, R 3 is -N(R)C(O)N(R) 2In some embodiments, R 3 is -N(R)C(O)OR. In some embodiments, R 3 is -OC(O)N(R) 2 In some embodiments, R 3 is -N(R)S(O) 2 R. In some embodiments, R 3 -SO 2 N(R) 2 In some embodiments, R 3 is -C(O)R. In some embodiments, R 3 is -C(O)OR. In some embodiments, R 3 is -OC(O)R. In some embodiments, R 3 is -S(O)R. In some embodiments, R 3 is -S(O) 2 It's R.
[0197] In some embodiments, R 3 is hydrogen. In some embodiments, R 3 is deuterium. In some embodiments, R 3 is replaced as necessary 1~6 In some embodiments, R 3 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R 3 is optionally substituted phenyl. In some embodiments, R 3 is an optionally substituted 8-10 membered bicyclic aryl ring. In some embodiments, R 3 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 3 is an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 3is an optionally substituted 6-10 membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 3 is an optionally substituted 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0198] In some embodiments, R 3 is Cl or Br. In some embodiments, R 3 is Cl.
[0199] As generally defined above, R 4 is -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 R is selected.
[0200] In some embodiments, R 4 is -R. In some embodiments, R 4 is a halogen. In some embodiments, R 4 In some embodiments, R 4 is -OR. In some embodiments, R 4 In some embodiments, R 4 is -N(R) 2 In some embodiments, R 4 is -N(R)C(O)R. In some embodiments, R 4 is -C(O)N(R) 2 In some embodiments, R 4 is -N(R)C(O)N(R) 2In some embodiments, R 4 is -N(R)C(O)OR. In some embodiments, R 4 is -OC(O)N(R) 2 In some embodiments, R 4 is -N(R)S(O) 2 R. In some embodiments, R 4 -SO 2 N(R) 2 In some embodiments, R 4 is -C(O)R. In some embodiments, R 4 is -C(O)OR. In some embodiments, R 4 is -OC(O)R. In some embodiments, R 4 is -S(O)R. In some embodiments, R 4 is -S(O) 2 It's R.
[0201] In some embodiments, R 4 is hydrogen. In some embodiments, R 4 is deuterium. In some embodiments, R 4 is replaced as necessary 1~6 In some embodiments, R 4 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R 4 is optionally substituted phenyl. In some embodiments, R 4 is an optionally substituted 8-10 membered bicyclic aryl ring. In some embodiments, R 4 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 4 is an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 4is an optionally substituted 6-10 membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 4 is an optionally substituted 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0202] In some embodiments, R 4 is Cl or Br. In some embodiments, R 4 is Cl.
[0203] As generally defined above, R 5 is -R, halogen, -CN, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 R is selected.
[0204] In some embodiments, R 5 is -R. In some embodiments, R 5 is a halogen. In some embodiments, R 5 In some embodiments, R 5 is -OR. In some embodiments, R 5 In some embodiments, R 5 is -N(R) 2 In some embodiments, R 5 is -N(R)C(O)R. In some embodiments, R 5 is -C(O)N(R) 2 In some embodiments, R 5 is -N(R)C(O)N(R) 2In some embodiments, R 5 is -N(R)C(O)OR. In some embodiments, R 5 is -OC(O)N(R) 2 In some embodiments, R 5 is -N(R)S(O) 2 R. In some embodiments, R 5 -SO 2 N(R) 2 In some embodiments, R 5 is -C(O)R. In some embodiments, R 5 is -C(O)OR. In some embodiments, R 5 is -OC(O)R. In some embodiments, R 5 is -S(O)R. In some embodiments, R 5 -S(O) 2 It's R.
[0205] In some embodiments, R 5 is hydrogen. In some embodiments, R 5 is deuterium. In some embodiments, R 5 is replaced as necessary 1~6 In some embodiments, R 5 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R 5 is optionally substituted phenyl. In some embodiments, R 5 is an optionally substituted 8-10 membered bicyclic aryl ring. In some embodiments, R 5 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 5 is an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 5is an optionally substituted 6-10 membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 5 is an optionally substituted 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0206] In some embodiments, R 5 is Cl or Br. In some embodiments, R 5 is Cl.
[0207] As generally described above, R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic.
[0208] In some embodiments, R a is C 1~4 In some embodiments, R a is C optionally substituted with one, two or three deuterium atoms 1~4 In some embodiments, R a is C optionally substituted by 1, 2 or 3 halogen atoms; 1~4 It is aliphatic.
[0209] In some embodiments, R a is C 1~4 In some embodiments, R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 In some embodiments, R a is C optionally substituted by 1, 2 or 3 halogen atoms; 1~4 In some embodiments, R ais methyl or ethyl, optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R a is methyl.
[0210] As generally defined above, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic.
[0211] In some embodiments, R b is C 1~4 In some embodiments, R b is C optionally substituted with one, two or three deuterium atoms 1~4 In some embodiments, R b is C optionally substituted by 1, 2 or 3 halogen atoms; 1~4 It is aliphatic.
[0212] In some embodiments, R b is C 1~4 In some embodiments, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 In some embodiments, R a is C optionally substituted by 1, 2 or 3 halogen atoms; 1~4 In some embodiments, R b is methyl or ethyl, optionally substituted with 1, 2, or 3 halogen atoms. In some embodiments, R b is methyl.
[0213] As generally defined above, in some embodiments, R a and R b together with the carbon atom to which they are attached form a 3-8 membered cycloalkyl or heterocyclyl ring containing 1 to 2 heteroatoms selected from nitrogen, oxygen and sulfur.
[0214] In some embodiments, R a and R b together with the carbon atom to which they are attached form a 3-8 membered cycloalkyl ring. a and R b together with the carbon atom to which they are attached form a 3-8 membered heterocyclyl ring containing 1 to 2 heteroatoms selected from nitrogen, oxygen and sulfur.
[0215] In some embodiments, R a and R b together with the carbon atom to which they are attached form a cyclopropyl ring, a cyclobutyl ring, or a cyclopentyl ring. a and R b together with the carbon atom to which they are attached form an oxirane, oxetane, tetrahydrofuran, or aziridine.
[0216] In some embodiments, R a and R b is methyl.
[0217] In some embodiments, the pharmaceutical composition comprises a compound of formula VI-a, VI-b, VI-c, or VI-d: [ka] or a pharma- ceutically acceptable salt thereof, R 1 , R 2 , R 3 , R 4 , R a and R b are each as defined herein and as described in the embodiments herein, both singly and in combination. Includes.
[0218] In some embodiments, the compound is of formula VI-a above.
[0219] In some embodiments, R 1 and R 4 is H.
[0220] In some embodiments, R 2 is H.
[0221] In some embodiments, R a and R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 alkyl or R a and R b together with the carbons to which they are attached form a 3-8 membered cycloalkyl or heterocyclyl ring containing 1 to 2 heteroatoms selected from nitrogen, oxygen and sulfur.
[0222] In some embodiments, R 3 , H, C 1~4 Alkyl, halogen, -NR, -OR, -SR, -CO 2 R or -C(O)R, where R is H, optionally substituted C 1~4 It is alkyl or optionally substituted phenyl.
[0223] In another embodiment, the compound is a compound of formula VI-e, VI-f, VI-g or VI-h [ka] or a pharma- ceutically acceptable salt thereof, R 2 , R 3 and R 4 are each as defined above and as described in embodiments herein, both singly and in combination. It is.
[0224] In another embodiment, the compound is a compound of formula VI-i, VI-j, VI-k, VI-l, VI-m or VI-n: [ka] or a pharma- ceutically acceptable salt thereof, R, R 1 , R 2 , R 3 , R a and R b are each as defined above and as described in the embodiments herein, both singly and in combination. It is.
[0225] In another embodiment, the pharmaceutical composition comprises a compound of formula VII-a: [ka] or a pharma- ceutically acceptable salt thereof, R 3 , R a and R b are each as defined above and as described in the embodiments herein, both singly and in combination. Includes.
[0226] In some embodiments, the compound is a compound of Formula I selected from those depicted in Table 1a below:
[0227] Table 1a [Table 1a-1] [Table 1a-2] [Table 1a-3] or a pharma- ceutically acceptable salt thereof.
[0228] In some embodiments, the compound is [ka] or a pharma- ceutically acceptable salt thereof.
[0229] In some embodiments, the compound is a compound depicted in Table 1b below.
[0230] Table 1b [Table 1b-1] [Table 1b-2] or a pharma- ceutically acceptable salt thereof.
[0231] In some embodiments, the compound is a compound depicted in Table 1c below.
[0232] Table 1c: Exemplary compounds of formula IV [Table 1c-1] [Table 1c-2] or a pharma- ceutically acceptable salt thereof.
[0233] In some embodiments, the pharmaceutical composition comprises a compound of formula VIII: [ka] or a pharma- ceutically acceptable salt thereof, Q, T and V are each independently selected from N or NH, S, O, CU and CH; [ka] represents two double bonds in a ring, which meet the valence requirements of the atoms and heteroatoms present in the ring; k is 0, 1, 2 or 3; Ra is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 is aliphatic, or R a and R b together with the carbon atom to which they are attached form a 3-8 membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; U is halogen, cyano, -R, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 is selected independently of R, two U's present on adjacent carbon atoms can form an optionally substituted fused ring selected from a fused phenyl ring; a fused 5-6 membered saturated or partially unsaturated fused heterocyclic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; and a fused 5-6 membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; R is hydrogen, deuterium, or C 1~6aliphatic; a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8-10 membered bicyclic aryl ring; a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur). Includes.
[0234] Each of k, U and R is as defined and described above.
[0235] As defined above and described herein, Q is selected from N or NH, S, O, CU and CH. In some embodiments, Q is N or NH. In some embodiments, Q is S. In some embodiments, Q is O. In some embodiments, Q is CU. In some embodiments, Q is CH.
[0236] As defined above and described herein, T is selected from N or NH, S, O, CU, and CH. In some embodiments, T is N or NH. In some embodiments, T is S. In some embodiments, T is O. In some embodiments, T is CU. In some embodiments, T is CH.
[0237] As defined above and described herein, V is selected from N or NH, S, O, CU, and CH. In some embodiments, V is N or NH. In some embodiments, V is S. In some embodiments, V is O. In some embodiments, V is CU. In some embodiments, V is CH.
[0238] As defined above and described herein, k is 0, 1, 2, or 3. In some embodiments, k is 0. In some embodiments, k is 1. In some embodiments, k is 2. In some embodiments, k is 3.
[0239] As defined above and described herein, [ka] represents two double bonds in the ring, which meets the valence requirements of the atoms and heteroatoms present in the ring. In some embodiments, the ring formed is a thiophene. In some embodiments, the ring formed is an oxazole. In some embodiments, the ring formed is an isothiazole.
[0240] In some embodiments, one or more of Q and V is CH and T is S; [ka] are arranged to form a thiophene, and k is 0. In some embodiments, one or more of Q is CH, T is N or NH, V is O, [ka] are arranged to form an isoxazole, and k is 0. In some embodiments, one or more of Q are S, T and V are CH; [ka] are arranged to form a thiophene, k is 1, and U is -S(O) 2 In some embodiments, one or more of Q is S, T and V are CH; [ka] are arranged to form a thiophene, k is 1, and U is -S(O) 2 CH 3 In some embodiments, one or more of Q is CH, T is N or NH, V is S; [ka] are arranged to form an isothiazole, and k is 0.
[0241] In some embodiments, the compound of formula VIII is selected from those depicted in Table 2 below.
[0242] Table 2: Exemplary compounds of formula VIII [Table 2]
[0243] In some embodiments, the compound is a compound of formula IX-A or IX-B: [ka] or a pharma- ceutically acceptable salt thereof, k is 0, 1, 2 or 3; R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 is aliphatic; or R a and R b together with the carbon atom to which they are attached form a 3-8 membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; U is halogen, cyano, -R, -OR, -SR, -N(R) 2, -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2 , -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 is selected independently of R, two U's present on adjacent carbon atoms can form an optionally substituted fused ring selected from a fused phenyl ring; a fused 5-6 membered saturated or partially unsaturated fused heterocyclic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; or a fused 5-6 membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; R is hydrogen, deuterium, and C 1~6 aliphatic; a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8-10 membered bicyclic aryl ring; a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur).
[0244] Each of k, U and R is as defined and described above.
[0245] In some embodiments, the compound of formula IX-A or IX-B is selected from those depicted in Table 3 below.
[0246] Table 3: Exemplary compounds of formula IX [Table 3]
[0247] 4.3. Deuterated Compounds In some embodiments, the compound is a deuterated form of the compound above or a pharma- ceutically acceptable salt thereof.
[0248] In some embodiments, the pharmaceutical composition comprises a compound of formula X: [ka] or a pharma- ceutically acceptable salt thereof, R 1 is -NH 2 , -NHD and -ND 2 is selected from R 2 is selected from hydrogen or deuterium; R 3 and R 4 is -CH 3 , -CH 2 D, -CHD 2 and -CD 3 are independently selected from R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium; However, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 or R 8 is or contains deuterium. Includes.
[0249] In some embodiments, the compound is a compound of formula XA: [ka] or a pharma- ceutically acceptable salt thereof, R 1 is -NH 2 , -NHD and -ND 2 is selected from R 2 is selected from hydrogen and deuterium; R 3 and R 4 -CH 3 , -CH 2 D, -CHD 2 and -CD 3 are independently selected from R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium; However, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 or R 8 is or contains deuterium. It is.
[0250] In some embodiments, the compound is a compound of formula XI-A or XI-B: [ka] or a pharma- ceutically acceptable salt thereof, R 1 is -NH 2 , -NHD and -ND 2 is selected from R 2 is selected from hydrogen and deuterium; R 3 and R 4 -CH 3 , -CH 2 D, -CHD 2 and -CD 3 are independently selected from R 5 , R 6 , R7 and R 8 are each independently selected from hydrogen and deuterium; However, R in formula XI-A 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 or R 8 is or contains deuterium. It is.
[0251] In some embodiments, the compound is a compound of formula XII-A, XII-B, or XII-C: [ka] or a pharma- ceutically acceptable salt thereof, R 1 is -NH 2 , -NHD and -ND 2 is selected from R 2 is selected from hydrogen and deuterium; R 3 and R 4 -CH 3 , -CH 2 D, -CHD 2 and -CD 3 are independently selected from R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium; However, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 or R 8 is or contains deuterium. It is.
[0252] In some embodiments, the compound is a compound of formula XIII: [ka] or a pharma- ceutically acceptable salt thereof, R 1 is -NH 2 , -NHD and -ND 2 is selected from R 2 is selected from hydrogen and deuterium; R 3 and R 4 is -CH 3 , -CH 2 D, -CHD 2 and -CD 3 are independently selected from R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium; However, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 or R 8 is or contains deuterium. It is.
[0253] In some embodiments, the compound is a compound of formula XIV: [ka] or a pharma- ceutically acceptable salt thereof, R 1 is -NH 2 , -NHD and -ND 2 is selected from R 2 is selected from hydrogen and deuterium; R 3 and R 4 is -CH 3, -CH 2 D, -CHD 2 and -CD 3 are independently selected from R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium; However, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 or R 8 is or contains deuterium. It is.
[0254] In some embodiments, the compound is a compound of formula XV-A or XV-B: [ka] or a pharma- ceutically acceptable salt thereof, Each A is independently hydrogen and deuterium; R 1 is -NH 2 , -NHD and -ND 2 is selected from R 2 is selected from hydrogen and deuterium; R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium; However, A, R 1 , R 2 , R 5 , R 6 , R 7 or R 8 is or contains deuterium. It is.
[0255] In some embodiments, the compound is a compound of formula XVI-A or XVI-B: [ka] or a pharma- ceutically acceptable salt thereof, Each A is independently hydrogen or deuterium; R 1 is -NH 2 , -NHD and -ND 2 is selected from R 2 is selected from hydrogen and deuterium; R 3 and R 4 -CH 3 , -CH 2 D, -CHD 2 and -CD 3 are independently selected from R 8 is selected from hydrogen and deuterium It is.
[0256] In some embodiments, the compound is a compound of formula XVII-A or XVII-B: [ka] or a pharma- ceutically acceptable salt thereof, Each A is independently hydrogen and deuterium; R 1 is -NH 2 , -NHD and -ND 2 is selected from R 2 is selected from hydrogen and deuterium; R 3 and R 4 -CH 3 , -CH 2 D, -CHD 2 and -CD 3 are independently selected from R 5 and R 8 are each independently selected from hydrogen and deuterium; However, A, R 1 , R 2 , R 3 , R 4 , R 5 or R 8 is or contains deuterium. It is.
[0257] In some embodiments, the compound is a compound of formula XVIII-A or XVIII-B: [ka] or a pharma- ceutically acceptable salt thereof, R 1 is -NH 2 , -NHD and -ND 2 is selected from R 2 is selected from hydrogen and deuterium; R 3 and R 4 -CH 3 , -CH 2 D, -CHD 2 and -CD 3 are independently selected from R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and deuterium; However, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 or R 8 is or contains deuterium. It is.
[0258] In some embodiments, the compound is a compound of formula XIX: [ka] or a pharma- ceutically acceptable salt thereof, R 1 is -NH 2 , -NHD and -ND 2 is selected from R 2 is selected from hydrogen and deuterium; R 3 and R 4 is -CH 3 , -CH 2 D, -CHD 2 and -CD 3 are independently selected from R 5 and R 6 are each independently selected from hydrogen and deuterium; However, R 1 , R 2 , R 3 , R 4 , R 5 or R 6 is or contains deuterium. It is.
[0259] The following embodiments are applicable to each of Formulas X-XIX above.
[0260] R, as defined above and described herein; 1 is -NH 2 , -NHD and -ND 2 is selected from.
[0261] In some embodiments, R 1 is -NH 2 In some embodiments, R 1 is -NH 2 and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 or R 8 At least one of is or contains deuterium.
[0262] In some embodiments, R 1 In some embodiments, R 1 is -NHD and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 or R 8 At least one of is or contains deuterium.
[0263] In some embodiments, R 1 -ND 2 In some embodiments, R 1 -ND 2 and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 or R 8 At least one of is or contains deuterium.
[0264] As defined above and described herein, A is selected from hydrogen and deuterium.
[0265] In some embodiments, A is hydrogen. In some embodiments, A is hydrogen and R 1 , R 3 , R 4 , R 5 , R 6 , R 7 or R 8 At least one of is or contains deuterium. In some embodiments, A is deuterium. In some embodiments, A is deuterium and R 1 , R 3 , R 4 , R 5 , R 6 , R 7 or R 8 At least one of is or contains deuterium.
[0266] R, as defined above and described herein; 2 is selected from hydrogen and deuterium.
[0267] In some embodiments, R 2 is hydrogen. In some embodiments, R 2 is hydrogen and R 1 , R 3 , R 4 , R 5 , R 6 , R 7 or R 8 At least one of R is or contains deuterium. 2 is deuterium. In some embodiments, R 2 is deuterium, R 1 , R 3 , R 4 , R 5 , R 6 , R 7 or R 8 At least one of is or contains deuterium.
[0268] R, as defined above and described herein; 3 -CH 3 , -CH 2 D, -CHD 2 and -CD 3 is selected from.
[0269] In some embodiments, R 3 -CH 3 In some embodiments, R 3 -CH 3 and R 1 , R 2 , R 4 , R 5 , R 6 , R 7 or R 8 At least one of is or contains deuterium.
[0270] In some embodiments, R 3 -CH2 In some embodiments, R 3 -CH 2 D and R 1 , R 2 , R 4 , R 5 , R 6 , R 7 or R 8 At least one of is or contains deuterium.
[0271] In some embodiments, R 3 -CHD 2 In some embodiments, R 3 -CHD 2 and R 1 , R 2 , R 4 , R 5 , R 6 , R 7 or R 8 At least one of is or contains deuterium.
[0272] In some embodiments, R 3 -CD 3 In some embodiments, R 3 -CD 3 and R 1 , R 2 , R 4 , R 5 , R 6 , R 7 or R 8 At least one of is or contains deuterium.
[0273] R, as defined above and described herein; 4 -CH 3 , -CH 2 D, -CHD 2 and -CD 3 is selected from.
[0274] In some embodiments, R 4 -CH 3 In some embodiments, R4 is -CH 3 and R 1 , R 2 , R 3 , R 5 , R 6 , R 7 or R 8 At least one of is or contains deuterium.
[0275] In some embodiments, R 4 is -CH 2 In some embodiments, R 4 is -CH 2 D and R 1 , R 2 , R 3 , R 5 , R 6 , R 7 or R 8 At least one of is or contains deuterium.
[0276] In some embodiments, R 4 -CHD 2 In some embodiments, R 4 -CHD 2 and R 1 , R 2 , R 3 , R 5 , R 6 , R 7 or R 8 At least one of is or contains deuterium.
[0277] In some embodiments, R 4 -CD 3 In some embodiments, R 4 -CD 3 and R 1 , R 2 , R 3 , R 5 , R 6 , R 7 or R 8 At least one of is or contains deuterium.
[0278] R, as defined above and described herein; 5 is selected from hydrogen and deuterium.
[0279] In some embodiments, R 5 is hydrogen. In some embodiments, R 5 is hydrogen and R 1 , R 2 , R 3 , R 4 , R 6 , R 7 or R 8 At least one of R is or contains deuterium. 5 is deuterium. In some embodiments, R 5 is deuterium, R 1 , R 2 , R 3 , R 4 , R 6 , R 7 or R 8 At least one of is or contains deuterium.
[0280] R, as defined above and described herein; 6 is selected from hydrogen and deuterium.
[0281] In some embodiments, R 6 is hydrogen. In some embodiments, R 6 is hydrogen and R 1 , R 2 , R 3 , R 4 , R 5 , R 7 or R 8 At least one of R is or contains deuterium. 6 is deuterium. In some embodiments, R 6 is deuterium, R 1 , R 2 , R 3 , R 4 , R 5 , R7 or R 8 At least one of is or contains deuterium.
[0282] R, as defined above and described herein; 7 is selected from hydrogen and deuterium.
[0283] In some embodiments, R 7 is hydrogen. In some embodiments, R 7 is hydrogen and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 or R 8 At least one of R is or contains deuterium. 7 is deuterium. In some embodiments, R 7 is deuterium, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 or R 8 At least one of is or contains deuterium.
[0284] R, as defined above and described herein; 8 is selected from hydrogen and deuterium.
[0285] In some embodiments, R 8 is hydrogen. In some embodiments, R 8 is hydrogen and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 or R 7 At least one of R is or contains deuterium. 8 is deuterium. In some embodiments, R 8 is deuterium, R1 , R 2 , R 3 , R 4 , R 5 , R 6 or R 7 At least one of is or contains deuterium.
[0286] In some embodiments, the compound is of formula X, XA, XI-A, XI-B, XII-A, XII-B, XII-C, XIII, or XIV, or a pharma- ceutically acceptable salt thereof; 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each defined above and described herein, and R 1 and R 2 are each as defined in the entries set forth in Table 4a below.
[0287] Table 4a: Exemplary compounds of formula X, XA, XI-A, XI-B, XII-A, XII-B, XII-C, XIII or XIV [Table 4a-1] [Table 4a-2]
[0288] In some embodiments, the compound is of formula X, XA, XI-A, XI-B, XII-A, XII-B, XII-C, XIII, or XIV, or a pharma- ceutically acceptable salt thereof; 1 , R 2 , R 5 , R 6 , R 7 and R 8 are each defined above and described herein, and R 3 and R 4are each as defined in the entries set forth in Table 4b below.
[0289] Table 4b: Exemplary compounds of formula X, XA, XI-A, XI-B, XII-A, XII-B, XII-C, XIII or XIV [Table 4b-1] [Table 4b-2]
[0290] In some embodiments, the compound is of formula X, XA, XI-A, XI-B, XII-A, XII-B, XII-C, XIII, or XIV, or a pharma- ceutically acceptable salt thereof; 1 , R 2 , R 3 and R 4 are each defined above and as described herein, and R 5 , R 6 , R 7 and R 8 are each as defined in the entries set forth in Table 4c below.
[0291] Table 4c: Exemplary compounds of formula X, XA, XI-A, XI-B, XII-A, XII-B, XII-C, XIII or XIV [Table 4c]
[0292] In some embodiments, the compound is of formula X, XA, XI-A, XI-B, XII-A, XII-B, XII-C, XIII, or XIV, or a pharma- ceutically acceptable salt thereof; 1 and R 2 are each as defined in the entries set forth in Table 4a above, and R 3 and R4 are each as defined in the entries in Table 4b above, and R 5 , R 6 , R 7 and R 8 are each as defined in the entries set forth in Table 4c above.
[0293] In some embodiments, the pharmaceutical composition comprises a compound selected from those listed in any of Tables 4a, 4b, or 4c, or a pharma- ceutically acceptable salt thereof.
[0294] In some embodiments, the pharmaceutical composition comprises a compound of formula X selected from the compounds depicted in Table 5 below.
[0295] Table 5: Representative compounds of formula X [Table 5-1] [Table 5-2] [Table 5-3] or a pharma- ceutically acceptable salt thereof.
[0296] In some embodiments, the pharmaceutical composition comprises a compound depicted in Table 5 above, or a pharma- ceutically acceptable salt thereof.
[0297] In some embodiments, the pharmaceutical compositions comprise deuterium-enriched analogs of the compounds depicted in Table 6 below, or pharma- ceutically acceptable salts thereof, that are enriched in deuterium at any available hydrogen.
[0298] Table 6: Representative compounds of formula X [Table 6-1] [Table 6-2]
[0299] In some embodiments, the compound is any of the compounds described herein that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 deuterium atoms.
[0300] In some embodiments, the compound is any of the compounds described above and herein in isolated form. As used herein, the term "isolated" means that the compound is provided in a form that is separated from other compounds that may be present in the normal environment of the compound. In some embodiments, the isolated compound is in solid form. In some embodiments, the compound provided contains deuterium in an amount of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% or about 100%. As used herein, in the context of deuterium enriched, the term "about" means ±2%.
[0301] 4.4. Other compounds In some embodiments, the pharmaceutical composition comprises a compound of formula XX: [ka] or a pharma- ceutically acceptable salt thereof, R 1 is H, D or a halogen, R 2 is H, D or a halogen, R 3 is H, D, Br or I, R 4 is H, D or a halogen, R 5 is H, D or a halogen, R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4It is aliphatic, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 (It is aliphatic) Includes.
[0302] As generally defined above, R 1 is H, D or a halogen.
[0303] In some embodiments, R 1 is H. In some embodiments, R 1 is D. In some embodiments, R 1 is a halogen. In some embodiments, R 1 is Cl. In some embodiments, R 1 is Br.
[0304] As generally defined above, R 2 is H, D or a halogen.
[0305] In some embodiments, R 2 is H. In some embodiments, R 2 is D. In some embodiments, R 2 is a halogen. In some embodiments, R 2 is Cl. In some embodiments, R 2 is Br.
[0306] As generally defined above, R 3 is H, D, Br or I.
[0307] In some embodiments, R 3 is H. In some embodiments, R 3 is D. In some embodiments, R 3 is Br. In some embodiments, R 3 is I.
[0308] As generally defined above, R 4is H, D or a halogen.
[0309] In some embodiments, R 4 is H. In some embodiments, R 4 is D. In some embodiments, R 4 is a halogen. In some embodiments, R 4 is Cl. In some embodiments, R 4 is Br.
[0310] As generally defined above, R 5 is H, D or a halogen.
[0311] In some embodiments, R 5 is H. In some embodiments, R 5 is D. In some embodiments, R 5 is a halogen. In some embodiments, R 5 is Cl. In some embodiments, R 5 is Br.
[0312] As generally defined above, R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic.
[0313] In some embodiments, R a is C substituted by one, two or three deuterium or halogen atoms; 1~4 In some embodiments, R a is C 1~4 In some embodiments, R a is C 1~4 In some embodiments, R a is methyl, ethyl, n-propyl, or isopropyl. a is methyl.
[0314] As generally defined above, R bis C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic.
[0315] In some embodiments, R b is C substituted by one, two or three deuterium or halogen atoms; 1~4 In some embodiments, R b is C 1~4 In some embodiments, R b is C 1~4 In some embodiments, R b is C optionally substituted by 1, 2 or 3 fluorine atoms; 1~4 In some embodiments, R b is methyl, ethyl, n-propyl, or isopropyl. b is methyl.
[0316] In some embodiments, R a and R b is methyl or ethyl. In some embodiments, R a and R b is methyl.
[0317] In some embodiments, the compound is a compound of formula XX-a: [ka] or a pharma- ceutically acceptable salt thereof, R 2 , R 3 , R 4 , R 5 , R a and R b are each as defined above, both singly and in combination, and as described in the embodiments herein. It is.
[0318] In some embodiments, the compound is a compound of formula XX-b: [ka] or a pharma- ceutically acceptable salt thereof, R 2 , R 4 , R 5 , R a and R b are each as defined above and as described in the embodiments herein, both singly and in combination.
[0319] In some embodiments, the compound is a compound of formula XX-c, XX-d, XX-e, or XX-f: [ka] or a pharma- ceutically acceptable salt thereof, R 2 , R 4 , R 5 , R a and R b are each as defined above and as described in the embodiments herein, both singly and in combination.
[0320] In some embodiments, the compound is a compound of formula XX-g, XX-h, XX-i, or XX-j: [ka] or a pharma- ceutically acceptable salt thereof, R 2 , R 4 , R 5 , R a and R b are each as defined above, both singly and in combination, and as described in the embodiments herein. It is.
[0321] In some embodiments, the compound is a compound of formula XX-k or XX-l: [ka] or a pharma- ceutically acceptable salt thereof, R a and R b are each as defined above, both singly and in combination, and as described in the embodiments herein. It is.
[0322] In some embodiments, the pharmaceutical composition comprises a compound of formula I-5: [ka] or a pharma- ceutically acceptable salt thereof, comprising at least one compound of formula XX: [ka] or a pharma- ceutically acceptable salt thereof, R 1 is H, D or a halogen, R 2 is H, D or a halogen, R 3 is H, D, Br or I, R 4 is H, D or a halogen, R 5 is H, D or a halogen, R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 or a pharma- ceutically acceptable salt thereof, in combination with a compound of formula I-5, wherein the compound is aliphatic.
[0323] In some embodiments, the pharmaceutical composition comprises a compound of formula I-5 or a pharma- ceutically acceptable salt thereof, and at least one compound according to formula XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k or XX-l; or a pharma- ceutically acceptable salt thereof.
[0324] In some embodiments, the pharmaceutical composition comprises a compound of formula I-5: [ka] or a pharma- ceutically acceptable salt thereof, and a compound selected from: [ka] or a pharma- ceutically acceptable salt thereof Includes.
[0325] In some embodiments, the pharmaceutical composition comprises a compound of formula I-5 or a pharma- ceutically acceptable salt thereof, and one additional compound selected from XX-1, XX-2, XX-3, XX-4, and XX-5, or a pharma- ceutically acceptable salt thereof.
[0326] In some embodiments, the pharmaceutical composition comprises a compound of formula I-5 or a pharma- ceutically acceptable salt thereof, and two additional compounds selected from XX-1, XX-2, XX-3, XX-4 and XX-5, or pharma- ceutically acceptable salts thereof.
[0327] In some embodiments, the pharmaceutical composition comprises a compound of formula I-5 or a pharma- ceutically acceptable salt thereof, and three additional compounds selected from XX-1, XX-2, XX-3, XX-4 and XX-5, or pharma- ceutically acceptable salts thereof.
[0328] In some embodiments, the pharmaceutical composition comprises a compound of formula I-5 or a pharma- ceutically acceptable salt thereof, and four additional compounds selected from XX-1, XX-2, XX-3, XX-4 and XX-5, or pharma- ceutically acceptable salts thereof.
[0329] In some embodiments, the pharmaceutical composition comprises a compound of formula I-5 or a pharma- ceutically acceptable salt thereof, and one additional compound selected from XX-2, XX-3, and XX-4, or a pharma- ceutically acceptable salt thereof.
[0330] In some embodiments, the pharmaceutical composition comprises a compound of formula I-5 or a pharma- ceutically acceptable salt thereof, and two additional compounds selected from XX-2, XX-3 and XX-4 or a pharma- ceutically acceptable salt thereof. In some embodiments, the composition comprises XX-2, XX-3 and XX-4 or a pharma- ceutically acceptable salt thereof.
[0331] In some embodiments, the pharmaceutical composition comprises compounds of formula I-5, or a pharma- ceutically acceptable salt thereof, and XX-1, or a pharma- ceutically acceptable salt thereof.
[0332] In some embodiments, the pharmaceutical composition comprises compounds of formula I-5, or a pharma- ceutically acceptable salt thereof, and XX-2, or a pharma- ceutically acceptable salt thereof.
[0333] In some embodiments, the pharmaceutical composition comprises compounds of formula I-5, or a pharma- ceutically acceptable salt thereof, and XX-3, or a pharma- ceutically acceptable salt thereof.
[0334] In some embodiments, the pharmaceutical composition comprises compounds of formula I-5, or a pharma- ceutically acceptable salt thereof, and XX-4, or a pharma- ceutically acceptable salt thereof.
[0335] In some embodiments, the pharmaceutical composition comprises compounds of formula I-5, or a pharma- ceutically acceptable salt thereof, and XX-5, or a pharma- ceutically acceptable salt thereof.
[0336] In some embodiments, the pharmaceutical composition comprises a compound of Formula XX selected from those depicted in Table 7 below.
[0337] Table 7: Representative compounds of formula XX [Table 7]
[0338] In some embodiments, the pharmaceutical composition comprises a compound depicted in Table 7 above, or a pharma- ceutically acceptable salt thereof.
[0339] In some embodiments, the compound for use in the pharmaceutical composition is any compound described above and herein in isolated form. As used herein, the term "isolated" means that the compound is provided in a form that is separated from other components that may be present in the normal environment of the compound. In some embodiments, the isolated compound is in solid form. In some embodiments, the isolated compound is at least about 50% pure as determined by a suitable HPLC method. In certain embodiments, the isolated compound is at least about 60%, 70%, 80%, 90%, 95%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, 99.99% or 99.999% pure as determined by a suitable HPLC method. Preparation methods applicable to certain compounds of the present invention are disclosed in US2013 / 0190500, published July 25, 2013, which is incorporated herein by reference.
[0340] In some embodiments, the pharmaceutical composition comprises at least about 97, 97.5, 98, 98.5, 99.0, 99.5, 99.8, 99.9, 99.95 or 99.999% by weight of any one of the compounds of formula XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k or XX-l, or a pharma- ceutically acceptable salt thereof, where the percentages are based on the free base of the compound and the total weight of the composition. In other embodiments, the composition contains no more than about 2.0 HPLC area percent of total organic impurities, or in other embodiments no more than about 1.5, 1.25, 1, 0.75, 0.5, 0.25, 0.2, 0.1, 0.01, 0.005 or 0.001 HPLC area percent of total organic impurities, based on the total area of the HPLC chromatogram.
[0341] In other embodiments, the pharmaceutical composition comprises a compound of formula I-5 or a pharma- ceutically acceptable salt thereof, at least one compound of formula XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k, or XX-l or a pharma- ceutically acceptable salt thereof, and at least one pharma- ceutically acceptable carrier. In some embodiments, the composition contains a compound of formula I-5 or a pharma- ceutically acceptable salt thereof in an amount of about 1% to about 99% by weight, the percentages being based on the free base of the compound and the total weight of the composition. In other embodiments, the composition contains less than about 2.0 HPLC area percent of total organic impurities, or in other embodiments, less than about 1.5, 1.25, 1, 0.75, 0.5, 0.25, 0.2, 0.1, 0.01, 0.005, or 0.001 HPLC area percent of total organic impurities based on the total area of the HPLC chromatogram.
[0342] In some embodiments, the pharmaceutical composition comprises a compound of formula I-5 or a pharma- ceutically acceptable salt thereof, and a compound of formula XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k, or XX-l, or a pharma- ceutically acceptable salt thereof, wherein the compound of formula I-5 or a pharma- ceutically acceptable salt thereof constitutes about 98% and the compound of formula XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k, or XX-l, or a pharma- ceutically acceptable salt thereof constitutes about 2% of the total weight of the compounds or pharma- ceutically acceptable salts thereof together, or of the total HPLC peak area of the compounds or pharma- ceutically acceptable salts thereof together. In some embodiments, the pharmaceutical composition comprises a compound of formula I-5 or a pharma- ceutically acceptable salt thereof and a compound of formula XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k or XX-l or a pharma- ceutically acceptable salt thereof, wherein the compound of formula I-5 or the pharma- ceutically acceptable salt thereof is about 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, 99.99% or 99.999%. %, and the compound of formula XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k or XX-l or a pharma- ceutically acceptable salt thereof constitutes about 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, 0.01% or 0.001% of the total weight of the compounds or pharma-ceutically acceptable salts thereof taken together, or the total HPLC peak area of the compounds or pharma-ceutically acceptable salts thereof taken together. In some embodiments, the compound of formula XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k or XX-l or a pharma- ceutically acceptable salt thereof comprises about 100 ppm, 50 ppm, 10 ppm, 1 ppm, 500 ppb, 100 ppb or 10 ppb of the total combined weight of the compounds or pharma- ceutically acceptable salts thereof.
[0343] In some embodiments, the pharmaceutical composition comprises a compound of formula I-5 or a pharma- ceutically acceptable salt thereof, and a compound of formula XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k, or XX-l or a pharma- ceutically acceptable salt thereof, wherein the compound of formula I-5 or a pharma- ceutically acceptable salt thereof is about 99%-99.9999%, 99.5-99.9999%, 99.6-99.9999%, 99.7-99.9999%, 99.8-99.9999%, 99.9-99.9999%, 99.95-99.9999%, 99.99-99.9 999% or 99.999-99.9999%, and the compound of formula XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k or XX-l or a pharma- ceutically acceptable salt thereof constitutes about 10 ppm-2%, 100 ppm-1%, 0.0001-0.5%, 0.0001-0.4%, 0.0001-0.3%, 0.0001-0.2%, 0.0001-0.1%, 0.0001-0.05%, 0.0001-0.01% or 0.0001-0.001% of the total weight of the compounds or pharma-ceutically acceptable salts thereof taken together.
[0344] In some embodiments, the compound of formula I-5 or a pharma- ceutically acceptable salt thereof and the compound of formula XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k or XX-l or a pharma- ceutically acceptable salt thereof are present in a ratio of about 98:2, 99:1, 99.5:0.5, 99.6:0.4, 99.7:0.3, 99.8:0.2, 99.9:0.1, 99.95:0.05, 99.99:0.01 or 99.999:0.001.
[0345] In some embodiments, the compound of any of formulas XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k, or XX-l, or a pharma- ceutically acceptable salt thereof, comprises about 0.01 to 0.20 area percent of the HPLC chromatogram relative to the compound of formula I-5, or a pharma- ceutically acceptable salt thereof. In some embodiments, the compound of formula XX, XX-a, XX-b, XX-c, XX-d, XX-e, XX-f, XX-g, XX-h, XX-i, XX-j, XX-k, or XX-l, or a pharma- ceutically acceptable salt thereof, comprises about 0.02-0.18, 0.03-0.16, 0.05-0.15, 0.075-0.13, 0.09-0.1, 0.1-0.2, or 0.15-0.2 area percent of the HPLC chromatogram relative to the compound of formula I-5, or a pharma- ceutically acceptable salt thereof. In some embodiments, the area percentage of the HPLC chromatogram is measured relative to the total area of the HPLC chromatogram.
[0346] The compound for the pharmaceutical composition can be synthesized using the process and scheme available to those skilled in the art.Synthetic schemes and processes are described in, for example, WO2006127945, WO2014100425, WO2014116593, WO2017035077, WO2017035082, WO2018039192 and WO2018039197, all of which are incorporated herein by reference.
[0347] In the pharmaceutical composition, the amount of the compound in the pharmaceutical composition is sufficient to achieve a therapeutically effective amount when administered to a subject.In some embodiments, the compound can be comprised as a part of the pharmaceutical composition about 0.01% w / v, 0.02% w / v, 0.05% w / v, 0.07% w / v, 0.1% w / v, 0.15% w / v, 0.2% w / v, 0.3% w / v, 0.4% w / v, 0.5% w / v, 0.6% w / v, 0.7% w / v, 0.8% w / v, 0.9% w / v, 1% w / v, 1.5% w / v, 2% w / v, 3% w / v, 4% w / v, 5% w / v, 6% w / v, 7% w / v, 8% w / v, 9% w / v or 10% w / v.
[0348] In some embodiments, the amount of compound in the pharmaceutical composition is from about 0.01% w / v to about 10% w / v, from about 0.02% w / v to about 10% w / v, from about 0.05% w / v to about 10% w / v, from about 0.07% w / v to about 10% w / v, from about 0.1% w / v to about 10% w / v, from about 0.15% w / v to about 10% w / v, from about 0.2% w / v to about 10% w / v, from about 0.3% w / v to about 10% w / v, from about 0.4% w / v to about 10% w / v, from about 0.5% w / v to about 10% w / v, or from about 0.6% w / v to about 10% w / v. % w / v to about 10% w / v, about 0.7% w / v to about 10% w / v, about 0.8% w / v to about 10% w / v, about 0.9% w / v to about 10% w / v, about 1% w / v to about 10% w / v, about 1.5% w / v to about 10% w / v, about 2% w / v to about 10% w / v, about 3% w / v to about 10% w / v, about 4% w / v to about 10% w / v, about 5% w / v to about 10% w / v, about 6% w / v to about 10% w / v, about 7% w / v to about 10% w / v, and about 8% w / v to about 10% w / v.
[0349] In some embodiments, the amount of compound in the pharmaceutical composition is from about 0.01% w / v to about 10% w / v, from about 0.02% w / v to about 9% w / v, from about 0.05% w / v to about 8% w / v, from about 0.07% w / v to about 7% w / v, from about 0.1% w / v to about 6% w / v, from about 0.2% w / v to about 5% w / v, from about 0.3% w / v to about 4% w / v, from about 0.4% w / v to about 3% w / v, or from about 0.5% w / v to about 2% w / v.
[0350] 4.5. Viscosity enhancing agents and hyaluronate preparations In some embodiments, the pharmaceutical composition comprises any of the above compounds and a viscosity enhancer. In some embodiments, the pharmaceutical composition has sufficient viscosity to reduce the sustained diffusion of the therapeutic agent contained in the pharmaceutical composition from the site where the composition is administered and / or to achieve delayed release of the compound. Suitable viscosity enhancers are selected from, among others, hyaluronate, hyaluronic acid or pharma-ceutically acceptable salts thereof; cross-linked hyaluronic acid; polyvinylpyrrolidone (PVP); hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxylethylcellulose, glycerol; and mixtures thereof. In some embodiments, a viscosity enhancer is selected that does not have a reactive aldehyde group that can react with the compounds described herein.
[0351] In some embodiments, the viscosity enhancing agent is sodium hyaluronate, polyvinylpyrrolidone (PVP), sodium hydroxypropylcellulose, or hydroxypropylmethylcellulose. The viscosity enhancing component is present in an amount effective to achieve a desired viscosity to the composition.
[0352] In some embodiments, the amount of viscosity enhancing agent is based on the agent used and will generally be in an amount of about 0.05-30% w / v. In some embodiments, the concentration of the viscosity enhancing agent is about 0.05-30% w / v, about 0.1% w / v to about 25% w / v, about 0.25% w / v to about 15% w / v, about 0.5% w / v to about 15% w / v, about 0.75% w / v to about 10% w / v, or about 1.0% w / v to about 5% w / v.
[0353] In some embodiments, the amount of viscosity enhancing agent in the pharmaceutical composition is between 0.05% w / v and 1.5% w / v; between 0.05% w / v and 0.5% w / v; between 0.1% w / v and 3.0% w / v; between 0.1% w / v and 1.5% w / v; between 0.1% w / v and 1.0% w / v; between 0.5% w / v and 1% w / v; between 0.5% w / v and 2.5% w / v; between 1.0% w / v and 3.0% w / v; between 1.0% w / v and 1.5% w / v; between 1.0% w / v and 1.25% w / v; between 1.25% w / v and 1.5% w / v; or between 1.5% w / v and 3.0% w / v.
[0354] In some embodiments, the amount of viscosity enhancing agent in the pharmaceutical composition is about 0.1% w / v, about 0.25% w / v, about 0.5% w / v, about 0.75% w / v, about 1.0% w / v, about 1.1% w / v, about 1.15% w / v, about 1.20% w / v, about 1.25% w / v, about 1.30% w / v, about 1.35% w / v, about 1.40% w / v, about 1.45% w / v, about 1.5% w / v, about 2% w / v, about 3% w / v, about 4% w / v, about 5% w / v, about 10% w / v, about 15% w / v, about 20% w / v, about 25% w / v, or about 30% w / v.
[0355] In some embodiments, the molecular weight of the viscosity enhancing agent is from about 500,000 to about 5×10 for polymers. 6 Daltons: Approximately 500,000 Daltons to approximately 3×10 6 Daltons: Approximately 500,000 to approximately 2 x 10 6 Dalton: Approximately 500,000 to approximately 1 x 10 6 Daltons: Approximately 500,000 to approximately 2 x 10 6 Dalton: Approximately 1 x 10 6 Dalton ~ approx. 3 x 10 6 Dalton: Approximately 1 x 10 6 Dalton ~ approx. 2.5 x 10 6 Dalton: Approximately 1 x 10 6 Dalton ~ approx. 2 x 10 6 Daltons; or approximately 1.2 x 10 6 Dalton ~ approx. 1.8 x 10 6 In some embodiments, the molecular weight is a number average molecular weight, and in other embodiments, the molecular weight is a weight average molecular weight.
[0356] In some embodiments, the viscosity of the pharmaceutical composition is about 300 kcP, about 250 kcP, about 200 kcP, about 150 kcP, about 140 kcP, about 130 kcP, about 120 kcP, about 110 kcP, about 100 kcP, about 90 kcP, about 80 kcP, about 70 kcP, about 40 kcP, about 30 kcP, about 25 kcP, about 20 kcP, about 10 kcP, about 5 kcP or about 1 kcP.
[0357] In some embodiments, the viscosity of the composition is from about 1 kcP to about 300 kcP; from about 1 kcP to about 200 kcP, from about 1 kcP to about 100 kcP; from about 1 kcP to about 50 kcP; from about 1 kcP to about 10 kcP; from about 10 kcP to about 50 kcP; from about 10 kcP to about 100 kcP; from about 50 kcP to about 100 kcP; from about 100 kcP to about 300 kcP; from about 50 kcP to about 200 kcP; from about 75 kcP to about 180 kcP; from about 100 kcP to about 150 kcP; from about 150 kcP to about 200 kcP; from about 200 kcP to about 250 kcP; or from about 250 kcP to about 300 kcP.
[0358] In some embodiments, the pharmaceutical composition comprises a compound of the present disclosure and hyaluronic acid or a pharma- ceutically acceptable salt of hyaluronic acid. Hyaluronic acid is a glycosaminoglycan, the molecular weight of which can vary from 50,000 Daltons to about 8,000,000 Daltons, and forms a viscous solution. In some embodiments, the hyaluronic acid contained in the formulation can be either in its acid form or in one of its pharma- ceutically acceptable salt forms, such as alkali metal or alkaline earth metal salts of hyaluronic acid, e.g., sodium hyaluronate, potassium hyaluronate, magnesium hyaluronate, calcium hyaluronate, etc. In some embodiments, the hyaluronic acid is in the form of sodium hyaluronate. In some embodiments, the hyaluronate is a sodium hyaluronate solution in combination with a citrate salt, e.g., trisodium citrate.
[0359] In some embodiments of the pharmaceutical composition, the hyaluronate is high molecular weight (HMW) hyaluronic acid or a pharma- ceutically acceptable salt thereof. As used herein, HMW hyaluronic acid refers to hyaluronic acid having a molecular weight of at least about 1×10 6 ~Approx. 5×10 6 HMW hyaluronic acid refers to hyaluronic acid substances having a molecular weight of 1×10 Daltons. In some embodiments, HMW hyaluronic acid refers to hyaluronic acid substances having a molecular weight of 1×10 Daltons. 6 ~Approx. 5×10 6 Dalton; 1.5 x 10 6 ~Approx. 4×10 6 Dalton, 2×10 6 ~Approx. 4×106 Dalton; 2×10 6 ~Approx. 4×10 6 Dalton; 1×10 6 ~Approx. 3×10 6 Daltons; or 1.5 × 10 6 ~about 2×10 6 In some embodiments, the HMW hyaluronic acid in the pharmaceutical composition is about 1×10 Daltons. 6 In some embodiments, the HMW hyaluronic acid can have a molecular weight of about 2.8×10 Daltons. 6 In some embodiments, the hyaluronic acid or salt thereof may have a molecular weight of 1×10 Daltons. 6 Weight average molecular weight not less than 1.3×10 Daltons, more preferably 1.3×10 6 ~3×10 6 In some embodiments, the molecular weight is about 1.7×10 6 It's Dalton.
[0360] In some embodiments, the hyaluronate is a low molecular weight (LMW) hyaluronic acid or a pharma- ceutically acceptable salt thereof. As used herein, LMW hyaluronic acid refers to hyaluronic acid having a molecular weight of about 1×10 6 LMW hyaluronic acid refers to hyaluronic acid substances having a molecular weight of less than about 200,000 to about 1×10 Daltons. In some embodiments, LMW hyaluronic acid refers to hyaluronic acid substances having a molecular weight of less than about 200,000 to about 1×10 Daltons. 6 The hyaluronate component may have a molecular weight of less than about 300,000 Daltons, for example, between about 300,000 and about 750,000 Daltons. In some embodiments, the average molecular weight is less than about 750,000. In some embodiments, the average molecular weight of the hyaluronate component is in the range of about 50,000, or about 100,000 Daltons to about 750,000 Daltons.
[0361] In some embodiments, the average molecular weight of the hyaluronic acid or salt thereof is about 10,000 Daltons, or about 2×10 6 In some embodiments, the average molecular weight of hyaluronic acid is in the range of about 100,000 daltons, or about 200,000 daltons to about 1×10 6Daltons or about 200,000 Daltons to about 1 × 10 6 In some embodiments, the molecular weight of the hyaluronic acid component can vary over a large range to obtain the desired final viscosity of the composition. In some embodiments, two or more different molecular weight ranges of hyaluronic acid can be used to improve the shear thinning properties of the composition. In some embodiments, the hyaluronate is a metal hyaluronate component preferably selected from alkali metal hyaluronate, alkaline earth metal hyaluronate and mixtures thereof, and even more preferably selected from sodium hyaluronate or potassium hyaluronate and mixtures thereof.
[0362] In some embodiments, the molecular weight of the hyaluronate or hyaluronic acid or a pharma- ceutically acceptable salt thereof is from about 500,000 to about 5×10 6 Dalton: Approximately 500,000 to approximately 3 x 10 6 Daltons: Approximately 500,000 to approximately 2 x 10 6 Dalton: Approximately 500,000 to approximately 1 x 10 6 Daltons: Approximately 500,000 to approximately 2 x 10 6 Dalton: Approximately 1 x 10 6 ~Approx. 3×10 6 Dalton: Approximately 1 x 10 6 ~Approx. 2.5×10 6 Dalton: Approximately 1 x 10 6 ~about 2×10 6 Daltons; or approximately 1.2 x 10 6 ~Approx. 1.8×10 6 It's Dalton.
[0363] In some embodiments, the amount of hyaluronate in the pharmaceutical composition is about 0.05% w / v; about 0.1% w / v, about 0.25% w / v, about 0.5% w / v, about 0.75% w / v, about 1.0% w / v, about 1.1% w / v, about 1.15% w / v, about 1.20% w / v, about 1.25% w / v, about 1.30% w / v, about 1.35% w / v, about 1.40% w / v, about 1.45% w / v, about 1.5% w / v; about 2% w / v; about 2.5% w / v; about 3% w / v; about 3.5% w / v; or about 4% w / v.
[0364] In some embodiments, the amount of hyaluronate in the pharmaceutical composition is from about 0.05% w / v to about 1.5% w / v; from about 0.05% w / v to about 0.5% w / v; from about 0.1% w / v to about 4.0% w / v; from about 0.1% w / v to about 3.0% w / v; from about 0.1% w / v to about 1.5% w / v; from about 0.1% w / v to about 1.0% w / v. w / v; about 0.5% w / v to about 1% w / v; about 0.5% w / v to about 2.5% w / v; about 1.0% w / v to about 3.0% w / v; about 1.0% w / v to about 1.5% w / v; about 1.0% w / v to about 1.25% w / v; about 1.25% w / v to about 1.5% w / v; or about 1.5% w / v to about 3.0% w / v.
[0365] In some embodiments, the hyaluronate is in an amount ranging from about 0.05% to about 0.5% (w / v). In some embodiments, the hyaluronate is present in an amount ranging from about 1% to about 4% (w / v). At higher concentrations, the high viscosity can result in a gel that slows particle precipitation and diffusion of dissolved solutes, such as upon injection into the eye. Such compositions can be provided in pre-filled syringes for ease of administration.
[0366] In some embodiments, the hyaluronic acid is crosslinked hyaluronic acid. In some embodiments, the hyaluronic acid is present in the form of crosslinked hyaluronic acid at about 50% to 99% by weight or 70% to 95% by weight, and hyaluronic acid present in free form or in a pharma-ceutically acceptable salt thereof at 1% to 50% by weight, preferably 5% to 30% by weight. In some embodiments, when the hyaluronic acid is crosslinked, the crosslinked hyaluronic acid may have a degree of modification in the range of 0.1 to 20%, preferably 0.4 to 10%. In some embodiments, the viscous crosslinked hyaluronic acid-based gel contains about 1% to about 10% or less of free hyaluronic acid material by volume, for example, about 5% or less of free hyaluronic acid material.
[0367] In some embodiments, crosslinked hyaluronic acid can be prepared by, among others, using dihyrazide, photocrosslinking, enzymatic crosslinking, epoxy crosslinking and click chemistry. "Degree of modification" refers to the ratio between the moles of crosslinker bound to hyaluronic acid and the moles of said crosslinked hyaluronic acid gel forming hyaluronic acid. Free hyaluronic acid is generally water-soluble and, as used herein, can be defined as "non-crosslinked" or slightly crosslinked component of macromolecular structure. Crosslinked hyaluronic acid and methods for their preparation are described, inter alia, in Schramm et al., 2012, Invest Ophthalmol Vis Sci. 53:613-621; Schramm et al., 2011, Invest Ophthalmol Vis Sci. 52:452; Egbu et al., 2018, Eur J Pharm Biopharm. 124:95-103; U.S. Patent No. 8,357,795; U.S. Patent No. 9,413,621; and U.S. Patent No. 6,211,511, all of which are incorporated by reference in their entirety herein. No. 925,309.
[0368] In some embodiments, the viscosity enhancing agent is hyaluronic acid crosslinked with dextran (see, e.g., Yu et al., 2015, Transl. Vis Sci Technol. 4(2):5). Synthesis of hyaluronic acid crosslinked with dextran can be achieved by chemical crosslinking between functionalized hyaluronic acid and thiolated dextran. In some embodiments, the viscosity enhancing agent is a copolymer of hyaluronic acid and poly(glycerylglycerol) (PGG) side chains linked via a hydrolyzable ester linker (see, e.g., Borke et al., 2018, Macromolecular Bioscience 18:1700200, incorporated herein by reference).
[0369] In some embodiments, for intraocular, e.g., intravitreal, formulations, the hyaluronate intraocular administration composition has a sufficient viscosity to reduce the large diffusion of the drug contained in the composition from the site where the composition is administered.In some embodiments, the pharmaceutical composition has a viscosity of at least about 10 cps, or at least about 100 cps, or at least about 1000 cps, more preferably at least about 10,000 cps, and even more preferably at least about 70,000 cps or more, for example, up to about 200,000 cps or about 250,000 cps, or about 300,000 cps or more, at a shear rate of 0.1 / s.In some embodiments, the composition has a sufficient viscosity to be able to be structured or formed, for example, by a 27 gauge needle, or even by a 30 gauge needle, but to be able to be injected into the posterior segment of the human or animal eye.
[0370] In some embodiments, the pharmaceutical composition comprising the compound disclosed herein and a viscosity enhancing agent further comprises one or more excipients.In some embodiments, the excipient is one or more of isotonicity agents, buffering agents, chelating agents, surfactants, preservatives, antioxidants, and additional viscosity enhancing agents different from the first viscosity enhancing agent.
[0371] In some embodiments, the pharmaceutical composition further comprises an isotonicity agent. In some embodiments, the pharmaceutical composition further comprises a buffering agent. In some embodiments, the pharmaceutical composition further comprises a chelating agent. In some embodiments, the pharmaceutical composition further comprises a surfactant. In some embodiments, the pharmaceutical composition further comprises a preservative. In some embodiments, the pharmaceutical composition further comprises an antioxidant. In some embodiments, the pharmaceutical composition further comprises an additional viscosity enhancing agent different from the first viscosity enhancing agent. In some embodiments, the excipient is suitable for intraocular administration, for example intravitreal administration.
[0372] 4.6. Liposomal formulations In some embodiments, pharmaceutical composition comprises the compound of the present disclosure formulated in liposome.Liposome is an artificial self-closing vesicle structure of various sizes and structures, in which one or several membranes encapsulate aqueous core.In some embodiments, liposome composition is selected that does not have aldehyde group that can react with the compound described herein.
[0373] In some embodiments, the types of liposomes include multilamellar vesicles (MLVs) or oligolamellar vesicles (OLVs), unilamellar vesicles (SUVs) and large unilamellar vesicles (LUVs).Generally, unilamellar liposomes are liposomes with a single bilayer of amphiphilic lipids or mixtures of such lipids, containing aqueous solution in the chamber.Generally, MLVs have more than one lipid bilayer, and the lipid bilayers of MLVs are separated from each other by aqueous solution.
[0374] In some embodiments, small unilamellar liposomes / vesicles (SUVs) have a diameter of up to 100 nm, e.g., 20 um to about 100 um. Large unilamellar liposomes / vesicles (LUVs) can have a diameter of more than 100 nm and up to several micrometers (μm), the latter sometimes referred to as giant unilamellar vesicles (GUVs). MLVs can have a diameter of 200 nm to 3 um, e.g., more than 0.5 um. In some embodiments, the diameter is an average diameter. As used herein, "average diameter" generally refers to the arithmetic mean value of a set of diameters, each diameter being considered for each liposome in a liposome population.
[0375] In some embodiments, the pharmaceutical composition comprises the compound of the present disclosure formulated in liposomes, preferably as small unilamellar vesicles (SUVs) or large unilamellar vesicles (LUVs) or multilamellar vesicles (MLVs). In some embodiments, the liposomes have an average diameter of less than about 1 um (i.e., submicron-sized liposomes).
[0376] In some embodiments, the liposomes have an average diameter of about 20 nm to about 1 um or less; about 20 nm to about 900 nm; about 20 nm to about 800 nm; about 20 nm to about 700 nm, about 20 nm to about 600 nm; about 20 nm to about 500 nm; about 20 nm to about 450 nm; about 20 nm to about 400 nm; about 20 nm to about 350 nm; about 20 nm to about 300 nm; about 20 nm to about 250 nm; about 20 nm to about 200 nm; about 20 nm to about 150 nm; about 20 nm to about 125 nm; about 20 nm to about 100 nm; about 20 nm to about 80 nm; about 20 nm to about 70 nm; or about 20 nm to about 50 nm.
[0377] In some embodiments, the liposomes have an average diameter of about 50 nm to about 900 nm; about 50 nm to about 800 nm; about 50 nm to about 700 nm; about 75 nm to about 600 nm; about 75 nm to about 500 nm; about 100 nm to about 400 nm; or 100 nm to about 300 nm.
[0378] In some embodiments, the liposomes are about 1 um, 900nm, 850nm, 800nm; 750nm; 700nm; 650nm; 600nm; 550nm; 500nm, 450nm, 400nm, 350nm, 300nm, 250nm, 200nm, 150nm, 125nm, 110nm, 100nm, 95nm, 90nm, 85nm, 80nm, 75nm, 70nm, 65nm, 60nm, 55nm, 50nm, 40nm, 30nm or 20nm. The size is, or is less than about 1 um, 900nm, 850nm, 800nm; 750nm; 700nm; 650nm; 600nm; 550nm; 500nm, 450nm, 400nm, 350nm, 300nm, 250nm, 200nm, 150nm, 125nm, 110nm, 100nm, 95nm, 90nm, 85nm, 80nm, 75nm, 70nm, 65nm, 60nm, 55nm, 50nm, 40nm, 30nm or 20nm.
[0379] In the context of various embodiments, the term "liposome formulation" refers to a preparation of liposomes, where the liposomes are artificially prepared vesicles made of lipid bilayers. The lipid bilayers can be in the form of a single or one lipid bilayer, or multiple lipid bilayers. The liposomes can be loaded with drugs or loaded with drugs. In general, liposomes are composed of amphiphilic lipids, such as phospholipids of natural or synthetic origin. In some embodiments, the membrane properties can be modified by the incorporation of other lipids, such as sterols or cholic acid derivatives. In some embodiments, the liposomes comprise one or more of fatty acyls, glycerolipids, phospholipids, glycerophospholipids, sphingolipids, sterol lipids, prenolipids, saccharolipids, and polyketide lipids.
[0380] In some embodiments, the liposome comprises lipid, and the lipid comprises one or more of phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, ganglioside, glycolipid, phosphatidylglycerol and cholesterol. Phosphatidylcholine includes, among others, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine. Phosphatidylethanolamine includes, among others, dimyristoylphosphatidylethanolamine, dipalmitoylphosphatidylethanolamine and distearoylphosphatidylethanolamine. Phosphatidic acid includes, among others, dimyristoylphosphatidic acid, dipalmitoylphosphatidic acid, distearoylphosphatidic acid and dicetylphosphate. Ganglioside includes, among others, ganglioside GM1, ganglioside GD1a and ganglioside GT1b. Glycolipids include, inter alia, galactosylceramide, glucosylceramide, lactosylceramide, phospholipids and globosides. Phosphatidylglycerols include, inter alia, dimyristoylphosphatidylglycerol, dipalmitoylphosphatidylglycerol and distearoylphosphatidylglycerol.
[0381] In some embodiments, the phosphatidylcholine is selected from L-α-phosphatidylcholine, egg phosphatidylcholine (EPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-O-ethyl-3-phosphocholine, 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and mixtures thereof. The phosphatidylcholine may be used alone or in combination with other lipids.
[0382] In various embodiments, each of the phosphatidylcholines can comprise at least one unsaturated fatty acid moiety.For example, each of the phosphatidylcholines can comprise L-α-phosphatidylcholine or 95% egg phosphatidylcholine (EPC).In some embodiments, each of the sphingolipids can comprise at least one unsaturated fatty acid moiety.For example, each of the sphingolipids can comprise hexadecanoyl sphingomyelin or egg sphingomyelin.
[0383] In some embodiments, the liposome comprises a lipid derivatized with a hydrophilic polymer. In some embodiments, the hydrophilic polymer is a biocompatible polymer, particularly for injection into the body, such as intraocular administration. Suitable hydrophilic polymers include, among others, polyvinylpyrrolidone, polyvinylmethylether, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyloxazoline, polyhydroxypropylmethacrylamide, polymethacrylamide, polydimethylacrylamide, polyhydroxypropylmethacrylate, polyhydroxyethylacrylate, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, polyethylene glycol, polyaspartamide, poly-L-lysine, and hydrophilic peptide sequences.
[0384] In some embodiments, the lipids in the liposomes are derivatized with polyethylene glycol, in some embodiments, the PEG chains have a molecular weight of about 300 to about 5,000 daltons.
[0385] In some embodiments, the liposome is surface-modified with poly-L-lysine. In some embodiments, the poly-L-lysine has a molecular weight of about 15,000 to 30,000 (see, for example, Sasaki et al., 2013, Eur J Pharm Biopharm. 83(3):364-9, which is incorporated herein by reference).
[0386] Methods for preparing lipids derivatized with hydrophilic polymers are described, for example, in U.S. Pat. No. 5,395,619; U.S. Pat. No. 5,556,948; U.S. Pat. No. 6,296,870; WO2014031429, all of which are incorporated by reference in their entirety.
[0387] In some embodiments, the liposome further comprises cholesterol or a derivative thereof. In some embodiments, the cholesterol derivative is cholestanol, dihydroxycholine, or cholinesterase. It may be hydrocholesterol, cholesteryl ester, phytosterol, sitosterol, stigmasterol, campesterol or mixtures thereof. In liposomes containing cholesterol or its derivatives, the amount may vary depending on the properties required or desired. In some embodiments, the content of cholesterol or cholesterol derivative in the liposome is about 0% to about 50% by weight of the liposome, about 0% to about 40% by weight of the liposome, about 0% to about 30% by weight of the liposome, about 0% to about 20% by weight of the liposome, about 0% to about 10% by weight of the liposome, about 10% to about 50% by weight of the liposome, about 10% to about 40% by weight of the liposome, about 10% to about 30% by weight of the liposome, about 10% to about 20% by weight of the liposome, about 20% to about 50% by weight of the liposome, about 20% to about 40% by weight of the liposome, about 20% to about 30% by weight of the liposome, or about 30% to about 40% by weight of the liposome. In some embodiments, the cholesterol content of the liposomes is about 10% to about 40% by weight of the liposomes.
[0388] In some embodiments, the liposome comprises a cationic lipid. In some embodiments, the liposome is a cationic liposome. In some embodiments, the cationic lipid is a linear C 8 ~C 20 In some embodiments, "C 8 ~C 20 "Alkyl" refers to a straight chain hydrocarbon group having 8 to 20 carbon atoms. 8 ~C 20 "Alkenyl" refers to a straight chain hydrocarbon group containing one or more double bonds and having 8 to 20 carbon atoms. 8 ~C 20 Alkyl or alkenyl amines include, but are not limited to, dodecylamine, tallow amine, stearylamine, coconut amine, octadecylamine, N-octyloctane-1-amine, 2-nonenylamine, di(2-nonenyl)amine, and mixtures thereof. These linear C 8 ~C 20The alkyl or alkenyl amines may be used alone or in combination. In some embodiments, linear C 8 ~C 20 The alkyl or alkenyl amine is stearylamine. For example, DPPC may or may not have stearylamine added. In some embodiments, the cationic lipid is 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA), dioctadecyl di-methylammonium (DODA(Br) / DDAB), dioctadecyl dimethylammonium chloride (DODAC), 1,2-dimyristoyloxypropyl-1,3-dimethylhydroxyethylammonium (DMRIE), 2,3-dioleoyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanammonium trifluoroacetate (DOSPA) analogues of these molecules with different compositions of acyl chain moieties. In some embodiments, the cationic liposome comprises one or more non-cationic lipids. In some embodiments, the non-cationic lipid is a neutral lipid, such as cholesterol (Chol) or sphingomyelin (SM).
[0389] In some embodiments, the liposome comprises 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC).
[0390] In some embodiments, the liposome comprises egg phosphatidylcholine (EPC) and l-α-distearoylphosphatidylcholine.
[0391] In some embodiments, the liposomes comprise egg phosphatidylcholine (EPC) or 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, and cholesterol or a derivative thereof.
[0392] In some embodiments, the liposomes comprise dioleoylphosphatidylcholine (DOPC), dioleoylphosphatidylglycerol (DOPG) and cholesterol, or derivatives thereof.
[0393] In some embodiments, the liposomes comprise dipalmitoylphosphatidylcholine (DPPC), palmitoyl-oleoylphosphatidylcholine (POPC) and cholesterol.
[0394] In various embodiments, liposomes can be prepared by various methods available in the art.In some embodiments, liposomes can be prepared using lipids in aqueous solution with mechanical stirring, freeze-drying, microemulsification, ultrasonication, French pressure cell, membrane extrusion or freeze-thawing.In some embodiments, liposomes can be prepared by solvent dispersion process, including ether injection, ethanol injection or double emulsion.Methods of preparing liposomes are described in, among others, International Patent Publication WO92 / 10166; US Patent Publication No. 20080274172; US Patent No. 4744989; US Patent No. 5395619; US Patent No. 5556948; US Patent No. 5549910; US Patent No. 6296870; and US Patent No. 8591942.
[0395] In some embodiments, the loading of drug compounds into liposomes is carried out, for example, by having the compound present during the formation of liposomes to encapsulate the compound in liposomes.In some embodiments, the compound can be present in lipid membranes, particularly hydrophobic compounds.In some embodiments, the compound can be incorporated into liposomes after the formation of liposomes.
[0396] In some embodiments, the pharmaceutical composition comprising the compound of the present disclosure in liposomes further comprises one or more excipients. In some embodiments, the excipient is one or more of an isotonicity agent, a viscosity enhancing agent, a buffering agent, a chelating agent, a surfactant, a preservative, and an antioxidant. In some embodiments, the liposomal pharmaceutical composition further comprises an isotonicity agent. In some embodiments, the liposomal pharmaceutical composition further comprises a buffering agent. In some embodiments, the liposomal pharmaceutical composition further comprises a viscosity enhancing agent. In some embodiments, the liposomal pharmaceutical composition further comprises a chelating agent. In some embodiments, the liposomal pharmaceutical composition further comprises a surfactant. In some embodiments, the liposomal pharmaceutical composition further comprises a preservative. In some embodiments, the liposomal pharmaceutical composition further comprises an antioxidant. In some embodiments, the excipient is suitable for intraocular administration, for example, intravitreal administration.
[0397] In some embodiments, the liposomes formulated with the compound further comprise at least a viscosity enhancing agent, as further described herein. In some embodiments, the viscosity enhancing agent is hyaluronate or hyaluronic acid or a pharma- ceutically acceptable salt thereof, as described herein.
[0398] In some embodiments, liposomes formulated with the compounds are dispersed in a non-ionic surface active poloxamer (e.g., Pluronic®). In some embodiments, the liposomes are dispersed in a poloxamer selected from P124, P188, P237, P338, P407, and mixtures thereof. In some embodiments, the poloxamer is P188, P407, or a mixture thereof (see, e.g., Fattal et al., 2004, Int J Pharm. 277(1-2):25-30, incorporated herein by reference). I want to be illuminated.
[0399] 4.7. Biodegradable Microparticles and Nanoparticles In another aspect, the compounds of the present disclosure are formulated into microparticles or nanoparticles, particularly of biodegradable polymers.Various types of biocompatible biodegradable polymers can be used by themselves or in combination, including but not limited to poly(ester), poly(ester amide), poly(anhydride), poly(carbonate), poly(amino acid), poly(amide), poly(urethane), poly(ortho-ester), poly(iminocarbonate) and poly(phosphazene).The polymers can be crosslinked or non-crosslinked.When crosslinked, the polymers can be less than 5% crosslinked, usually less than 1% crosslinked.In some embodiments, the microparticle and nanoparticle compositions do not have free aldehyde groups that can react with the compounds described herein.
[0400] In some embodiments, the biodegradable polymer comprises a hydroxyaliphatic carboxylic acid, a homopolymer or copolymer, and / or a polysaccharide. In some embodiments, the polymer is a homopolymer or copolymer of D-lactic acid, L-lactic acid, racemic lactic acid, glycolic acid, caprolactone, and combinations thereof. In some embodiments, the polymer of the composition comprises, among others, poly(lactide) (PLA), poly(lactide-co-glycolide) (PLGA), polyglycolide (PGA), polyhydroxybutyric acid, polycaprolactone (e.g., poly(ε-caprolactone; PCL), polyvalerolactone, polyphosphazene, and polyorthoester. In some embodiments, the PLA can comprise poly-D-lactic acid (PDLA) or poly-L-lactic acid (PLLA).
[0401] In some embodiments, the pharmaceutical composition comprises a block copolymer of polyester and polyethylene glycol (PEG). PLGA / PEG block copolymers are fabricated as diblock (PLGA-PEG) or triblock molecules with both ABA (PLGA-PEG-PLGA) and BAB (PEG-PLGA-PEG) types. In diblock copolymers, the PEG chains orient themselves toward the external aqueous phase in the micelle, thus surrounding the encapsulated species. The layer of PEG acts as a barrier and reduces interactions with other molecules due to steric and hydration repulsion for enhancing storage stability. In triblock copolymers, ABA and BAB type polymers can act as thermogels with the A block covalently linked to the B-block by an ester linking group. The copolymers are usually free-flowing solutions at low temperatures and can form high viscosity gels at body temperature. These temperature-responsive copolymers, PLGA-PEG-PLGA or PEG-PLGA-PEG, are a type of block copolymers composed of hydrophobic PLGA segments and hydrophilic PEG segments. The hydrophobic PLGA segments form associative crosslinks, while the hydrophilic PEG segments allow the copolymer molecules to remain in solution. At lower temperatures, hydrogen bonds between the hydrophilic PEG segments and water molecules predominate in aqueous solutions, leading to their dissolution in water. As the temperature increases, the hydrogen bonds become weaker, while the hydrophobic forces between the PLGA segments become stronger, leading to a solution-gel transition.
[0402] In some embodiments, the polymer is a copolymer of glycolic acid and lactic acid (e.g., PLGA). In some embodiments, the biodegradable polymer matrix comprises a mixture of hydrophilic and hydrophobic-ended PLGA, which is useful for modulating the rate of degradation of the polymer matrix. When terminated with hydrophobic moieties, also referred to as capped or capped ends, PLGA has the hydrophobic nature of the ester linking groups at the polymer ends. Exemplary hydrophobic end groups include, but are not limited to, alkyl esters and aromatic esters. When terminated with hydrophilic moieties, also referred to as uncapped, PLGA has the hydrophilic nature of the end groups at the polymer ends. PLGA with hydrophilic end groups at the polymer ends usually degrade faster than hydrophobic-ended PLGA, as they take up water and undergo hydrolysis at a faster rate (see, e.g., Tracy et al., 1999, Biomaterials 20:1057-1062, incorporated herein by reference). Examples of suitable hydrophilic end groups that can be incorporated to enhance hydrolysis include, but are not limited to, carboxyl, hydroxyl, and polyethylene glycol.
[0403] In some embodiments, the percentage of each monomer in a poly(lactic-co-glycolic) acid (PLGA) copolymer can be 0-100%, about 15-85%, about 25-75%, or about 35-65%. In some embodiments, the PLGA polymer can have a lactide to glycolide ratio of about 10:90, 15:85, 20:80, 25:75, 30:70; 35:65, 40:60, 45:55, 50 / 50, 60:40; 65:35; 70:30 75:25, or 80:20. In some embodiments, the percentage of glycolic acid in the polymer is used to modulate the degradation rate. Increasing the percentage of glycolic acid generally results in greater weight loss of the polymer. For example, PLGA 50:50 (PLA / PGA) shows faster degradation than PLGA 65:35 due to preferential degradation of the glycolic acid moieties conferred by their greater hydrophilicity. It is shown that PLGA 65:35 degrades faster than PLGA 75:25, which in turn degrades faster than PLGA 85:15. The glycolic acid content also affects the hydrophilicity of the matrix, thus affecting the degradation rate and drug release rate.
[0404] In some embodiments, the microparticles or nanoparticles comprise poly(ester amides) ("PEAs") (see, e.g., Andres-Guerrero et al., 2015, J Controlled Release 211, 10:105-117, which are incorporated herein by reference). PEAs are synthetic polycondensation products composed of biocompatible building blocks such as hydrophobic L-amino acids, aliphatic dicarboxylic acids, and α,ω-diols (see, e.g., U.S. Patent Publication No. 20170119813(A1); Tsitlanadze, et al., 2004, J. Biomater. Sci. Polym. Edn. 15:1-24; U.S. Patent No. 9,873,764; and Rodriguez-Galin, et al., 2003 ... and U.S. Patent No. 9,8 et al., Biodegradable Poly (Ester Amide)s: Synthesis and Applications," In Biodegradable Polymer: Processing and Degradation, G. Felton ed., See Chapter 4, pages 207-272, Nova Science Publishers (2011) (All publications are incorporated herein by reference in their entirety). In some embodiments, the PEA comprises an α-amino acid (e.g., glycine, 4-aminobutyric acid, L-alanine, L-phenylalanine, etc.). In some embodiments, the PEA comprises L-alanine. In some embodiments, the α-amino acid content is about 100%, about 90%, about 80%, about 70%, about 50%, or about 30%.
[0405] In some embodiments, the PEA comprises a copolymer of an α-hydroxy acid and an α-amino acid. In some embodiments, the PEA comprises poly[(e-caprolactam)-co-(e-caprolactone). In some embodiments, the PEA is a random aliphatic poly(ester amide) (e.g., based on adipic acid, 6-aminohexanoic acid, and 1,4-butanediol).
[0406] In some embodiments, the weight average molecular weight (MW) of the polymer, including the copolymer, can be in the range of about 10,000 to about 400,000 Daltons, or about 60,000 to about 250,000 Daltons. In some embodiments, the weight average molecular weight (MW) of the polymer is about 8000 to about 14000 Daltons, and the molecular weight is about 13000 to about 16000 Daltons. Polymers with higher molecular weights, having longer polymer chains, are used to reduce the degradation rate. However, this can be the opposite for PLLA, since crystallinity and molecular weight are inversely proportional.
[0407] In some embodiments, the pharmaceutical composition is a microsphere particle, a microcapsule particle, or a microparticle. In some embodiments, the microparticle has an average particle size of about 1 to about 250 um, about 1 to about 200 μm, about 1 to about 150 μm, about 1 to about 100 μm, about 1 to about 50 μm, about 1 to about 40 μm, about 1 to about 30 μm, about 1 to about 20 μm, about 1 to about 10 μm, or about 1 to about 5 μm.
[0408] In some embodiments, the biodegradable pharmaceutical composition is in the form of nanoparticles. In some embodiments, the nanoparticles have an average size of less than about 1 um (submicron). In some embodiments, the nanoparticles have an average size of less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, or less than about 100 nm. In some embodiments, the average particle size of the nanoparticles is about 100 to about 200 nm; about 200 to about 300 nm; about 300 to about 400 nm; or about 400 to about 500 nm. In some embodiments, the average particle size of the nanoparticles is about 50 to about 900 nm, about 50 to about 800 nm, about 50 to about 700 nm, about 50 to about 600 nm, about 50 to about 500 nm, about 50 to about 400 nm, about 50 to about 300 nm, about 50 to about 200 nm, or about 50 to about 100 nm. In some embodiments, the average particle size is about 50 to about 500 nm. In other embodiments, the average particle size is about 50 to about 400 nm. In further embodiments, the average particle size is about 50 to about 300 nm. In further embodiments, the average particle size is about 50 to about 200 nm. In further embodiments, the average particle size is about 50 to about 100 nm. In further embodiments, the average particle size is about 50 to about 75 nm. In some embodiments, the average particle size is about 50 to about 60 nm.
[0409] In some embodiments of nanoparticles containing PLGA, the PLGA has an average molecular weight of about 2,000 to about 10,000 daltons. In other embodiments, the PLGA has an average molecular weight of about 2,000 to about 7,000 daltons. In other embodiments, the PLGA has an average molecular weight of about 2,000 to about 5,000 daltons. In some embodiments, the PLGA has an average molecular weight of about 4,000 to about 20,000 daltons or about 4,000 to about 10,000 daltons or about 4,000 to about 5,000 daltons. In still other embodiments, the PLGA has an average molecular weight of about 2,000 daltons, about 4,500 daltons, about 5,000 daltons, about 7,000 daltons, or about 10,000 daltons.
[0410] In some embodiments, the microparticles or nanoparticles can have an associated non-active agent. In some embodiments, the non-active agent is one or more of polyethylene glycol (PEG), fatty acid, amino acid, aliphatic or non-aliphatic molecule, aliphatic thiol, aliphatic amine, etc. In some embodiments, the non-active agent is PEG of different chain length. In some embodiments, the non-active agent is a stabilizer such as polyvinyl alcohol (PVA).
[0411] In some embodiments, the pharmaceutical composition is a biocompatible injectable intraocular drug delivery system comprising: (a) a plurality of microparticles having an average diameter of about 8 um to about 14 um; and (b) an aqueous vehicle for the microspheres, wherein the microspheres comprise: (1) a compound disclosed herein, the compound constituting about 0.1% to about 10% by weight of the microparticles; and (2) one or more biodegradable polymers, including a PLA polymer or a PLGA polymer, the PLA polymer or the PLGA polymer having a viscosity of between about 0.4 dL / gm to about 0.8 dL / gm, the PLA polymer or the PLGA polymer constituting about 85% to about 99.5% by weight of the microspheres, the drug delivery system comprising the biodegradable polymers capable of being injected into an intraocular location with a 20-26 gauge syringe needle.
[0412] In some embodiments, microparticles and nanoparticles can be prepared by a variety of methods, including oil / water emulsions, solvent / oil / water emulsions, oil / oil emulsions, and spray drying. Methods are described, for example, in Wischke and Schwendeman, 2008, "Principles of encapsulating hydrophobic compounds in PLA / PLGA microparticles," Intl J Pharmaceutics 364:298-327; and patent publication US20160143851(A1). In some embodiments, the microparticles are prepared by an oil-in-water emulsion process by dissolving the polymer (e.g., PLGA) in a water-immiscible volatile organic solvent (such as dichloromethane (DCM), tetrahydrofuran (THF) or ethyl acetate) and then dissolving the compound (sometimes prepared as particles (e.g., 20-30 um) in the prepared solution) or alternatively dissolving the compound in a miscible co-solvent and mixing. Co-solvents are generally used in the case of drugs that do not exhibit high solubility in the primary organic solvent. The resulting organic oil phase is then emulsified in an aqueous solution (continuous phase) containing a suitable emulsifier, e.g., polyvinyl alcohol. The emulsifier contained in the aqueous phase can act as a stabilizer in the case of oil-in-water emulsions. The emulsion is then subjected to solvent removal, either by solvent evaporation to solidify the oil droplets or by an extraction process. In general, the volatile solvent can be removed from such emulsions by solvent evaporation into the gas phase or, in any case, by extraction into a continuous phase. For example, in the former case of solvent evaporation, the emulsion is maintained at reduced or atmospheric pressure and the stirring speed is reduced while the temperature is elevated to allow the volatile solvent to evaporate. In the latter case of extraction into a continuous phase, the emulsion is transferred to a large volume of water (with or without surfactant) or other quenching medium, in which the solvent with the oil droplets is dispersed. A combination of solvent evaporation and extraction is also applicable. The solid microspheres thus obtained are then washed and collected by sieving. They are then dried under suitable conditions, such as by vacuum drying or freeze-drying.
[0413] In some embodiments, the microparticles are prepared by solvent / oil / water emulsion, which can be used when the compound cannot be dissolved in the carrier solvent or solvent mixture, or when significant drug loss into the continuous phase cannot be avoided when using a co-solvent system. In the case of solvent / oil / water emulsion, the compound is dispersed in the oil phase of an organic solvent or solvent mixture, and a polymer dissolved in this phase. The s / o / w method generally uses small drug particle sizes to allow complete encapsulation of drug crystals.
[0414] In some embodiments, the microparticles are prepared by oil / oil emulsion. This method can be used in the case of compounds classified as hydrophobic but that show some solubility in aqueous media. The compound and polymer to be encapsulated are dissolved in an organic solvent (e.g., acetonitrile), and then this solution is emulsified in a continuous phase of a solution of an emulsifier (usually with an HLB of <8) in oil, e.g., cottonseed oil or mineral oil. The first oil phase solvent (e.g., acetonitrile) is extracted into the external oil phase, which can be a non-solvent for both the polymer and the drug. An alternative method concerns the s / o / o technique, which combines the concepts of the s / o / w and o / o methods. Removal of the continuous phase can be done by washing the particles with hexane or petroleum ether. The emulsification step can be achieved by mechanical stirring, high shear mixers and / or static mixers.
[0415] In some embodiments, microspheres or microparticles can be prepared by spraying a solution or suspension of a compound in an organic solution of a polymer, such as a solid-in-oil dispersion or a water-in-oil emulsion. In general, spray drying is defined as the conversion of a feed from a liquid state (solution or dispersion) to a dry particulate form by spraying the feed into a gaseous drying medium (e.g., heated air). In some embodiments, various spray drying systems can be used, which can be classified as rotary atomization, compression atomization, and two-fluid atomization, depending on the nozzle design. In some embodiments, the spray drying process uses a coaxial capillary flow technique that produces monodispersed micro / nanoparticles with either a single-shell or core-shell structure.
[0416] To prepare nanoparticles, techniques used in preparing microparticles can be used. Adjustment of processing parameters usually allows the production of nanoparticles. In some embodiments, the process uses a small dispersed phase ratio and stirring speed. In some embodiments, nanoparticles are prepared by an emulsification-solvent evaporation process, especially for encapsulating hydrophobic compounds. For more hydrophilic compounds, double or multiple emulsions can be used. High-speed stirring, e.g., emulsification with a high-speed homogenizer, can be used to reduce the size of the particles formed.
[0417] In some embodiments, nanoparticles are prepared by nanoprecipitation process. In some embodiments, polymer and compound are dissolved in organic solvent (e.g., acetone) and added to aqueous solution containing surfactant such as Pluronic, especially Pluronic F68. Solvent evaporation of organic solvent at appropriate temperature and reduced pressure leaves nanoparticles with drug compound encapsulated by polymer. Salt precipitation is another method that first forms water-in-oil emulsion containing polymer, solvent (usually non-chlorinated solvent, e.g., acetone), salt (e.g., magnesium acetate tetrahydrate) and stabilizer. Water is then added to the solution until the volume is sufficient to allow acetone to diffuse into the water, resulting in nanoparticle formulation.
[0418] In some embodiments, the pharmaceutical composition of the compound in the form of biodegradable polymer microparticles or nanoparticles further comprises one or more excipients selected from isotonicity agents, viscosity enhancing agents, buffering agents, chelating agents, surfactants, preservatives, and antioxidants.
[0419] In some embodiments, the pharmaceutical composition of the compound in the form of biodegradable polymer microparticles or nanoparticles further comprises an isotonicity agent. In some embodiments, the pharmaceutical composition of the compound in the form of biodegradable polymer microparticles or nanoparticles further comprises a buffering agent. In some embodiments, the pharmaceutical composition of the compound in the form of biodegradable polymer microparticles or nanoparticles further comprises a viscosity enhancing agent. In some embodiments, the pharmaceutical composition of the compound in the form of biodegradable polymer microparticles or nanoparticles further comprises a chelating agent. In some embodiments, the pharmaceutical composition of the compound in the form of biodegradable polymer microparticles or nanoparticles further comprises a surfactant. In some embodiments, the pharmaceutical composition of the compound in the form of biodegradable polymer microparticles or nanoparticles further comprises a preservative. In some embodiments, the pharmaceutical composition of the compound in the form of biodegradable polymer microparticles or nanoparticles further comprises an antioxidant. In some embodiments, the excipient is suitable for intraocular administration, for example intravitreal administration.
[0420] 4.8. Calcium phosphate particles In some embodiments, the pharmaceutical composition comprises a compound formulated as calcium phosphate particles, particularly calcium phosphate nanoparticles (see, e.g., Patent Publication WO2004050065A1; Chen et al., 2010, Pharm Soc Japan 130(3):419-24; U.S. Patent No. 828,628; 7914; Patent Publication WO2008129562; European Patent Publication No. 2041025(A2); all publications are incorporated herein by reference). The low solubility of hydroxyapatite (HA) type calcium phosphate (CaP) in physiological conditions allows for long-term retention after replacement in vivo. In some embodiments, the calcium phosphate particles have an average particle size of about 200 nm to about 4000 nm. In some embodiments, the calcium phosphate particles have an average particle size of about 300 nm to about 4000 nm; about 300 nm to about 2000 nm; about 300 nm to about 1000 nm. In some embodiments, the calcium phosphate particle composition does not have free aldehyde groups capable of reacting with the compounds described herein.
[0421] In some embodiments, the calcium phosphate particles have an average particle size of less than 1000 nm (submicron size). In some embodiments, the calcium phosphate particles have an average particle size of about 200 to less than 1000 nm; about 200 to about 900 nm; about 200 to about 800 nm; about 200 to about 600 nm, or about 200 to about 400 nm. In some embodiments, the nanoparticle core particles have a geometry that is generally and substantially spherical in shape.
[0422] In some embodiments, the calcium phosphate nanoparticles are comprised of various stoichiometric amounts of Ca. 2+ and P.O. 4 3- In some embodiments, P, Na + , K + , Mg 2+ and CO 3 2+Substitution of some ions of the crystallographic structure with ions such as calcium phosphate can provide different properties to the substituted calcium phosphate. In some embodiments, the calcium phosphate is hydroxyapatite (HA). In general, the resorption rate is proportional to the solubility of the calcium phosphate, which is also affected by pH. In general, CaP can be in the order of decreasing solubility as follows: dicalcium phosphate dihydrate (DCPD)>dicalcium phosphate anhydrous (DCPA)>amorphous calcium phosphate (ACP)>tetracalcium phosphate (TTCP)>α-tricalcium phosphate (α-TCP)>octacalcium phosphate (OCP)>tricalcium phosphate (β-TCP)>hydroxyapatite. In some embodiments, the calcium phosphate particles include dicalcium phosphate dihydrate (DCPD), dicalcium phosphate anhydrous, amorphous calcium phosphate (ACP), tetracalcium phosphate (TTCP), α-tricalcium phosphate (α-TCP), octacalcium phosphate (OCP), tricalcium phosphate (β-TCP) or hydroxyapatite. In some embodiments, the calcium phosphate particles include calcium phosphate, calcium hydroxyapatite, alpha tricalcium phosphate, beta tricalcium phosphate, calcium pyrophosphate, tetracalcium phosphate, or octacalcium phosphate. In some embodiments, the calcium phosphate particles include hydroxyapatite. In some embodiments, the calcium phosphate is β-tricalcium phosphate (β-TCP), which is bioresorbable.
[0423] In some embodiments, calcium phosphate particles can be prepared as a suspension in an aqueous medium by reacting a soluble calcium salt with a soluble phosphate salt, more particularly by reacting calcium chloride with sodium phosphate under sterile conditions. For example, an aqueous solution of calcium chloride having a concentration between about 5 mM and about 300 mM is combined by mixing with an aqueous solution of sodium citrate in a suitable distilled water base having a concentration between about 5 mM and about 300 mM. The presence of sodium citrate contributes to the formation of an electrostatic layer around the core particles, which helps to stabilize the attractive and repulsive forces between the core particles, resulting in physically stable calcium phosphate core particles. An aqueous solution of disodium hydrogen phosphate having a concentration between about 5 mM and about 300 mM is then mixed with the calcium chloride / sodium citrate solution. The solution generally becomes cloudy, which indicates the formation of calcium phosphate core particles. In some embodiments, mixing is generally continued for at least about 48 hours or until a suitable core particle size is obtained, as determined by sampling the suspension and measuring the core particle size using known methods. The core particles may be stored, if desired, prior to further use and allowed to equilibrate at room temperature for a sufficient period of time, for example about 7 days, to achieve size and pH stabilization.
[0424] In some embodiments, the calcium phosphate particles have a calcium / phosphate molar ratio selected from the ranges of about 1-400, about 2-400, about 5-400, about 10-400, about 15-400, about 20-400, about 25-400, about 50-400, about 75-400, about 100-400, about 150-400, or about 200-400. In some embodiments, the calcium to phosphate molar ratio is about 2-350, about 5-300, about 10-250, about 15-200, about 20-150, about 25-100, or about 50-75. In some embodiments, the calcium phosphate particles have a calcium / phosphate molar ratio (Ca / P) of 1, 2, 5, 10. 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 350 or 400.
[0425] In some embodiments, the particles may be at least partially coated with or impregnated with a pharmacologically active agent, or both, where the pharmacologically active agent is placed on the surface of the core particle, and optionally held in place by a surface modifier sufficient to bind the agent to the core particle. In some embodiments, surface modifiers suitable for use in the particles include modified carbohydrates, carbohydrate derivatives, and other macromolecules with carbohydrate-like components characterized by abundant -OH side groups; polyethylene glycol (PEG); and modified PEGs such as PEG-inositol 1,3,4,5,6-pentakisphosphate (PEG-IP5). Surface modifiers are described, for example, in U.S. Patent Nos. 5,460,830; 5,462,751; 5,460,831; 5,219,577; and Huang et al., 2017, ACS Appl. Mater. Interfaces 9 (12):10435-10445, the entire contents of each of which are incorporated herein by reference. Incorporated into the specification.
[0426] In some embodiments, the calcium phosphate particles are coated with a lipid (see, e.g., Huang et al., 2018, J Drug Targeting 26(5-6)). In some embodiments, the lipid is one or more of phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, ganglioside, glycolipid, phosphatidylglycerol and cholesterol.In some embodiments, the phosphatidylcholine is L-α-phosphatidylcholine, egg phosphatidylcholine (EPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-O-ethyl-3-phosphocholine, 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and mixtures thereof.
[0427] In some embodiments, the lipid coating on the surface of the calcium phosphate particles is 1,2 dioleoyl-3-trimethylammonium propane (DOTAP) and cholesterol. In some embodiments, the lipid coating on the surface of the calcium phosphate particles is soy lecithin and cholesterol.
[0428] Coating of the core particles with the pharmacologically active agent can be carried out by suspending the core particles in a solution containing the dispersed surface modifier, for example, a solution containing about 0.1 to about 30% by weight of the surface modifier. The cores can be maintained in the solution of the surface modifier for a suitable period of time, typically about 1 hour, and agitated, for example, by rocking or sonication. The coated core particles can be separated from the suspension, including from any unbound surface modifier, by centrifugation. The coated core particles can then be resuspended in a solution containing the pharmacologically active agent attached to the at least partially coated core particles. If desired, a second layer of surface modifier can also be applied to the pharmacologically active agent attached to the particles.
[0429] In some embodiments, the pharmaceutical composition comprising the compound of the present disclosure formulated as calcium phosphate nanoparticles further comprises one or more suitable excipients. In some embodiments, the excipient is one or more of an isotonicity agent, a buffering agent, a viscosity enhancing agent, a chelating agent, a surfactant, a preservative, and an antioxidant.
[0430] In some embodiments, the calcium phosphate nanoparticle composition further comprises an isotonicity agent. In some embodiments, the calcium phosphate nanoparticle composition further comprises a buffering agent. In some embodiments, the calcium phosphate nanoparticle pharmaceutical composition further comprises a viscosity enhancing agent. In some embodiments, the calcium phosphate nanoparticle pharmaceutical composition further comprises a chelating agent. In some embodiments, the calcium phosphate nanoparticle pharmaceutical composition further comprises a surfactant. In some embodiments, the calcium phosphate nanoparticle pharmaceutical composition further comprises a preservative. In some embodiments, the calcium phosphate particle pharmaceutical composition further comprises an antioxidant. In some embodiments, the excipient is suitable for intraocular administration, e.g., intravitreal administration.
[0431] 4.9. Complexing Agents In some embodiments, the compounds of the present disclosure are prepared as pharmaceutical compositions that include a complexing agent. The complexing agent can form a complex with one or more endogenous components of a tissue or tissue fluid, such as the vitreous, to form a viscosity-enhanced mass. Complexation can occur through ionic interactions between the complexing agent and one or more components of the tissue, although other interactions (e.g., chemical reactions) can alternatively or additionally form complexes. In some embodiments, the complexing agent is cationic (i.e., positively) charged, such that the complexing agent can form an ionic complex with endogenous hyaluronic acid, collagen, or both in the tissue or tissue fluid to form a viscosity-enhanced mass. In some embodiments, the complexing agent can be a positively charged polymer. In some embodiments, the complexes formed between the complexing agent and endogenous tissue components (e.g., hyaluronic acid) and the viscosity-enhanced mass formed thereby are biodegradable in the tissue, aiding in the gradual degradation of the mass and / or complexes after their formation. In some embodiments, the pharmaceutical composition of the complexing agent does not have free aldehyde groups capable of reacting with the compounds described herein.
[0432] In some embodiments, the complexing agent is, by way of example and without limitation, a polyamino acid, a galactomannan (e.g., cationic derivatized), a cellulose polymer, an amine compound, a quaternary ammonium compound, or any combination thereof. In some embodiments, the complexing agent can be provided in a polymeric form and / or a positively charged form. The complexing agent can be present in the composition in an amount of at least 0.01 w / v%, at least 0.1 w / v%, or at least 0.5 w / v%. In some embodiments, the concentration of the complexing agent is also usually about 10 w / v% or less, more usually about 3 w / v% or less, and possibly 1.0 w / v% or less.
[0433] In some embodiments, the complexing agent is a polyamino acid formed from multiple repeating units of an amino acid. Exemplary poly-amino acid complexing agents include, but are not limited to, polylysine, polyarginine, polyhistidine, and the like. In some embodiments, the polyamino acid, when used, is typically present in the composition at a concentration of at least 0.05% w / v, at least 0.2% w / v, at least 0.7% w / v, or at least 1% w / v. In some embodiments, the poly-amino acid is generally at a concentration that is less than 10% w / v, less than 5.0% w / v, or less than 1.4% w / v. Exemplary polylysines include poly-L-lysine, poly-D-lysine, racemic poly-DL-lysine, derivatives thereof, and combinations thereof. In some embodiments, any of alpha polylysine, epsilon polylysine, poly-L-lysine, poly-D-lysine, any derivatives thereof, any combinations thereof, and the like may be used in the pharmaceutical composition. In some embodiments, the complexing agent is poly-cL-lysine. In some embodiments, the lysine of the composition can be completely or substantially completely poly-cL-lysine, which term means that at least 70% by weight, and more preferably at least 90% by weight, of the lysine of the composition is poly-cL-lysine, such as substantially completely, such as poly-cL-lysine.
[0434] In some embodiments, the polylysine in the composition has an average molecular weight of at least 50,000 daltons, more usually at least 150,000 daltons or at least 300,000 daltons. In some embodiments, the average molecular weight of the polylysine is from about 50,000 to about 500,000 daltons; from about 50,000 to about 400,000 daltons; or from about 50,000 to about 300,000 daltons.
[0435] In some embodiments, the complexing agent is a positively charged amine compound, particularly a positively charged amine polymer. The amine polymer can be a primary amine, a secondary amine, a tertiary amine, or a combination thereof. Such amine compounds or amine polymers can contain or be derived from aromatic or heterocyclic basic groups such as aniline, pyridine, etc. Nucleosides and polymers derived therefrom are one particularly preferred class of amine compounds suitable as complexing agents for the compositions of the present invention. Polysaccharides containing amine groups are also preferred for the compositions of the present invention. Examples of amine containing polysaccharides include chitosan and water-soluble derivatives of chitosan.
[0436] In some embodiments, the complexing agent is a derivative of a natural polymer that has been modified to be positively charged and / or soluble in water. Cellulose polymers are preferred within this class. In some embodiments, the complexing agent comprises a positively charged cellulose polymer. In some embodiments, the cellulose polymer comprises a copolymer of polyethoxylated cellulose or dimethyldiallylammonium chloride. In some embodiments, the polymer comprises CELQUAT SC-230M® and CELQUAT SC-240C® (Akzo-Nobel). Advantageously, these polymers can be modified to include various amounts of nitrogen (i.e., nitrogen substitutions), but the use of more or fewer substitutions can improve or decrease the degree of complexation, respectively. Positively charged natural (e.g., cellulose) polymers, when included, are typically present in the composition at a concentration of at least 0.01 w / v%, more typically at least 0.05 w / v%, and even more typically at least 0.2 w / v%, and typically at a concentration of less than 4.0 w / v%, more typically less than 1.0 w / v%, and even more typically less than 0.4 w / v%.
[0437] In some embodiments, the complexing agent is a quaternary ammonium compound.Various quaternary copolymers, which are variously quaternized, can be synthesized based on homopolymers or copolymers of aminoacrylates with methyl, ethyl or propyl side chains.These monomers can be copolymerized with other non-ionic monomers, including quaternary acrylic homopolymers such as 2-methacryloxyethyltrimethylammonium chloride and 2-methacryloxyethylmethyldiethylammonium bromide, and copolymers of quaternary acrylate monomers and water-soluble monomers.When included, the quaternary ammonium compound can be present in the composition at a concentration of at least about 0.01 w / v%, more usually at least 0.05 w / v%, and even more usually at least 0.2 w / v%, and usually less than 4.0 w / v%, more usually less than 1.0 w / v%, and even more usually less than 0.4 w / v%.
[0438] A useful polymeric complexing agent is a quaternary ammonium salt polymer of hydroxyethyl cellulose and trimethylammonium chloride-substituted epoxide. This complexing agent is both a quaternary ammonium compound and a cellulose polymer and has the CTFA name Polyquaternium-10. A suitable polymer is sold under the trade name UCARE JR-30M, which is commercially available from Rhodia or CELQUAT L-200 and H-100 (Akzo Nobel). In some embodiments, a suitable quaternary ammonium / cellulose agent is an alkyl-modified quaternary ammonium salt of hydroxyethyl cellulose and trimethylammonium chloride-substituted epoxide, which has the CTFA name Polyquaternium-24. An example of such a polymer is sold under the trade name QUATRISOFT LM-200, which is commercially available from Amerchol Corp., Edison, NJ. Other useful polymeric complexing agents that are both quaternary ammonium compounds and cellulose polymers include various quaternary ammonium salts of hydroxyethyl cellulose sold under the trade name SOFTCAT, which is commercially available from The Dow Chemical Company, Midland, Mich.
[0439] In some embodiments, the complexing agent is a galactomannan polymer, such as a cationic derivatized galactomannan polymer, which can also generally be considered as a cellulose polymer. A useful polymer is a positively charged guar. Guar (e.g., guar gum) or other galactomannan polymers substituted with positively charged chemical moieties can be used. In some embodiments, the galactomannan polymer can have a cationic degree of substitution (DS) with a lower limit of 0.01% and an upper limit of 3.0%, preferably a lower limit of 0.1% or 0.3%, and an upper limit of 2.5%. In particular for guar gum, the galactomannan usually has a number weight average molecular weight (MW) with a lower limit of 50,000 and an upper limit of about 1,000,000, more preferably a lower limit of 100,000 or 300,000, and an upper limit of about 700,000. An exemplary galactomannan is a positively charged guar gum, such as O-[2-hydroxy-3-(trimethylammonium)propyl]guar chloride, which is commercially available under the trade name C261N from Cosmedia. In some embodiments, the galactomannan polymer (e.g., guar gum) compound exhibits low toxicity. In some embodiments, the galactomannan polymer is typically present in the composition at a concentration of at least 0.04 w / v%, more typically at least 0.20 w / v%, and even more typically at least 0.5 w / v%, and typically at a concentration of less than 7.0 w / v%, more typically less than 3.0 w / v%, and even more typically less than 1.2 w / v%.
[0440] In some embodiments, the pharmaceutical composition comprising the compound of interest and the complexing agent is formulated as a solution or suspension. In some embodiments, the pharmaceutical composition is aqueous and comprises at least 50%, more usually at least 95%, water.
[0441] In some embodiments, for intraocular or intravitreal injection, the composition prepared with the complexing agent consists essentially or substantially of the complexing agent, the therapeutic compound and water. As used herein, substantially the complexing agent, the therapeutic agent and water means that the composition contains less than 5.0 w / v%, more usually less than 4.0 w / v%, and even more preferably less than 2.0 w / v% of any component other than the complexing agent, the therapeutic agent and water.
[0442] In some embodiments, the pharmaceutical composition of the compound and complexing agent further comprises one or more excipients selected from an isotonicity agent, a viscosity enhancing agent, a buffering agent, a chelating agent, a surfactant, a preservative, and an antioxidant.
[0443] In some embodiments, a suspending agent may be used, which in some embodiments is a polysaccharide, such as, but not limited to, xanthan gum, carboxymethylcellulose, chondroitin sulfate, or a carboxyvinyl polymer.
[0444] 4.10. Cyclodextrin Compositions In some embodiments, the compound of the present disclosure is formulated as a pharmaceutical composition comprising cyclodextrin.The formulation of aldehyde scavenger compound and cyclodextrin is disclosed in US Patent No. 9,814,701, which is incorporated herein by reference.In some embodiments, the pharmaceutical composition comprises the compound of the present disclosure, cyclodextrin, and one or more excipients.In some embodiments, the excipient is suitable for intraocular administration, for example intravitreal administration.
[0445] In some embodiments, the cyclodextrin for use in the present methods and compositions is selected from α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, derivatives thereof, and combinations thereof. In particular, the cyclodextrin for use in the present methods is selected from β-cyclodextrin, γ-cyclodextrin, derivatives thereof, and combinations thereof.
[0446] In some embodiments, the cyclodextrin or derivative thereof is selected from carboxyalkyl cyclodextrins, hydroxyalkyl cyclodextrins, sulfoalkyl ether cyclodextrins, and alkyl cyclodextrins. In various embodiments, the alkyl group in the cyclodextrin is methyl, ethyl, propyl, butyl, pentyl, or hexyl.
[0447] In some embodiments, the cyclodextrin is α-cyclodextrin or its derivative. In some embodiments, the α-cyclodextrin or its derivative is selected from carboxyalkyl-α-cyclodextrin, hydroxyalkyl-α-cyclodextrin, sulfoalkylether-α-cyclodextrin, alkyl-α-cyclodextrin, and combinations thereof. In some embodiments, the alkyl group in the α-cyclodextrin derivative is methyl, ethyl, propyl, butyl, pentyl, or hexyl.
[0448] In some embodiments, the cyclodextrin is β-cyclodextrin or a derivative thereof. In some embodiments, the β-cyclodextrin or a derivative thereof is selected from carboxyalkyl-β-cyclodextrin, hydroxyalkyl-β-cyclodextrin, sulfoalkylether-β-cyclodextrin, alkyl-β-cyclodextrin, and combinations thereof. In some embodiments, the alkyl group in the β-cyclodextrin derivative is methyl, ethyl, propyl, butyl, pentyl, or hexyl.
[0449] In some embodiments, the β-cyclodextrin or derivative thereof is a hydroxyalkyl-β-cyclodextrin or a sulfoalkylether-β-cyclodextrin. In some embodiments, the hydroxyalkyl-β-cyclodextrin is a hydroxypropyl-β-cyclodextrin. In some embodiments, the sulfoalkylether-β-cyclodextrin is a sulfobutylether-β-cyclodextrin. In some embodiments, the β-cyclodextrin or derivative thereof is an alkyl-β-cyclodextrin, in particular a methyl-β-cyclodextrin. In some embodiments using a methyl-β-cyclodextrin, the β-cyclodextrin is a randomly methylated β-cyclodextrin.
[0450] In some embodiments, the cyclodextrin is γ-cyclodextrin or a derivative thereof. In some embodiments, the γ-cyclodextrin or a derivative thereof is selected from carboxyalkyl-γ-cyclodextrin, hydroxyalkyl-γ-cyclodextrin, sulfoalkylether-γ-cyclodextrin, and alkyl-γ-cyclodextrin. In some embodiments, the alkyl group in the γ-cyclodextrin derivative is methyl, ethyl, propyl, butyl, pentyl, or hexyl. In some embodiments, the γ-cyclodextrin or a derivative thereof is hydroxyalkyl-γ-cyclodextrin or sulfoalkylether-γ-cyclodextrin. In some embodiments, the hydroxyalkyl-γ-cyclodextrin is hydroxypropyl-γ-cyclodextrin, such as 2-hydroxypropyl-γ-cyclodextrin. In some embodiments, the γ-cyclodextrin or a derivative thereof is S-2-carboxyalkyl-thio-γ-cyclodextrin, such as S-2-carboxyethyl-thio-γ-cyclodextrin.
[0451] In some embodiments, various salts of cyclodextrin or salts of cyclodextrin derivatives can be used in the compositions and methods herein. In some embodiments, the salt is a pharmaceutically acceptable salt, which refers to such salt of a compound, i.e., cyclodextrin, that is safe and effective for use in mammals and has the desired biological activity. Pharmaceutically acceptable salts include salts of acidic or basic groups present in cyclodextrin. Pharmaceutically acceptable acid addition salts include, but are not limited to, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, hydrogen sulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, benzoic acid ... Suitable base salts include aldehydes, glutamates, methanesulfonates, ethanesulfonates, benzenesulfonates and p-toluenesulfonates. Suitable base salts include, but are not limited to, aluminum, calcium, lithium, magnesium, potassium, sodium, zinc and diethanolamine salts. In some embodiments, the cyclodextrin is in the form of a sodium or potassium salt. Guidance regarding suitable pharma- ceutically acceptable salts and their use in drug formulations can be found in Remington's Pharmaceutical Sciences, 17th Ed., Mack Publishing Company, Easton, PA., 1985 and Berge, et al., 1977, "Pharmaceutical Salts," J Pharm Sci. 66:1-19, both of which are incorporated herein by reference.
[0452] In some embodiments, the cyclodextrin is a mixture of cyclodextrins, which can be a combination of α-cyclodextrin and β-cyclodextrin (including a combination of α-cyclodextrin and a β-cyclodextrin derivative), a combination of α-cyclodextrin and γ-cyclodextrin (including a combination of α-cyclodextrin and a γ-cyclodextrin derivative), a combination of β-cyclodextrin and γ-cyclodextrin (including a combination of β-cyclodextrin and a γ-cyclodextrin derivative), or a combination of α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin (including a combination of α-cyclodextrin, β-cyclodextrin, and a γ-cyclodextrin derivative).
[0453] In some embodiments, the cyclodextrin (e.g., α-, β-, or γ-cyclodextrin), such as in the compositions described herein, is present at about 0.1% to about 30% w / v, about 0.1% to about 25% w / v, about 0.1% to about 20% w / v, about 0.2% to about 15% w / v, about 0.5% to about 10% w / v, about 0.5% to about 7.5% w / v, or about 1% to about 5% w / v. For example, an exemplary cyclodextrin is sulfobutylether-β-cyclodextrin, which may be present at about 0.1% to about 30% w / v, about 0.1% to about 25% w / v, about 0.1% to about 20% w / v, about 0.2% to about 15% w / v, about 0.5% to about 10% w / v, about 0.5% to about 7.5% w / v, or about 1% to about 5% w / v. In some embodiments, an exemplary cyclodextrin is hydroxypropyl-β-cyclodextrin, which may be present at about 0.1% to about 30% w / v, about 0.1% to about 25% w / v, about 0.1% to about 20% w / v, about 0.2% to about 15% w / v, about 0.5% to about 10% w / v, about 0.5% to about 7.5% w / v, or about 1% to about 5% w / v. In some embodiments, an exemplary cyclodextrin is hydroxypropyl-γ-cyclodextrin, which can be present at about 0.1% to about 30% w / v, about 0.1% to about 25% w / v, about 0.1% to about 20% w / v, about 0.2% to about 15% w / v, about 0.5% to about 10% w / v, about 0.5% to about 7.5% w / v, or about 1% to about 5% w / v.
[0454] In embodiments where a mixture of cyclodextrins is used, such as a mixture of sulfobutylether-β-cyclodextrin and hydroxypropyl-β-cyclodextrin, the total amount of cyclodextrin can be present from about 0.1% to about 30% w / v, from about 0.1% to about 25% w / v, from about 0.1% to about 20% w / v, from about 0.2% to about 15% w / v, from about 0.5% to about 10% w / v, from about 0.5% to about 7.5% w / v, or from about 1% to about 5% w / v.
[0455] In some embodiments, the cyclodextrin in the compositions, particularly ophthalmic solutions, for use in the methods herein is present at about 0.1% w / v, about 0.2% w / v, about 0.5% w / v, about 1% w / v, about 2% w / v, about 3% w / v, about 4% w / v, about 5% w / v, about 6% w / v, about 7% w / v, about 8% w / v, about 9% w / v, about 10% w / v, about 11% w / v, about 12% w / v, about 13% w / v, about 14% w / v, about 15% w / v, about 16% w / v, about 18% w / v, about 20% w / v, about 25% w / v or about 30% w / v. For example, a β-cyclodextrin, such as sulfobutylether-β-cyclodextrin, can be present at about 0.1% w / v, about 0.2% w / v, about 0.5% w / v, about 1% w / v, about 2% w / v, about 3% w / v, about 4% w / v, about 5% w / v, about 6% w / v, about 7% w / v, about 8% w / v, about 9% w / v, about 10% w / v, about 11% w / v, about 12% w / v, about 13% w / v, about 14% w / v, about 15% w / v, about 16% w / v, about 18% w / v, about 20% w / v, about 25% w / v or about 30% w / v. In some embodiments, the β-cyclodextrin, e.g., hydroxypropyl-β-cyclodextrin, can be present at about 0.1% w / v, about 0.2% w / v, about 0.5% w / v, about 1% w / v, about 2% w / v, about 3% w / v, about 4% w / v, about 5% w / v, about 6% w / v, about 7% w / v, about 8% w / v, about 9% w / v, about 10% w / v, about 11% w / v, about 12% w / v, about 13% w / v, about 14% w / v, about 15% w / v, about 16% w / v, about 18% w / v, about 20% w / v, about 25% w / v, or about 30% w / v. In some embodiments, the gamma-cyclodextrin, e.g., hydroxypropyl-gamma-cyclodextrin, can be present at about 0.1% w / v, about 0.2% w / v, about 0.5% w / v, about 1% w / v, about 2% w / v, about 3% w / v, about 4% w / v, about 5% w / v, about 6% w / v, about 7% w / v, about 8% w / v, about 9% w / v, about 10% w / v, about 11% w / v, about 12% w / v, about 13% w / v, about 14% w / v, about 15% w / v, about 16% w / v, about 18% w / v, about 20% w / v, about 25% w / v, or about 30% w / v.
[0456] In some embodiments where a mixture of cyclodextrins is used, e.g., a mixture of sulfobutylether-β-cyclodextrin and hydroxypropyl-β-cyclodextrin, the total amount of cyclodextrin can be present at about 0.1% w / v, about 0.2% w / v, about 0.5% w / v, about 1% w / v, about 2% w / v, about 3% w / v, about 4% w / v, about 5% w / v, about 6% w / v, about 7% w / v, about 8% w / v, about 9% w / v, about 10% w / v, about 11% w / v, about 12% w / v, about 13% w / v, about 14% w / v, about 15% w / v, about 16% w / v, about 18% w / v, about 20% w / v, about 25% w / v, or about 30% w / v.
[0457] Cyclodextrin levels (e.g., concentrations) for administration are given for the exemplary cyclodextrins sulfobutylether-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, and hydroxypropyl-γ-cyclodextrin, although it should be understood that equivalent concentrations for other particular cyclodextrins can be readily determined by one of skill in the art.
[0458] In various embodiments containing a compound formulated with a cyclodextrin, the composition includes one or more excipients. In some embodiments, the excipient is one or more of a tonicity agent, a buffering agent, a viscosity enhancing agent, a chelating agent, a surfactant, a preservative, and an antioxidant. In some embodiments, the cyclodextrin composition includes a tonicity agent. In some embodiments, the cyclodextrin composition includes a buffering agent. In some embodiments, the cyclodextrin composition includes a viscosity enhancing agent. In some embodiments, the cyclodextrin composition includes a chelating agent. In some embodiments, the cyclodextrin composition includes a surfactant. In some embodiments, the cyclodextrin composition includes an antioxidant. In some embodiments, the cyclodextrin composition includes a preservative.
[0459] In some embodiments, the composition of the compound and cyclodextrin containing one or more excipients is suitable for intraocular administration, for example intravitreal administration.In some embodiments, the composition of the compound and cyclodextrin containing one or more excipients is suitable for subcutaneous administration, intradermal administration or intramuscular administration.In some embodiments, the composition of the compound and cyclodextrin containing one or more excipients is formulated to be suitable for intravenous administration.
[0460] In some embodiments, the pharmaceutical composition of the compound and cyclodextrin does not include carboxymethylcellulose. In some embodiments, the pharmaceutical composition of the compound and cyclodextrin does not include hydroxypropylcellulose. In some embodiments, when hydroxypropylmethylcellulose is present, its concentration is greater than 1% w / v.
[0461] 4.11. Injectable hydrogels In some embodiments, the pharmaceutical composition comprises a compound of the present disclosure and a hydrogel, particularly an injectable hydrogel. In general, an injectable hydrogel can undergo a "sol-gel" transition, where the transition is triggered by a change in environmental conditions. In some embodiments, the conditions for the "sol-gel" transition include properties such as pH, temperature, ionic environment, glucose, or a combination thereof. Injectable hydrogels are injected in liquid form into a tissue, organ (e.g., eye) or body part, and once administered, undergo gelation in situ (see, e.g., US20160331738; WO2006122183A2, which are incorporated herein by reference). A compound of interest is incorporated and suspended in the hydrogel in a "sol" state. In some embodiments, the hydrogel composition does not have free aldehyde groups that can react with the compounds described herein.
[0462] In some embodiments, the hydrogel is at a concentration such that the composition is liquid at pre-administration conditions and forms a gel upon administration to a tissue, organ or body part. For example, at a concentration of 20% w / v or higher, an aqueous solution of poloxamer F407, described below, remains liquid at low temperatures (<15° C.) and transitions to a viscous, semi-solid gel upon intraocular administration.
[0463] In some embodiments, the injectable hydrogel is composed of polyethylene oxide; polypropylene oxide; polyoxyethylene-polyoxypropylene block copolymers (e.g., poloxamer 407 and poloxamer 188); acrylic polymers such as, but not limited to, polyacrylic acid (PAA) (e.g., carbomer, Carbopol® 974P, etc.); polyvinylpyrrolidone; polyethylene glycol (PEG) (e.g., from Nektar); gelatin, polyvinyl alcohol (PVA); polyhydroxyethyl methacrylate (poly-HEMA or PHEMA); cellulose; alginate; chitin, or combinations thereof.
[0464] In some embodiments, the hydrogel is a biodegradable hydrogel. Biodegradable hydrogels can incorporate biodegradable linking groups in the hydrogel and / or the precursors can be hydrodegradable or enzymatically degradable. Exemplary hydrodegradable biodegradable linking groups include polymers, copolymers and oligomers of glycolide, dl-lactide, 1-lactide, dioxanone, esters, carbonates and trimethylene carbonate. Exemplary enzymatically biodegradable linking groups include peptide linking groups cleavable by metalloproteinases and collagenases. Examples of biodegradable linking groups include polymers and copolymers of poly(hydroxy acids), poly(orthocarbonates), poly(anhydrides), poly(lactones), poly(amino acids), poly(carbonates) and poly(phosphonates). In some embodiments, the gel degrades in physiological fluids without causing inflammation by decomposing into biocompatible and non-acidic components. In some embodiments, the hydrogel adheres to tissue.
[0465] In some embodiments, the hydrogel is a thermoresponsive hydrogel. In certain embodiments, the thermoresponsive hydrogel has a lower critical solution temperature (LCST) below body temperature. In some embodiments of therapeutic use, the thermoresponsive hydrogel remains fluid below physiological temperature (e.g., 37°C for humans) or at room temperature (e.g., 25°C) or below room temperature, forms a hydrogel at physiological temperature, and is biocompatible. In some embodiments, the thermoresponsive hydrogel can be liquid at temperatures below 34°C and reversibly solidifies into a gelling composition at temperatures above 34°C. In some embodiments, the hydrogel composition is a solution at about 20°C to 27°C and a gel at about 34°C to 37°C.
[0466] Thermoresponsive hydrogels can be selected from naturally derived and synthetic polymers that exhibit such behavior. Natural polymers include elastin-like peptides and polysaccharide derivatives, while synthetic polymers include those composed of poly(n-isopropylacrylamide) (PNIPAAm), poly(N,N-dimethylacrylamide-co-N-phenylacrylamide), poly(glycidyl methacrylate-co-N-isopropylacrylamide), poly(ethylene oxide)-β-poly(propylene oxide)-β-poly(ethylene oxide), poly(ethylene glycol)-polyester copolymers, and amphiphilic block copolymers. In some embodiments, the amphiphilic block copolymer comprises a hydrophilic component selected from polyethylene oxide (PEO), polyvinyl alcohol (PVA), polyglycolic acid (PGA), poly(N-isopropylacrylamide), poly(acrylic acid) (PAA), polyvinylpyrrolidone (PVP), or a mixture thereof, and a hydrophobic component selected from polypropylene oxide (PPO), poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), poly(β-benzoyl L-aspartate) (PBLA), poly(γ-benzyl-L-glutamate) (PBLG), poly(aspartic acid), poly(L-lysine), poly(spermine), poly(caprolactone), or a mixture thereof. Exemplary amphiphilic block copolymers include (PEO)(PPO)(PEO) block copolymers (PEO / PPO), and poly(lactic acid-co-glycolic acid) block copolymers (PLGA), such as (PEO)(PLGA)(PEO) block copolymers.
[0467] In some embodiments, the hydrogel is composed of polyacrylamide (e.g., poly-N-isopropylacrylamide), polyethylene oxide / polypropylene oxide, or a combination of the two (e.g., Pluronic® or Tectronic®), butyl methacrylate, polyethylene glycol diacrylate, polyethylene glycols of various molecular weights, polyacrylic acid, poly-methacrylic acid, poly-lactic acid, poly(tetramethylene ether glycol), poly(N,N'-diethylaminoethyl methacrylate), methyl methacrylate, and N,N'-dimethylaminoethyl methacrylate.
[0468] In some embodiments, the hydrogel is selected from xolglucan, gelatin, agarose, amylase, amylopectin, cellulose derivatives and gellan, which exhibit thermoreversible gelation behavior. For example, chitosan-based injectable thermogels have been engineered by grafting an appropriate amount of PEG onto the chitosan backbone and used to extend drug release in vitro (see, for example, U.S. Patent No. 6,730,735; U.S. Patent No. 8,663,686, which are incorporated herein by reference).
[0469] In some embodiments, the hydrogel is composed of poly(ethylene oxide)-β-poly(propylene oxide)-β-poly(ethylene oxide), also known as poloxamers, Pluronics®, or Tetronics®. In some embodiments, the poloxamer is P124, P188, P237, P338, P407, or mixtures thereof (e.g., Pluronics®, e.g., L44NF, F68NF, F87NF, F108NF, and F127NF). In some embodiments, the hydrogel is composed of P188 or P407, or mixtures thereof. In some embodiments, the hydrogel is a mixture of P188 and P407. In some embodiments, the poloxamer hydrogel can include additional polymers, such as polyethylene glycol, PAA, methylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, etc., that provide a phase transition temperature higher than room temperature (25° C.) and gelation at tissue, organ, or body temperature (e.g., anterior corneal temperature of 35° C.).
[0470] In some embodiments, the hydrogel is a pH-sensitive hydrogel. In some embodiments, the hydrogel is selected from polymethylmethacrylate (PMMA), polyacrylamide (PAAm), polyacrylic acid (PAA), poly-dimethylaminoethyl methacrylate (PDEAEMA) and polyethylene glycol. These polymers are generally hydrophobic, but swell in water in response to a wide range of pH of the external environment. In some embodiments, the pH-sensitive hydrogel can be a copolymer of PMMA and polyhydroxyethylmethylacrylate (PHEMA), which is an anionic copolymer that swells highly at neutral or high pH, but does not swell in acidic media.
[0471] In some embodiments, the hydrogel comprises a carbomer (e.g., Carbopol®), which is a crosslinked acrylic acid polymer (PAA) that exhibits a pH-induced phase transition when the pH is increased above its pKa, which is about 5.5. Carbomers include carbomer homopolymers, which are polymers of acrylic acid crosslinked with allyl sucrose or allyl pentaerythritol; C tetramers, which are crosslinked with acrylic acid and allyl pentaerythritol; 10 ~C 30 Carbomer copolymers are available as polymers with alkyl acrylates; and carbomer interpolymers are carbomer homopolymers or copolymers containing block copolymers of polyethylene glycol and long chain alkyl acid esters. In some embodiments, the carbomer is selected from Carbopol 71G NF, 971P NF, 974P NF, 980NF, 981NF, 5984EP and ETD2020NF, Ultrez 10NF. In some embodiments, the hydrogel comprises a carbomer and a suitable viscosity enhancer, such as hydroxypropyl methylcellulose or methylcellulose, in an amount sufficient to allow for a reduction in PAA concentration without in situ gelling properties. In some embodiments, the hydrogel is comprised of Carbopol® 940 and Methocel E50LV (HPMC).
[0472] In some embodiments, the hydrogel can include from about 15% to about 30% by weight of poloxamer, more particularly from about 17.5% to about 25%, and even more particularly from about 20% to about 25%. In some embodiments, the hydrogel can also include from about 0.2% to about 4% by weight of carbomer, more particularly from about 0.5% to about 2.0%, and even more particularly from about 0.7% to about 1.5%.
[0473] In some embodiments, the compound is placed in a hydrogel. In some embodiments, the compound is formulated in a microparticle or nanoparticle as described herein, and in a microparticle and / or nanoparticle placed in a hydrogel. In some embodiments, the compound of the present disclosure is formulated in a liposome as described herein, and in a liposome placed in a hydrogel. In some embodiments, the compound of the present disclosure is formulated in a calcium phosphate particle as described herein, and in a calcium phosphate particle placed in a hydrogel.
[0474] In some embodiments, the pharmaceutical composition of the compound formulated in a hydrogel further comprises one or more excipients selected from a tonicity agent, a viscosity enhancing agent, a buffering agent, a chelating agent, a surfactant, a preservative, and an antioxidant.
[0475] In some embodiments, the pharmaceutical composition of the compound formulated in the hydrogel further comprises an isotonicity agent. In some embodiments, the pharmaceutical composition of the compound formulated in the hydrogel further comprises a viscosity enhancing agent. In some embodiments, the pharmaceutical composition of the compound formulated in the hydrogel further comprises a buffering agent. In some embodiments, the pharmaceutical composition of the compound formulated in the hydrogel further comprises a chelating agent. In some embodiments, the pharmaceutical composition of the compound formulated in the hydrogel further comprises a surfactant. In some embodiments, the pharmaceutical composition of the compound formulated in the hydrogel further comprises a preservative. In some embodiments, the pharmaceutical composition of the compound formulated in the hydrogel further comprises an antioxidant. In some embodiments, the hydrogel and excipients are suitable for intraocular administration, for example, intravitreal administration.
[0476] 4.12. Excipients In some embodiments, the pharmaceutical composition comprises one or more pharma- ceutically acceptable additives or excipients suitable for injection, including subcutaneous, intradermal, intramuscular, intraperitoneal, intraocular, and in some embodiments, intravenous administration.In particular, one or more excipients are suitable for intraocular administration, for example intravitreal administration.In some embodiments, the excipient is selected from isotonicity agents, buffering agents, viscosity enhancers, chelating agents, surfactants, preservatives, and antioxidants.
[0477] 4.12.1. Tonicity agents In some embodiments, the pharmaceutical composition can have one or more isotonicity agents that can be used to adjust the tonicity of the composition to suit the mode of administration.Suitable isotonicity agents include, by way of example and without limitation, dextran (e.g., dextran 40 or 70), dextrose, glycerin, propylene glycol, and salts such as potassium salts or sodium salts.For example, equivalent amounts of one or more salts consisting of cations such as potassium, ammonium, and anions such as chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate, hydrogen sulfate anion, sodium bicarbonate and ammonium sulfate salts can also be used.
[0478] The amount of tonicity agent will vary depending on the particular agent added. In general, however, the composition can have a sufficient amount of tonicity agent to cause the final composition to have a physiologically acceptable osmolality, such as an ophthalmically acceptable osmolality. In some embodiments, the cyclodextrin composition has an osmolality of about 200 to about 1000 mOsm / L or about 200 to about 500 mOsm / L, or any specified value within said ranges (e.g., 200 mOsm / L, 210 mOsm / L, 220 mOsm / L, 230 mOsm / L, 240 mOsm / L, 250 mOsm / L, 260 mOsm / L, 270 mOsm / L, 280 mOsm / L, 290 mOsm / L, 300 mOsm / L, 310 mOsm / L, 320 mOsm / L, 330 mOsm / L, 340 mOsm / L, 350 mOsm / L, 360 mOsm / L, 370 mOsm / L, 380 mOsm / L, 390 mOsm / L, 400 mOsm / L, 410 mOsm / L, 420 mOsm / L, 430 mOsm / L, 440 mOsm / L, 450 mOsm / L, 460 mOsm / L, 470 mOsm / L, 480 mOsm / L, 490 mOsm / L, 500 mOsm / L, 510 mOsm / L, 520 mOsm / L, 530 mOsm / L, 540 m In certain embodiments, the ophthalmic formulation has an osmolality of about 250 to about 450 mOsm / L or about 250 to about 350 mOsm / L using a tonicity agent.
[0479] Antioxidants In some embodiments, the pharmaceutical composition comprises an antioxidant that is tolerated by the subject or tissue to be treated, such as intraocular tissue. In some embodiments, suitable antioxidants are glucose, ascorbate, sulfide, superoxide dismutase (SOD), cysteine and their derivatives. In some embodiments, the antioxidant is sodium bisulfite, sodium metabisulfite, ascorbate, sodium sulfite or thioglycerol. In some embodiments, other antioxidants that are tolerated by intraocular tissues known in the literature can be used, such as water-soluble antioxidants, antioxidants with at least one -SH or -CHO group, peptides and enzymes.
[0480] In some embodiments, the antioxidant is glutathione, N-acetylcysteine, tocopherol, ascorbic acid, tetrahexyldecyl ascorbate, butylated hydroxytoluene (BHT), butylated hydroxyanisole, methylgentisate, L-carnosine, tert-butylhydroquinone (TBHQ), glutathione (including derivatives, combinations and mixtures thereof). In some embodiments, the antioxidant can be present at a concentration of 0.01% to 1% w / v, about 0.02% to 1% w / v; about 0.05% to 1% w / v; about 0.01 to 0.5% w / v; about 0.02% to 0.5% w / v; or about 0.05% to 0.5% w / v. In some embodiments, the pharmaceutical composition does not include an antioxidant.
[0481] Buffers In some embodiments, the pharmaceutical composition may have one or more buffering agents to adjust and / or maintain the pH of the composition. In some embodiments, one or more buffering agents are used to provide a pH range that is compatible with tissues exposed to treatment or administration, such as subcutaneous or intraocular environments. In general, the volume of the buffer should be large enough to maintain the product pH for a reasonably long shelf life, but small enough to allow the product to be rapidly readjusted to physiological pH upon administration. In general, a buffer volume of about 0.01 to 0.1 may be used, particularly at a concentration that provides sufficient buffering capacity and minimizes adverse effects, such as irritation to tissues. Exemplary buffering agents include, by way of example and without limitation, various salts (e.g., sodium, potassium, etc.), where appropriate, acids or bases of the above agents including acetate, borate, phosphate, citrate, bicarbonate, carbonate, succinate, tartrate, lactate, tetraborate, diphosphate, tromethamine, hydroxyethylmorpholine or THAM (trishydroxymethylamino-methane), among others.
[0482] In some embodiments, the buffering agent can be present at about 0.01 mM to about 100 mM, about 0.05 mM to about 100 mM, about 0.5 mM to about 100 mM, about 1 mM to about 50 mM, about 1 mM to about 40 mM, about 1 mM to about 30 mM, about 1 mM to about 20 mM, or about 1 mM to about 10 mM. In some embodiments, the buffering agent can be present at about 0.01 mM, about 0.05 mM, about 0.1 mM, about 0.2 mM, about 0.5 mM, about 1 mM, about 5 mM, about 10 mM, about 20 mM, about 30 mM, about 40 mM, about 50 mM, or about 100 mM.
[0483] Surfactants In some embodiments, the pharmaceutical composition comprises one or more suitable surfactants, particularly non-ionic surfactants. In some embodiments, the surfactant is a non-ionic surfactant that is a polyol ester, such as polyoxyethylene ester, poloxamer, glycol and glycerol ester, and a sorbitan derivative. In some embodiments, the non-ionic surfactant is selected from polyoxyethylene (20) sorbitan monolaurate (Tween® 20), polyoxyethylene (20) sorbitan monopalmitate (Tween® 40), polyoxyethylene (20) sorbitan monostearate (Tween® 60), polyoxyethylene (20) sorbitan monooleate (Tween® 80), polyoxyethylene (20) sorbitan tristearate (Tween® 65), polyoxyethylene (20) sorbitan trioleate (Tween® 85), sorbitan monopalmitate (Span® 40), sorbitan monostearate (Span® 60), sorbitan monooleate (Span® 80), sorbitan tristearate (Span® 65), and sorbitan trioleate (Span® 8).
[0484] In some embodiments, the surfactant is a poloxamer or poloxamine. In some embodiments, the poloxamer is P124, P188, P237, P338, P407, and mixtures thereof (see, e.g., Bermudez et al., 2011, Intl Res J Pharmacy Pharmacol. 1(6):109-118; Xuan et al., 2011, Drug Delivery 18(5):305-31, all publications hereby incorporated by reference in their entirety). Poloxamers are also available under the Pluronic® trade name, e.g., L44NF, F68NF, F87NF, F108NF, and F127NF.
[0485] In some embodiments, the surfactant is selected from polyoxyethylene 15 hydroxystearate; polyoxyethylene alkyl ethers, polyoxyethylene stearates, and polyoxyethylene castor oils, such as Cremophor EL, ELP, and RH 40. In some embodiments, the non-ionic surfactant is selected from Cremophor EL, Cremophor RH 40, Cremophor RH 60, d-α-tocopherol polyethylene glycol 1000 succinate, polysorbate 20, polysorbate 80, Solutol HS 15, sorbitan monooleate, poloxamer 407, Labrafil M-1944CS, Labrafil M-2125CS, Labrasol, Gellucire 44 / 14, Softigen 767, and mono- and di-fatty acid esters of PEG 300, 400, or 1750.
[0486] In some embodiments, the surfactant can be present at about 0.00001% to about 2% w / v; about 0.00005% to about 2% w / v; about 0.0001% to about 2% w / v; about 0.0005% to about 2% w / v; about 0.001% to about 2% w / v; about 0.005% to about 2% w / v; about 0.01% to about 2% w / v; about 0.02% to about 2% w / v; about 0.05% to about 2% w / v; 0.1% to about 2% w / v; about 0.15% to about 2% w / v; about 0.2% to about 2% w / v; about 0.5% to about 2% w / v; or about 1% to about 2% w / v. In some embodiments, the surfactant may be present at about 0.00001% to about 1.5% w / v; about 0.0001% to about 1% w / v; about 0.0005% to about 1% w / v; about 0.001% to about 1% w / v; about 0.005% to about 0.5% w / v; or about 0.01% to about 0.2% w / v.
[0487] 4.12.5. Suspending or viscosity enhancing agents In some embodiments, the pharmaceutical composition for injection comprises one or more suitable suspending agents or viscosity enhancing agents.Suspending agents can enhance the physical stability of the composition, and viscosity enhancing agents can increase the viscosity of the composition.Suspending agents and viscosity enhancing agents can overlap.In some embodiments, suspending agents or viscosity enhancing agents are compatible with the tissue of administration or the tissue to be treated.
[0488] For example, the vitreous humor contained in the posterior chamber of the eye is highly viscous. Thus, intravitreal injection of a substantially less viscous fluid or suspension into the posterior segment can result in the presence of two somewhat immiscible phases or layers within the eye, which can result in "pooling" of the injected fluid or suspension at the bottom of the posterior chamber and inhomogeneous or inconsistent administration to the tissues of the posterior segment.
[0489] Suspension of the therapeutic compound in a formulation with a relatively high viscosity, such as one that is close to the viscosity of the vitreous humor, can limit the uneven distribution of the therapeutic agent. Such high viscosity formulations include viscosity-inducing components. The therapeutic agent of the present invention may be administered, without limitation, as an aqueous injection, suspension, emulsion, solution, gel, or in a sustained release or sustained release implant, either biodegradable or non-biodegradable.
[0490] In some embodiments, the suspending agent or viscosity enhancing agent is selected from carbopol, polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), polyvinyl acetate, gelatin, xanthan, gum tragacanth, gum acacia, sodium alginate, and cellulose derivatives. In some embodiments, the cellulose derivatives include hydroxypropyl methylcellulose (HPMC), hydroxyethyl cellulose (HEC), and methylcellulose. In some embodiments, the concentration of the suspending agent or viscosity enhancing agent can be present at about 0.1% to about 2% w / v, about 0.5% to about 1% w / v, or any particular value within those ranges.
[0491] In some embodiments, the suspending agent or viscosity enhancing agent is present in an amount of about 0.1% to about 1.0% w / v, or any particular value within said range (e.g., 0.1-0.2%, 0.2-0.3%, 0.3-0.4%, 0.4-0.5%, 0.5-0.6%, 0.6-0.7%, 0.7-0.8%, 0.8-0.9%, 0.9-1.0%; about 0.2%, about 0.21%, about 0.22%, about 0.23%, about 0.24%, about 0.25%, about 0.26%, about 0.27%, about 0.28%, about 0.29%, about 0.30%, about 0.31%, about 0.32%, about 0.33%, about 0.34%, about 0.35%, about 0.36%, about 0.37%, about 0.38%, about 0.39%, about 0.40%, about 0.41%, about 0.42%, about 0.43%, about 0.44%, about 0.45%, about 0.46%, about 0.47%, about 0.48%, about 0.49%, about 0.50%, about 0.51%, about 0.52%, about 0.53%, about 0.54%, about 0.55%, about 0.56%, about 0.57%, about 0.58%, about 0.59%, about 0.60%, about 0.61%, about 0.62%, about 0.63%, about 0.64%, about 0.65%, about 0.66%, about 0.67%, about 0.68%, about 0.69%, about 0.70%, about 0.71%, about 0.72%, about 0.73%, about 0 0.6%, about 0.27%, about 0.28%, about 0.29%, about 0.30%, about 0.70%, about 0.71%, about 0.72%, about 0.73%, about 0.74%, about 0.75%, about 0.76%, about 0.77%, about 0.78%, about 0.79%, about 0.80%, about 0.81%, about 0.82%, about 0.83%, about 0.84%, about 0.85%, about 0.86%, about 0.87%, about 0.88%, about 0.89% or about 0.90%). Where the primary component of the pharmaceutical composition also has viscosity enhancing properties, a suspending agent or viscosity enhancing agent can be used to enhance the properties of the pharmaceutical composition. In some embodiments, the viscosity-inducing component is present in an amount ranging from about 0.5% or about 1.0% to about 5% or about 10% or about 20% (w / v) of the composition. Preservatives
[0492] In some embodiments, the pharmaceutical composition can have one or more suitable preservatives, for example, to extend shelf life or limit bacterial growth during storage and administration to a subject. Preservatives that can be used include, among others, benzalkonium chloride, benzethonium chloride, benzododecinium bromide, cetylpyridinium chloride, chlorobutanol, ethylenediaminetetraacetic acid (EDTA), thimerosol, phenylmercuric nitrate, phenylmercuric acetate, methylpyrparaben / propylparaben, phenylethyl alcohol, sodium benzoate, sodium propionate, sorbic acid and sodium perborate. The amount of preservative in the solution can be at a level that enhances shelf life, limits bacterial growth, or otherwise preserves the composition (e.g., ophthalmic composition, subcutaneous, etc.) with minimal toxicity to affected tissue (see, for example, The United States Pharmacopeia, 22nd rev., and The National Formulary, 17th Ed. Rockville, MD). Suitable levels of preservatives for use in the compositions herein can be determined by one of skill in the art. In some embodiments, the preservatives can be used in an amount of about 0.001% to about 1.0% w / v. For example, the preservatives can be present at about 0.005% to about 0.05% w / v, 0.005% to about 0.04% w / v, 0.01% to about 0.03% w / v, 0.01% to about 0.02% w / v, or about 0.01% to about 0.015% w / v. In some embodiments, the amount of preservative can be about 0.005% w / v, about 0.01% w / v, about 0.012% w / v, about 0.014% w / v, about 0.016% w / v, about 0.018% w / v, about 0.02% w / v, about 0.03% w / v, about 0.04% w / v, or about 0.05% w / v. In some embodiments, no preservatives are used in the composition.
[0493] The pharmaceutical compositions described herein are described in detail in the Remington: Science and Practice They can be prepared following the guidance provided herein and standard techniques, such as those described in The American College of Pharmacy, 21st Ed. (2005).
[0494] 4.13. Treatment disorders and diseases In another aspect, the pharmaceutical composition is used to treat a disease, disorder or condition characterized by the presence of toxic aldehydes. As used herein, the term "treating" or "treatment" of a disease, disorder or condition includes (i) preventing the development of a disease, disorder or syndrome in a subject, i.e., the induction of clinical symptoms of a disease, disorder or syndrome that has not yet developed in a subject that may be exposed to or susceptible to a disease, disorder or syndrome, but has not yet developed or exhibited symptoms of the disease, disorder or syndrome; (ii) inhibiting a disease, disorder or syndrome, i.e., arresting its development; and (iii) alleviating a disease, disorder or syndrome, i.e., causing the regression of a disease, disorder or syndrome. As known in the art, systemic adjustments with respect to local delivery, age, weight, general health, sex, diet, time of administration, drug interactions, and severity of the condition can be made and determined by the skilled artisan, especially in light of the guidance provided in this disclosure.
[0495] In some embodiments, treatment is administered after one or more symptoms have developed. In other embodiments, treatment is administered in the absence of symptoms. For example, treatment is administered to susceptible individuals prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment may also be continued after resolution of symptoms, for example, to prevent, delay, or reduce the severity of their recurrence.
[0496] In embodiments relating to the treatment of a disease, disorder, or condition, a subject in need of treatment is administered a pharmaceutical composition comprising a therapeutically effective amount of a compound described herein. The term "therapeutically effective amount" refers to an amount that, when administered to a subject for treating a disease, disorder, or condition, is sufficient to effect such treatment for the disease, disorder, or condition.
[0497] In some embodiments, the pharmaceutical composition of the present disclosure is administered to a subject in an effective amount to reduce the risk of or prevent a disease, disorder, or condition characterized by increased or elevated levels of toxic aldehydes. In some embodiments, a prophylactically effective amount of the pharmaceutical composition of the present disclosure is administered to a subject in need thereof to reduce the risk of or prevent a disease, disorder, or condition characterized by increased or elevated levels of toxic aldehydes.
[0498] In some embodiments, the disease, disorder, or condition is characterized by the accumulation of malondialdehyde (MDA), 4-hydroxynonenal (HNE), frans-2-heptenal, irani-2-nonenal, acrolein, aminoazoline, benzoyl peroxidase ... The compound described herein is characterized by an increase or enhancement of aldehydes such as dipic acid semialdehyde (AASA), retinaldehyde (intraocular), acetaldehyde, glyoxal, methylglyoxal, succinic acid semialdehyde and / or phosphatidylcholine gamma-hydroxyalkenal (PC-HA).In some embodiments, the increase or enhancement of aldehydes is at least 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 2.5-fold, 5-fold, 10-fold compared to those in normal cells, tissues or organs.The compound described herein can reduce aldehyde (e.g., MDA and HNE) concentration in a concentration-dependent manner. The amount or concentration of aldehydes (e.g., MDA, HNE and / or acrolein) may be determined by the methods described in Tukozkan et al., 2006, Furat Tip Dergisi 11: 88-92, Grotto et al., 2006, Furat Tip Dergisi 11: 88-92, which are incorporated herein by reference. 2009, Quim. Nova 32(1)1, and Rauli et al., 1998, J. Biochem. 123:918-923.
[0499] 4.13.1. Treatment of eye disorders In some embodiments, the composition is used to treat, reduce the risk of, or prevent ocular diseases, disorders, or conditions characterized by increased or elevated levels of toxic aldehydes. In some embodiments, the ocular disease, disorder, or condition is characterized by the presence of a pathological inflammatory response. In some embodiments, the method of treating, reducing the risk of, or preventing the occurrence of ocular diseases, disorders, or conditions characterized by increased or elevated levels of toxic aldehydes comprises administering a therapeutically effective amount of the pharmaceutical composition of the present disclosure to a subject in need thereof. In some embodiments, the pharmaceutical composition is administered intraocularly, for example, intravitreally.
[0500] In some embodiments, ocular diseases, disorders or conditions for treatment or prevention include macular degeneration, including age-related macular degeneration (AMD), wet age-related macular degeneration, dry age-related macular degeneration; Stargardt's disease; dry eye syndrome or disease; cataracts; keratoconus; bullous and other keratopathy; Fuchs endothelial dystrophy; allergic conjunctivitis; ocular cicatricial pemphigoid; lacrimal gland dysfunction; uveitis, including anterior uveitis, posterior uveitis and panuveitis; scleritis; ocular Stevens-Johnson syndrome; ocular rosacea with or without meibomian gland dysfunction; diabetic macular edema (DME), macular edema, including non-clinically significant macular edema (non-CSME) and clinically significant macular edema (CSME); endophthalmitis; and inflammation and / or fibrosis associated with ocular injury.
[0501] In some embodiments, the ocular disease, disorder or condition for treatment with the pharmaceutical composition is inflammation and / or fibrosis associated with ocular injury, such as from trauma or surgery to the eye, including corneal fibrosis. In some embodiments, the ocular disease, disorder or condition for treatment with the pharmaceutical composition is traumatic ocular injury; cataract surgery; laser eye surgery, including penetrating keratoplasty (PK), phototherapeutic keratectomy (PTK) and corneal transplant surgery, refractive surgery, including photorefractive keratectomy (PRK), laser thermokeratoplasty (LTK) and radial keratotomy (RK), and vitreoretinal surgery, including vitrectomy, retinal detachment repair and posterior scleral incision.
[0502] In some embodiments, the pharmaceutical compositions are used to treat ocular diseases, disorders, or conditions characterized by increased or elevated levels of toxic aldehydes, and the ocular diseases, disorders, or conditions affect the posterior segment of the eye (i.e., the back of the eye). A posterior segment condition of the eye (posterior segment condition) is a disease, disorder, or condition that severely affects or involves tissue or cell types in a posterior ocular region or area (i.e., in a posterior position relative to the plane along the posterior wall of the lens capsule), such as portions of the choroid or sclera, the vitreous, the vitreous chamber, the retina, the optic nerve (e.g., the optic nerve head), and the blood vessels and nerves that vascularize or innervate the posterior ocular (or posterior segment) region or area.
[0503] In some embodiments, the posterior segment or posterior ocular disease, disorder or condition may be selected from macular degeneration, such as age-related macular degeneration, wet age-related macular degeneration; acute macular neuroretinopathy; macular edema, such as cystoid macular edema or diabetic macular edema; diabetic retinopathy (including proliferative diabetic retinopathy); posterior uveitis; panuveitis, Stargardt's disease, ocular trauma affecting a posterior ocular site or location; posterior ocular conditions caused or affected by ocular laser procedures, photodynamic therapy, photocoagulation, radiation retinopathy, and glaucoma.
[0504] In some embodiments, the pharmaceutical composition is used to treat ocular diseases, disorders or conditions characterized by increased or elevated levels of toxic aldehydes, and the ocular diseases, disorders or conditions affect the anterior segment of the eye (i.e., the front of the eye). An "anterior ocular condition" is a disease, disorder or condition that affects or includes an anterior (i.e., the front of the eye) ocular region or site, such as the periocular muscles, eyelids, or ocular tissues or fluids that are anterior to the posterior wall of the lens capsule or ciliary muscle. An anterior ocular condition primarily affects or includes the conjunctiva, cornea, anterior chamber, iris, posterior chamber (behind the iris but in front of the posterior wall of the lens capsule), lens or lens capsule, and blood vessels and nerves that vascularize or innervate the posterior ocular region or site.
[0505] Ocular conditions of the anterior part of the eye can include diseases, disorders or conditions such as, for example, conjunctivitis, allergic conjunctivitis; dry eye syndrome; anterior uveitis, panuveitis, lacrimal system diseases; lacrimal duct obstruction, Fuchs endothelial dystrophy, and Stevens-Johnson syndrome.
[0506] 4.13.2. Treatment of non-ocular disorders In some embodiments, the pharmaceutical composition is used to treat non-ocular diseases, disorders or conditions characterized by the presence of toxic aldehydes.In some embodiments, the non-ocular diseases, disorders or conditions with elevated levels of toxic aldehydes include inflammatory diseases, disorders or conditions; autoimmune diseases or disorders; neurodegenerative diseases or disorders; chronic liver diseases or disorders; chronic obstructive pulmonary diseases or disorders; and non-ocular fibrotic diseases or disorders.
[0507] In some embodiments, non-ocular disorders for treatment with the pharmaceutical compositions include psoriasis, topical (disciform) lupus, contact dermatitis, atopic dermatitis, allergic dermatitis, radiation dermatitis, acne vulgaris, Sjogren-Larsson syndrome (SLS) and / or its associated ichthyoses, succinic semialdehyde dehydrogenase deficiency (SSADH) deficiency, actinic elastosis / wrinkles, skin damage, thermal skin damage, chemical burns or injuries, and scleroderma.
[0508] In some embodiments, the disease, disorder or condition treated by the pharmaceutical composition is chronic liver disease or disorder.In some embodiments, the chronic liver disease is non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, primary sclerosing cholangitis.
[0509] In some embodiments, the disease, disorder or condition for treatment with the pharmaceutical composition is chronic obstructive pulmonary disease. In some embodiments, the disease, disorder or condition is asthma and chronic obstructive pulmonary disease (COPD).
[0510] In some embodiments, the disease, disorder or condition for treating with the pharmaceutical composition is an inflammatory disease, disorder or condition. In some embodiments, the disease, disorder or condition is selected from inflammatory bowel disease (IBD), sepsis, atherosclerosis, ischemia-reperfusion injury, diabetes (e.g., type 2), Crohn's disease, ulcerative colitis, irritable bowel syndrome, elastic fibrosis, ankylosing spondylitis, osteoporosis, sarcoidosis, rheumatoid arthritis (RA), osteoarthritis, psoriatic arthritis, atherosclerosis, pulmonary arterial hypertension, lupus nephritis, diabetic neuropathy, preeclampsia and fibrotic diseases (renal, hepatic, pulmonary, etc.), chronic kidney disease, eosinophilic esophagitis and myocardial fibrosis.
[0511] In some embodiments, the disease, disorder or condition for treatment with the pharmaceutical composition is an autoimmune disease, disorder or condition. In some embodiments, the disease, disorder or condition is selected from diabetes (e.g., type 1), lupus, rheumatoid arthritis, lupus, systemic lupus erythematosus, psoriasis and scleroderma.
[0512] In some embodiments, the disease, disorder or condition that is to be treated by the pharmaceutical composition is a chronic neurological disease.In some embodiments, the disease, disorder or condition is selected from Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple sclerosis, pyridoxine-dependent epilepsy, the neurological and / or motor neuron effects of SLS, the neurological and / or motor neuron effects of SSADH deficiency, and amyotrophic lateral sclerosis.
[0513] In some embodiments, the disease, disorder or condition for treatment with the pharmaceutical composition is a genetic condition that has a defect in aldehyde metabolism, resulting in increased or elevated levels of toxic aldehydes. In some embodiments, the disease, disorder or condition is Sjogren-Larsson syndrome or succinic semialdehyde dehydrogenase (SSADH) deficiency.
[0514] Those skilled in the art understand that the diseases, disorders or conditions listed herein may include more than one pathological mechanism.For example, the diseases, disorders or conditions listed herein may include dysregulation of immunological and / or inflammatory response.Therefore, the above classification of diseases, disorders or conditions is not absolute, and the diseases, disorders or conditions may be considered as immunological, inflammatory, cardiovascular, neurological and / or metabolic diseases, disorders or conditions.
[0515] 4.14. Administration and Dosage In various embodiments, the pharmaceutical compositions are administered by injection. In some embodiments, the pharmaceutical compositions are administered parenterally. In some embodiments, the pharmaceutical compositions disclosed herein can be "administered locally", administered near or within the vicinity of the site where a therapeutic result or outcome is desired. In some embodiments, the pharmaceutical compositions are administered systemically for distribution throughout the body. As discussed herein, the pharmaceutical compositions can be administered subcutaneously, intradermally, intramuscularly, intraperitoneally, intraocularly, intraarticularly and intralesionally, or intravenously, as appropriate and suitable for the composition.
[0516] In some embodiments of treating ocular disorders, the pharmaceutical composition is administered intraocularly, including intravitreal, subconjunctival or periocular injection. In some embodiments, when treating diseases, disorders or conditions that affect the back of the eye, the pharmaceutical composition is administered to the posterior segment of the eye. In some embodiments of intraocular administration, the pharmaceutical composition is administered to provide a depot of the pharmaceutical composition. For example, to treat ocular conditions such as macular edema or macular degeneration or uveitis, the pharmaceutical composition of the compound formulated as a viscous composition can be intravitreal injected or implanted, which is an example of local administration.
[0517] In various embodiments, the dosage administered is an amount effective to treat a disease or disorder. As stated, the dosage administered can take into account the compound, age, body weight, general health, sex, diet, time of administration, mode of administration, drug interactions, and the disease, disorder or condition being treated and its severity.
[0518] In some embodiments, the pharmaceutical composition containing the compound is preferably formulated in dosage unit form to facilitate administration and ensure dosage uniformity.The expression "dosage unit form" as used herein refers to a physically separate unit of drug suitable for the patient being treated.However, it is understood that the total amount of the compound and composition of the present invention that is used per day can be determined by attending physician within the scope of sound medical judgment.
[0519] In some embodiments, the compound as part of a pharmaceutical composition is administered parenterally at dosage levels of about 0.01 mg / kg to about 100 mg / kg, about 0.01 mg / kg to about 50 mg / kg, and preferably about 1 mg / kg to about 25 mg / kg of the subject's body weight per day, one or more times per day to obtain the desired therapeutic effect.
[0520] In some embodiments, when administered topically, the compounds are administered at a dosage level of about 0.001 mg to about 5 mg or more, about 0.002 mg to about 5 mg, about 0.005 mg to about 5 mg, about 0.01 mg to about 5 mg, about 0.02 mg to about 5 mg, about 0.05 mg to about 5 mg, about 0.1 mg to about 5 mg, about 0.2 mg to about 5 mg, about 0.5 mg to about 5 mg, about 1 mg to about 5 mg, or about 2 mg to about 5 mg. In some embodiments, when administered topically, the compounds are administered at a dosage level of about 0.001 mg, 0.002 mg, 0.005 mg, 0.01 mg, 0.02 mg, 0.05 mg, 0.1 mg, 0.2 mg, 0.5 mg, or 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, or more.
[0521] In some embodiments, the pharmaceutical composition is administered intraocularly, for example, by intravitreal administration, to treat certain eye disorders.In some embodiments, for intraocular administration, the composition is administered to the eye using a syringe.In some embodiments, the composition can be administered to the eye during eye surgery, such as vitrectomy.
[0522] In some embodiments, the volume administered intraocularly is about 1 μL to about 100 uL, at least about 5 uL to about 100 uL, about 10 μL to about 100 uL; about 20 μL to about 100 uL, about 30 uL to about 100 uL; about 40 uL to about 100 uL, about 50 uL to about 100 uL; about 60 uL to about 100 uL; about 70 uL. In some embodiments, the volume administered can be up to 4 mL, depending on the mode of administration. In some embodiments, the volume administered can be up to 3 mL, up to 2.5 mL, up to 2 mL, up to 1.5 mL, or up to 1 mL. In some embodiments, the volume administered to the eye is less than 1 mL. In some embodiments, the volume administered intraocularly is between about 1 μL and about 95 uL, at least about 5 uL to about 90 uL, between about 10 μL to about 85 uL; between about 20 μL to about 80 uL; between about 30 uL to about 75 uL; or between about 40 uL to about 70 uL.
[0523] In some embodiments, the volume administered intraocularly is at least about 1 μL, at least about 5 uL, about 10 μL; about 20 μL, about 30 uL; about 40 uL, about 50 uL; about 60 uL; about 70 uL; about 80 uL; about 90 uL; or about 100 μL.
[0524] In some embodiments, the compounds may be administered daily, more than once daily, twice a week, three times a week, weekly, biweekly, monthly, bimonthly, semi-annually, annually and / or biennially.
[0525] The following examples are provided to further illustrate the disclosed methods, and compounds and compositions for use in the methods. The examples described are for illustrative purposes only and are not intended to limit the scope of the invention in any way. EXAMPLES
[0526] As illustrated in the Examples below, in certain exemplary embodiments, the compounds can be used to treat a disease, disorder, or condition characterized by the presence of an aldehyde, according to the following procedure: While the method illustrates the use of an exemplary compound, it is understood that the following general method may be applied to other compounds described herein, and subclasses and species thereof. Example 1 Effects of compounds I-5 and I-22 on endotoxin-induced uveitis in rats
[0527] In vivo studies were performed to evaluate the efficacy of intravitreal administration of compounds I-5 and I-22 in a rat model of endotoxin-induced uveitis, one of the best models for studying noninfectious uveitis (NIU) (Smith et al., 1998, Immunol Cell Biol. 76(6):497-512) (Toxikon Study 16-04078-N1). Ocular inflammation was induced in female Lewis rats (n=10 / group) by a single injection of lipopolysaccharide (LPS) (100 μL) into the foot pad (Herbort et al., 1988, Graefes Arch Clin Exp Ophthalmol. 226(6):553-8).
[0528] Compounds I-5 or I-22 (50 μg) were administered topically (TO) to the eyes at 1, 3, 7, 10, and 17 hours after LPS induction, or by a single intravitreal (IVT) injection (25 μg) at 1 hour after LPS induction (n=10 per group). Ocular examinations were performed 6 and 24 hours after LPS injection. The anterior segment was scored using a combination of the Draize and McDonald-Shattuck scoring systems, and the posterior segment was scored using a 0-1 (vitreous, optic nerve head, retinal vessels) and 0-4 (retinal and choroidal hemorrhage, exudate, and detachment) scales. Statistical significance from vehicle controls was determined by ANOVA followed by Tukey's post-hoc test. Test compounds, e.g., compound I-22 (5 mg / mL), were administered intravitreally to each eye (25 μg / eye) within 1 hour of LPS administration. Balanced salt solution (BSS) served as the vehicle control. Prior to the start of the study and 6 and 24 hours after LPS administration, retinal examinations were performed and scored using a combination of the Draize and McDonald-Shadduck scoring systems based on assessment of (a) retinal vascular damage; (2) retinal hemorrhage, exudate, or detachment; and (3) retinal hemorrhage, exudate, or detachment.
[0529] In the LPS-induced uveal model, 6 and 24 hours after topical (TO) administration of compound I-5 or compound I-22, the ocular examination scores were significantly improved compared to vehicle (total ocular inflammation - Figures 1A and 1B; anterior chamber inflammation - Figures 2A and 2B; and retina-choroidal inflammation - Figures 3A and 3B). After intravitreal (IVT) administration of compound I-5 or compound I-22, the ocular examination scores were also significantly improved compared to vehicle (total ocular inflammation - Figures 4A and 4B; anterior chamber inflammation - Figures 5A and 5B; and retina-choroidal inflammation - Figures 6A and 6B). Small, but not significant, reductions in MDA adducts were observed in the compound I-5 and compound I-22 groups after TO and IVT administration (data not shown). To control for variability between individual animals, within-subject statistical analyses testing the covariates of treatment and time were performed on the retina-choroidal scores from the IVT group. The retina-choroid scores of rats were significantly improved after IVT treatment with either compound I-5 or compound I-22 compared to vehicle controls. Example 2 Effect of compounds I-5 and I-22 on the formation of N-retinylidene-N-retinylethanolamine (A2E)
[0530] The activity of compounds I-5 and I-22 was tested using a mouse knockout model (abcr- / -) of macular degeneration (MD). The retinal transport protein, ABCA4, is not expressed in these mice, and retinaldehyde is not expressed during the light cycle. This allowed the formation of toxic metabolites with phosphatidylethanolamine, N-retinylidene-phosphatidylethanolamine (A2E). Mice were treated intraperitoneally (IP) with 10 mg / kg compound I-5 (n=24), compound I-22 (n=24) or vehicle (n=22) for 56 days, starting at 10-12 weeks of age. On the first day of treatment, the untreated control group (n=12) was sacrificed. After treatment, A2E concentrations in the retina were measured by HPLC. Statistical significance from vehicle control was determined by t-test.
[0531] In the MD model, daily treatment with compound I-5 or compound I-22 reduced the formation of A2E by 71% or 69%, respectively, compared to vehicle control (Figure 7). In another study, systemic (IP) dose of compound I-5, administered at 5 times the effective dose in the A2E study, for 56 days, had no effect on dark adaptation (data not shown). Daily treatment with compound I-5 or compound I-22 for 56 days had no effect on body weight, and no drug-related adverse effects were observed. Example 3 Effect of compound I-22 on diabetic macular edema
[0532] Diabetic macular edema (DME) is a common cause of blindness. Hyperglycemia can lead to the accumulation of toxic aldehydes, such as methylglyoxal, 4-hydroxy-trans-2-nonenal, and malondialdehyde, which result in carbonyl stress in the retina and induce inflammatory changes in the eye, including the development of DME.
[0533] To evaluate the effect of compound I-22 in a rat model of diabetic macular edema (DME), type 1 diabetes was induced in male Brown Norway rats by intraperitoneal administration of streptozotocin (STZ; 55 mg / kg). Forty days after STZ administration, animals were tested for diabetic status by examining blood glucose levels.
[0534] Animals with diabetes were assigned to groups of 10 and received either vehicle (HPβCD) or compound I-22. A group of 4 animals that did not receive STZ or drug treatment served as non-diabetic controls. On day 41 (approximately 6 weeks) after STZ induction, animals received a single intravitreal injection of compound I-22 (3.5 μL; 17.5 μg) or vehicle per eye. On day 57 (approximately 8 weeks) after STZ induction, animals received a second intravitreal injection of compound I-22 or vehicle.
[0535] On day 70 (approximately 10 weeks) after STZ induction, animals were euthanized and retinas were processed for histological examination. Sections (3-5 μm) were stained with hematoxylin and eosin and evaluated by light microscopy. Changes in retinal thickness were assessed on a 0-4 scale, with 0 meaning no change, 1 meaning minimal change, 2 meaning mild change, 3 meaning moderate change, and 4 meaning severe change, relative to nondiabetic controls. Six microscopic sections were examined for each eye, and the retina was also evaluated and scored by a pathologist for changes in vascularity and neutrophil infiltration.
[0536] Results. Retinal thickness in STZ-induced animals was significantly thicker than in control animals, as illustrated in FIG. 8. Treatment of STZ-induced animals with compound I-22 resulted in a significant reduction in retinal thickness compared to that of untreated STZ-induced animals. The scoring used was: 0=normal, 1=minimal changes visible under the microscope; 2=mild changes visible under the microscope; 3=moderate changes visible under the microscope; 4=severe changes visible under the microscope. Nonparametric Dunn's multiple comparisons followed by Kruskal-Wallis test revealed that the retinal thickness was significantly reduced in STZ-induced animals compared to untreated STZ-induced animals. ** Statistical analysis was performed with p<0.01.
[0537] The reduction in retinal thickness was accompanied by a significant reduction in neutrophil infiltration compared to vehicle based on evaluation of retinal microscopic sections, shown in Figure 9. Scoring was based on: 0=normal, 1=minimal visible microscopic changes; 2=mild visible microscopic changes; 3=moderate visible microscopic changes, 4=severe visible microscopic changes. Non-parametric Dunn's multiple comparisons followed by Kruskal-Wallis test confirmed the neutrophil infiltration rate. ** Statistical analysis was performed with p<0.01.
[0538] Vascular leakage of retinal microscopic sections was also evaluated. Compound I-22 treatment inhibited diabetes-induced retinal vascular changes, as shown by a 36% decrease in retinal vascularity score (p<0.05) in the compound I-22 treatment group compared to vehicle. However, the decrease in retinal vascularity compared to vehicle was not statistically significant (see Figure 10). Retinal vascularity was based on the following score: 0=normal, 1=minimal visible microscopic changes; 2=mild visible microscopic changes; 3=moderate visible microscopic changes; 4=severe visible microscopic changes.
[0539] SUMMARY: Diabetic retinopathy was successfully induced in STZ-treated rats. Diabetic animals lost approximately 10% of their body weight during the first week after STZ administration and maintained this weight by the end of the study. Nonfasting glucose blood levels were significantly improved in diabetic rats compared to nondiabetic rats.
[0540] Increased retinal thickness, vascularity and neutrophil infiltration were observed in vehicle-treated diabetic rats compared to non-diabetic rats. Compound I-22 treatment reduced retinal inflammation as measured by a statistically significant reduction in retinal thickness, neutrophil infiltration and retinal vascular changes.
[0541] In conclusion, these data suggest that aldehyde sequestration represents a novel therapeutic approach for the treatment of the sequelae of diabetic ocular inflammation. In this model of DME, compound I-22 reduced retinal inflammation, blocked neutrophil infiltration, and inhibited retinal vascular changes. Compound I-22 was also well tolerated in the retina.
[0542] These data suggest that compound I-22 may be useful for treating retinal diseases such as DME, particularly via intravitreal administration.
[0543] All publications, patents, patent applications, and other documents cited in this application are herein incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent, patent application, or other document was individually indicated to be incorporated by reference for all purposes.
[0544] While various specific embodiments have been illustrated and described, it will be understood that various modifications can be made without departing from the spirit and scope of the invention. In one embodiment, for example, the following items are provided: (Item 1) Compounds of Formula I: [ka] or a pharma- ceutically acceptable salt thereof, wherein W, X, Y and Z are N, O, S, CU, CH and C-NH 2 and one of W, X, Y or Z is C-NH 2 and R a is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 It is aliphatic, R b is C optionally substituted by one, two or three deuterium or halogen atoms; 1~4 Aliphatic; or R a and R b together with the carbon atom to which they are attached form a 3-8 membered cycloalkyl or heterocyclyl ring containing 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; k is 0, 1, 2, 3 or 4; U is halogen, cyano, -R, -OR, -SR, -N(R) 2 , -N(R)C(O)R, -C(O)N(R) 2 , -N(R)C(O)N(R) 2, -N(R)C(O)OR, -OC(O)N(R) 2 , -N(R)S(O) 2 R, -SO 2 N(R) 2 , -C(O)R, -C(O)OR, -OC(O)R, -S(O)R and -S(O) 2 is selected independently of R, two U's present on adjacent carbon atoms can form an optionally substituted fused ring selected from a fused phenyl ring; a fused 5-6 membered saturated or partially unsaturated fused heterocyclic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; and a fused 5-6 membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; R is hydrogen, deuterium, and C 1~6 and optionally substituted groups selected from aliphatic; a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring; phenyl; an 8-10 membered bicyclic aryl ring; a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; The pharmaceutical composition is an injectable composition. Pharmaceutical compositions. (Item 2) The injectable composition comprises: (a) Viscosity enhancer (b) Liposome (c) Biodegradable polymer microparticles or nanoparticles (d) Calcium phosphate particles (e) a cyclodextrin, wherein the composition is suitable for parenteral administration; or (f) Hydrogel 2. The pharmaceutical composition according to item 1, comprising: (Item 3) 3. The pharmaceutical composition according to item 2, comprising a viscosity enhancing agent. (Item 4) 4. The pharmaceutical composition according to item 3, wherein the viscosity enhancing agent is selected from the group consisting of hyaluronate, hyaluronic acid, cross-linked hyaluronic acid, polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyl ethyl cellulose, glycerol or a mixture thereof. (Item 5) 5. The pharmaceutical composition according to any one of items 3 or 4, wherein the pharmaceutical composition has a viscosity between 1 kcP and 200 kcP. (Item 6) 6. The pharmaceutical composition according to any one of items 3 to 5, wherein the viscosity enhancing agent is hyaluronate, hyaluronic acid or a pharma- ceutically acceptable salt thereof. (Item 7) The hyaluronate or hyaluronic acid or a pharma- ceutically acceptable salt thereof is about 500,000 to about 5 × 10 6 7. The pharmaceutical composition according to item 6, having a molecular weight of 100 ng / L Daltons. (Item 8) 8. The pharmaceutical composition according to any one of items 3 to 7, further comprising one or more excipients selected from isotonicity agents, buffering agents, chelating agents, surfactants, preservatives and antioxidants. (Item 9) 3. The pharmaceutical composition according to item 2, comprising liposomes. (Item 10) 10. The pharmaceutical composition according to item 9, wherein the liposomes are submicron-sized liposomes. (Item 11) 11. The pharmaceutical composition according to any one of items 9 to 10, wherein the liposomes have an average diameter of about 20 nm to about 1 um. (Item 12) 12. The pharmaceutical composition according to any one of items 9 to 11, wherein the liposome comprises 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC). (Item 13) 12. The pharmaceutical composition according to any one of items 9 to 11, wherein the liposome comprises egg phosphatidylcholine (EPC) and l-α-distearoylphosphatidylcholine (DSPC). (Item 14) 12. The pharmaceutical composition according to any one of items 9 to 11, wherein the liposome comprises egg phosphatidylcholine (EPC) or 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and cholesterol or a derivative thereof. (Item 15) 12. The pharmaceutical composition according to any one of items 9 to 11, wherein the liposome comprises dioleoylphosphatidylcholine (DOPC), dioleoylphosphatidylglycerol (DOPG) and cholesterol. (Item 16) 12. The pharmaceutical composition according to any one of items 9 to 11, wherein the liposome comprises dipalmitoylphosphatidylcholine (DPPC), palmitoyl-oleoylphosphatidylcholine (POPC) and cholesterol. (Item 17) 17. The pharmaceutical composition according to any one of items 9 to 16, further comprising one or more excipients selected from isotonicity agents, viscosity enhancing agents, buffering agents, chelating agents, surfactants, preservatives and antioxidants. (Item 18) 18. The pharmaceutical composition of claim 17, wherein the liposomes formulated with the compound further comprise at least a viscosity enhancing agent. (Item 19) 19. The pharmaceutical composition according to item 18, wherein the viscosity enhancing agent is a Pluronic. (Item 20) 20. The pharmaceutical composition according to any one of items 9 to 19, wherein the liposome comprises a lipid-PEG conjugate. (Item 21) 20. The pharmaceutical composition according to any one of items 9 to 19, wherein the liposome is surface-modified with poly-L-lysine. (Item 22) 3. The pharmaceutical composition according to item 2, comprising microparticles or nanoparticles of a biodegradable polymer. (Item 23) 23. The pharmaceutical composition according to item 22, wherein the biodegradable polymer comprises a poly(ester), poly(ester amide), poly(anhydride), poly(carbonate), poly(amino acid), poly(amide), poly(urethane), poly(ortho-ester), poly(iminocarbonate), poly(phosphazene) or a combination thereof. (Item 24) 24. The pharmaceutical composition according to item 23, wherein the biodegradable polymer comprises poly(lactide) (PLA), poly(lactide-co-glycolide) (PLGA), polyglycolide (PGA), polyhydroxybutyric acid, polycaprolactone, polyvalerolactone, polyphosphazene, polyorthoester or a combination thereof. (Item 25) 24. The pharmaceutical composition of claim 23, wherein the biodegradable polymer comprises poly(lactide-co-glycolide) (PLGA). (Item 26) 26. The pharmaceutical composition of item 25, wherein the PLGA has a lactide to glycolide ratio of about 10:90, 15:85, 20:80, 25:75, 30:70; 35:65, 40:60, 45:55 or 50 / 50. (Item 27) 24. The pharmaceutical composition according to item 23, wherein the biodegradable polymer is a poly(ester amide). (Item 28) 28. The pharmaceutical composition according to any one of items 22 to 27, wherein the compound is formulated in microparticles composed of biodegradable polymers. (Item 29) 29. The pharmaceutical composition according to item 28, wherein the microparticles have an average particle size of about 1 um to about 250 um. (Item 30) 28. The pharmaceutical composition according to any one of items 22 to 27, wherein the compound is formulated in nanoparticles composed of biodegradable polymers. (Item 31) 31. The pharmaceutical composition according to item 30, wherein the nanoparticles have an average particle size of less than 1 um. (Item 32) 32. The pharmaceutical composition according to any one of items 22 to 31, further comprising one or more excipients selected from isotonicity agents, viscosity enhancing agents, buffering agents, chelating agents, surfactants, preservatives and antioxidants. (Item 33) 33. The pharmaceutical composition according to item 32, wherein the composition further comprises at least a viscosity enhancing agent. (Item 34) 3. The pharmaceutical composition according to item 2, comprising calcium phosphate particles. (Item 35) 35. The pharmaceutical composition according to item 34, wherein the calcium phosphate is tricalcium phosphate (β-TCP) or hydroxyapatite. (Item 36) 36. The pharmaceutical composition according to any one of items 34 to 35, wherein said calcium phosphate particles have an average particle size of less than 1 um. (Item 37) 37. The pharmaceutical composition according to any one of items 34 to 36, wherein the calcium phosphate particles have a surface coating of polyethylene glycol. (Item 38) 38. The pharmaceutical composition according to item 37, wherein the compound is disposed on the surface of the calcium phosphate particles. (Item 39) 2. The pharmaceutical composition according to item 1, comprising a complexing agent selected from polyamino acids, galactomannans or cationic galactomannan polymers, cellulose polymers, quaternary ammonium polymers and combinations thereof. (Item 40) 40. The pharmaceutical composition according to item 39, wherein th...
Claims
[Claim 1] The invention described in the specification.
Citation Information
Cited By
Medium reader-writer and storage medium
CN121706814A
